https://crcwarriors.org/ 2026-08-11 daily 1.0 https://crcwarriors.org/ensayos-clinicos 2026-08-11 daily 0.9 https://crcwarriors.org/medicamentos 2026-08-11 weekly 0.9 https://crcwarriors.org/noticias-cientificas 2026-08-11 daily 0.8 https://crcwarriors.org/noticias 2026-08-11 daily 0.8 https://crcwarriors.org/combinaciones 2026-08-01 weekly 0.8 https://crcwarriors.org/eficacia 2026-08-01 weekly 0.8 https://crcwarriors.org/eficacia/kras 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/braf 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msi 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/biomarker-unselected 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/her2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/mmr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ras 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/mss 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3ca 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/nras 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tp53 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/all 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/apc 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/met 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tmb 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ddr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/alk 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pten 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ret 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/vegf 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/atm 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/smad4 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1a 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/mlh1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pd-l1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/fbxw7 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ros1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tie2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/blm 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ccnd1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pole 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ccne1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/brca1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cdh17 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/mutyh 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pms2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/brca2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/egfr+pathway 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk3 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ctnnb1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msh2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msi-h%2Fdmmr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/nf1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/palb2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb3 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ntrk1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/prex2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/rb1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/bcl2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/chek2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/erbb4 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr3 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/idh2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/smarca4 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tgfbr2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/arid1b 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk4 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cna 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/igf1r 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/line-1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/myc 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/nthl1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pi3k+pathway 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pold1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/sox9 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfa 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/arid2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cdk6 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/fgfr1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/hpv 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/jag1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/map2k1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51c 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/ras%2Fbraf%2Fegfr%2Fpik3ca%2Fmap2k1%2Fmet%2Fret%2Falk%2Fros1%2Fntrk%2F 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/smad2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/stk11 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/vegfr 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/actl6b 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/cdkn2a 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/idh1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/keap1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/msh6 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/notch1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pathogenic+variants 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/pik3r1 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/rad51d 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/tcf7l2 2026-08-01 monthly 0.7 https://crcwarriors.org/eficacia/wild-type 2026-08-01 monthly 0.7 https://crcwarriors.org/nuestra-historia 2026-08-01 monthly 0.7 https://crcwarriors.org/contacto 2026-08-01 monthly 0.6 https://crcwarriors.org/ayuda 2026-08-01 monthly 0.6 https://crcwarriors.org/colabora 2026-08-01 monthly 0.6 https://crcwarriors.org/ensayo/NCT07406633/kqb198-en-combinacion-con-imatinib-en-participantes-con-gist-avanzado-metastasico-en-primera-linea-de-tratamiento 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07406633/kqb198-in-combination-with-imatinib-in-participants-with-advanced-metastatic-gist-in-1st-line-setting-synergist-1st-line 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07236983/biodiversidad-de-la-microbiota-intestinal-en-pacientes-con-tumores-solidos-tratados-con-inhibidores-de-puntos-de-control-inmunitario-icpi-un-estudio-prospectivo-monocentrico-para-identificar-las 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07236983/gut-microbiota-gm-biodiversity-in-patients-with-solid-tumors-treated-with-immune-checkpoint-inhibitors-icis-a-monocenter-prospective-study-to-identify-the-interactions-between-gm-and-icis 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05384444/efecto-de-la-fmd-en-pacientes-con-cancer-colorrectal 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05384444/effect-of-fmd-on-colorectal-cancer-patients 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04443543/un-estudio-de-cohorte-prospectivo-con-diseno-adaptativo-sobre-la-estrategia-de-observacion-y-espera-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04443543/an-adaptive-design-prospective-cohort-study-of-watch-and-wait-strategy-in-patients-with-locally-advanced-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06710561/seguridad-tolerabilidad-farmacocinetica-y-eficacia-preliminar-del-spn01-inyectable-en-la-fase-i 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06710561/the-safety-tolerability-pharmacokinetics-and-preliminary-efficacy-of-injectable-spn01-in-phase-i 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06124378/tislelizumab-neoadyuvante-en-combinacion-con-quimioterapia-para-el-tratamiento-del-cancer-colorrectal-mss 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06124378/neoadjuvant-tislelizumab-with-chemotherapy-for-the-treatment-of-mss-colon-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07297030/sib-rt-combinado-con-capox-y-un-inhibidor-de-pd-1-para-el-cancer-colorrectal-de-alto-riesgo 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07297030/sib-rt-combined-with-capox-and-pd-1-for-high-risk-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06368141/quimioterapia-neoadyuvante-combinada-con-terapia-secuencial-con-inhibidores-de-puntos-de-control-inmunitario-ici-en-el-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06368141/neoadjuvant-chemotherapy-plus-sequential-immune-checkpoint-inhibitor-ici-therapy-in-locally-advanced-colon-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05463796/inadvance-vigilancia-prevencion-e-intervencion-en-una-poblacion-con-riesgo-de-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05463796/inadvance-surveillance-prevention-and-interception-in-a-population-at-risk-for-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04161092/el-estudio-sueco-sobre-el-trasplante-hepatico-para-metastasis-de-cancer-colorrectal-no-susceptibles-de-reseccion 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04161092/the-swedish-study-of-liver-transplantation-for-non-resectable-colorectal-cancer-metastases 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06356714/esqueleto-de-la-pared-celular-de-nocardia-rubra-en-combinacion-con-regimenes-previos-de-segunda-o-tercera-linea-para-el-tratamiento-del-cancer-colorrectal-en-estadio-de-enfermedad-estable-sd-con 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06356714/nocardia-rubra-cell-wall-skeleton-in-combination-with-prior-second-or-third-line-regimens-for-the-treatment-of-potentially-hazardous-colorectal-cancer-sd-status 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07248020/un-estudio-de-fase-ii-de-un-solo-brazo-sobre-la-administracion-de-curcumina-de-alta-biodisponibilidad-como-quimiorradioterapia-neoadyuvante-en-el-cancer-de-recto-medio-a-bajo-analisis-clinico-y 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07248020/a-phase-ii-single-arm-study-of-high-bioavailability-curcumin-as-neoadjuvant-chemoradiotherapy-in-mid-to-low-rectal-cancer-integrated-clinical-and-translational-analysis-of-tumor-tissue 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07284992/scrt-frente-a-lcrt-seguido-de-un-inhibidor-de-pd-l1-mas-capeox-como-terapia-neoadyuvante-en-pacientes-con-cancer-colorrectal-localmente-avanzado-larc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07284992/scrt-vs-lcrt-followed-by-pd-l1-inhibitor-plus-capeox-as-tnt-in-patients-with-larc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06405139/irinotecano-nanoliposomal-oxaliplatino-mas-capecitabina-como-terapia-de-conversion-en-el-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06405139/nanoliposomal-irinotecan-oxaliplatin-plus-capecitabine-as-conversion-therapy-of-locally-advanced-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06441487/mpath-cloud-para-la-deteccion-del-cancer-colorrectal 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06441487/mpath-cloud-for-colorectal-cancer-screening 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06790212/quimioterapia-neoadyuvante-con-capox-mas-ivonescimab-frente-a-capox-en-el-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06790212/neoadjuvant-capox-plus-ivonescimab-versus-capox-for-locally-advanced-colon-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07505472/comparacion-de-la-eficacia-y-la-seguridad-de-un-ciclo-corto-de-radioterapia-seguido-de-quimioterapia-con-capeox-mas-toripalimab-con-o-sin-surufatinib-concomitante-en-la-terapia-neoadyuvante-para-el 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07505472/efficacy-and-safety-comparison-of-short-course-radiotherapy-followed-by-capeox-chemotherapy-plus-toripalimab-with-or-without-concurrent-surufatinib-in-neoadjuvant-therapy-for-mid-to-low-localized 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07509424/radioterapia-neoadyuvante-de-corta-duracion-seguida-de-una-combinacion-de-disitamab-vedotina-sintilimab-y-capecitabina-en-el-cancer-colorrectal-localmente-avanzado-con-expresion-de-her2 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07509424/neoadjuvant-short-course-radiotherapy-followed-by-a-combination-of-disitamab-vedotin-sintilimab-and-capecitabine-in-locally-advanced-her2-expressing-rectal-cance 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07736495/papel-protector-del-acido-alfa-lipoico-en-la-mucositis-inducida-por-la-quimioterapia 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07736495/protective-role-of-alpha-lipoic-acid-in-chemotherapy-induced-mucositis 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07622017/kortuc-krc-01-mas-radioterapia-para-la-preservacion-de-organos-en-el-cancer-de-recto 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622017/kortuc-krc-01-plus-radiotherapy-for-organ-preservation-in-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07741435/prueba-de-perfil-de-metilacion-methylscape-en-fluidos-corporales-para-la-deteccion-y-el-seguimiento-de-multiples-tipos-de-cancer-en-colombia 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07741435/methylation-profile-test-methylscape-in-body-fluids-for-multi-cancer-detection-and-monitoring-in-colombia 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07742410/la-estrategia-de-cribado-mediante-endoscopia-con-imagenes-secuenciales-vinculadas-que-combina-la-prueba-de-inmunoensayo-fecal-para-la-deteccion-de-sangre-oculta-y-la-calprotectina-para-el-seguimiento 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07742410/the-fecal-immunoassay-occult-blood-test-combined-with-calprotectin-sequential-linkage-imaging-endoscopy-screening-strategy-for-monitoring-tumor-changes-associated-with-long-duration-ulcerative-colitis 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07740720/un-estudio-sobre-la-duracion-del-tratamiento-con-dostarlimab-en-pacientes-no-tratados-con-cancer-colorrectal-localmente-avanzado-con-deficiencia-en-la-reparacion-de-desajustes-dmmr-y-alta 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07740720/a-study-of-the-duration-of-dostarlimab-in-untreated-mismatch-repair-deficient-dmmr-microsatellite-instability-high-msi-h-locally-advanced-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06204094/radioterapia-que-preserva-los-ganglios-linfaticos-combinada-con-quimioterapia-neoadyuvante-total-con-capox-y-sintilimab-para-el-cancer-colorrectal-medio-y-bajo-con-mss 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06204094/node-sparing-radiotherapy-combined-with-total-neoadjuvant-capox-and-sintilimab-for-mss-middle-and-low-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06055439/un-estudio-de-fase-1-2-para-evaluar-chm-2101-una-terapia-celular-t-con-receptor-quimerico-de-antigeno-17-car-autologa 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06055439/a-phase-1-2-study-to-evaluate-chm-2101-an-autologous-cadherin-17-chimeric-antigen-receptor-car-t-cell-therapy 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07750951/estudio-clinico-de-fase-ii-de-un-solo-brazo-para-evaluar-la-seguridad-y-la-eficacia-de-sintilimab-en-combinacion-con-ibi-310-y-quimioterapia-como-terapia-neoadyuvante-para-el-cancer-colorrectal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07750951/single-arm-phase-ii-clinical-study-evaluating-the-safety-and-efficacy-of-sintilimab-combined-with-ibi-310-and-chemotherapy-as-neoadjuvant-therapy-for-locally-advanced-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06770270/pucotenlimab-mas-radioterapia-y-quimioterapia-para-el-tratamiento-neoadyuvante-del-cancer-de-recto-localmente-avanzado-pucrt 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06770270/pucotenlimab-plus-radiotherapy-and-chemotherapy-for-neoadjuvant-treatment-of-locally-advanced-rectal-cance-pucrt 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06337760/jovenes-adultos-con-canceres-gastrointestinales-y-neuroendocrinos 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06337760/young-adults-with-gastro-intestinal-gi-and-neuroendocrine-cancers 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03179540/manejo-no-quirurgico-del-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03179540/non-operative-management-for-locally-advanced-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06534918/intervenciones-precisas-en-oncologia-a-traves-de-la-nutricion-y-el-entrenamiento-onpoint 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06534918/precise-oncology-interventions-in-nutrition-and-training-onpoint 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07755124/dietary-arginine-deprivation-combined-with-chemoradiotherapy-for-neoadjuvant-treatment-of-rectal-cancer-a-randomized-controlled-trial 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05856305/terapia-de-radiacion-estereotactica-en-tumores-del-tracto-nervioso-con-o-sin-clorofilina 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05856305/scrt-in-tnt-with-or-without-chlorophyllin 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07528209/quimioterapia-neoadyuvante-con-capox-con-o-sin-pucotenlimab-mas-radioterapia-selectiva-para-el-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07528209/neoadjuvant-capox-with-or-without-pucotenlimab-plus-selective-radiotherapy-for-locally-advanced-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07528937/aplicacion-de-la-reconstruccion-tridimensional-para-la-planificacion-preoperatoria-del-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07528937/application-of-3d-reconstruction-for-preoperative-strategy-of-locally-advanced-colon-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07200141/aumento-simultaneo-de-la-dosis-en-la-radioterapia-neoadyuvante-para-el-cancer-de-recto 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07200141/simultaneous-boost-in-neoadjuvant-radiotherapy-for-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05973487/un-estudio-basket-de-terapias-celulares-autologas-de-tcr-t-personalizadas-en-pacientes-con-tumores-solidos-metastasicos-o-localmente-avanzados-irresecables 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05973487/a-basket-study-of-customized-autologous-tcr-t-cell-therapies-in-patients-with-locally-advanced-unresectable-or-metastatic-solid-tumors 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06962670/prediccion-del-riesgo-de-cancer-mediante-marcadores-digitales-y-moleculares 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06962670/predicting-cancer-risk-with-digital-and-molecular-markers 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04313114/el-ensayo-prime-crc-para-promover-la-deteccion-del-cancer-colorrectal-en-comunidades-rurales 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04313114/the-prime-crc-trial-to-promote-crc-screening-in-rural-communities 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07644286/un-estudio-de-fase-ii-de-pirfenidona-mas-un-inhibidor-de-pd-1-con-o-sin-radioterapia-hipofraccionada-para-el-cancer-colorrectal-refractario-pmmr-mss 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07644286/a-phase-ii-study-of-pirfenidone-plus-pd-1-inhibitor-with-or-without-hypofractionated-radiotherapy-for-refractory-pmmr-mss-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07646639/diferentes-dosis-de-radioterapia-estereotactica-scrt-mas-capox-bloqueo-de-pd-1-e-il-2-en-el-cancer-colorrectal-localmente-avanzado-larc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07646639/different-dose-scrt-plus-capox-pd-1-blockade-and-il-2-in-larc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05723562/un-estudio-de-dostarlimab-en-pacientes-con-cancer-colorrectal-localmente-avanzado-dmmr-msi-h-no-tratados-previamente 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05723562/a-study-of-dostarlimab-in-untreated-dmmr-msi-h-locally-advanced-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05523245/prediccion-de-la-eficacia-de-la-terapia-neoadyuvante-en-pacientes-con-cancer-colorrectal-localmente-avanzado-mediante-una-plataforma-de-inteligencia-artificial-basada-en-la-resonancia-magnetica 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05523245/predicting-the-efficacy-of-neoadjuvant-therapy-in-patients-with-locally-advanced-rectal-cancer-using-an-ai-platform-based-on-multi-parametric-mri 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06477991/eficacia-de-la-estrategia-de-observacion-y-espera-o-de-la-cirugia-tras-la-inmunoterapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado-con-dmmr-msi-h-guiada-por-el-seguimiento-dinamico-de 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06477991/the-efficacy-of-watch-and-wait-strategy-or-surgery-after-neoadjuvant-immunotherapy-for-locally-advanced-colorectal-cancer-with-dmmr-msi-h-guided-by-mrd-dynamic-monitoring-a-single-center-open-label 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05219734/el-ensayo-de-enfermedad-residual-minima-erm-evalua-la-recurrencia-y-la-respuesta-mediante-una-evaluacion-basada-en-el-tumor 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05219734/mrd-assay-evaluates-recurrence-and-response-via-a-tumor-informed-assessment 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06843655/marcadores-radiologicos-en-el-cancer-de-recto-localmente-avanzado 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06843655/radiological-markers-in-locally-advanced-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06252142/estudio-que-evalua-si-la-estrategia-de-esperar-y-observar-es-adecuada-en-el-cancer-de-recto 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06252142/study-for-wait-and-watch-suitable-in-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06276686/ejercicio-para-mejorar-la-eficacia-de-la-quimiorradioterapia-prolongada-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06276686/exercise-for-improving-long-course-chemoradiotherapy-efficacy-in-people-with-locally-advanced-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04928807/radioterapia-de-corta-duracion-seguida-de-quimioterapia-neoadyuvante-y-camrelizumab-en-el-cancer-colorrectal-localmente-avanzado-union 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04928807/short-course-radiotherapy-followed-by-neoadjuvant-chemotherapy-and-camrelizumab-in-locally-advanced-rectal-cancer-union 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07536321/precision-diagnostica-y-valor-pronostico-de-la-tomografia-por-emision-de-positrones-con-18f-fdg-18f-fdg-pet-ct-en-el-seguimiento-de-pacientes-con-carcinoma-colorrectal 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07536321/diagnostic-accuracy-and-prognostic-value-of-18f-fdg-pet-ct-in-the-follow-up-of-patients-with-colorectal-carcinoma 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07104877/un-estudio-de-sys6010-en-combinacion-con-syh2051-en-pacientes-con-cancer-colorrectal-avanzado-y-otros-tumores-gastrointestinales 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07104877/a-study-of-sys6010-in-combination-with-syh2051-in-patients-with-advanced-colorectal-cancer-and-other-gastrointestinal-tumors 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03981497/ablacion-por-microondas-para-el-tratamiento-de-tumores-renales-pequenos-y-neoplasias-hepaticas-primarias-y-secundarias 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03981497/microwave-ablation-for-treatment-of-small-renal-tumors-and-primary-and-secondary-liver-neoplasms 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07020468/terapia-neoadyuvante-nalirifox-para-el-cancer-colorrectal-localmente-avanzado-y-el-cancer-del-recto-superior 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07020468/neoadjuvant-therapy-nalirifox-for-locally-advanced-colon-and-upper-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05601505/estrategia-de-tratamiento-neoadyuvante-guiada-por-el-adn-tumoral-circulante-para-el-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05601505/circulating-tumor-dna-guided-neoadjuvant-treatment-strategy-for-locally-advanced-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07542704/un-estudio-para-investigar-la-seguridad-y-la-eficacia-de-kqb368-como-terapia-unica-en-participantes-con-tumores-solidos-avanzados 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07542704/a-study-to-investigate-the-safety-and-efficacy-of-kqb368-as-monotherapy-in-participants-with-advanced-solid-malignancies 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT02359565/pembrolizumab-en-el-tratamiento-de-pacientes-jovenes-con-gliomas-de-alto-grado-recurrentes-progresivos-o-refractarios-gliomas-intrinsecos-del-tronco-encefalico-difusos-tumores-cerebrales-hipermutados 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT02359565/pembrolizumab-in-treating-younger-patients-with-recurrent-progressive-or-refractory-high-grade-gliomas-diffuse-intrinsic-pontine-gliomas-hypermutated-brain-tumors-ependymoma-or-medulloblastoma 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07359989/leucina-mas-quimiorradioterapia-para-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07359989/leucine-plus-radiochemotherapy-for-neoadjuvant-treatment-of-locally-advanced-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05772923/preservacion-de-organos-en-el-cancer-de-recto-braquiterapia-de-contacto-con-rayos-x-frente-a-la-prolongacion-del-intervalo-de-espera-y-la-escision-local 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05772923/organ-preservation-in-rectal-cancer-contact-x-ray-brachytherapy-vs-extending-the-waiting-interval-and-local-excision 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07154316/ensayo-clinico-fase-ii-aleatorizado-y-controlado-que-compara-la-quimiorradioterapia-neoadyuvante-lcrt-frente-a-la-radioterapia-neoadyuvante-de-corta-duracion-scrt-combinada-con-capox-un-inhibidor-de 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07154316/phase-ii-rct-of-lcrt-vs-scrt-capox-pd-1i-cox-2i-in-mss-locally-advanced-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05914766/una-intervencion-informativa-y-de-apoyo-para-pacientes-con-cancer-de-recto-localmente-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05914766/an-informational-and-supportive-care-intervention-for-patients-with-locally-advanced-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06846268/adg126-y-pembrolizumab-como-tratamiento-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06846268/neoadjuvant-adg126-and-pembrolizumab-in-locally-advanced-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07361107/evaluacion-de-la-respuesta-inmune-circulatoria-tras-el-tratamiento-con-histosonics-en-el-cancer-colorrectal-echo-crc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07361107/evaluation-of-circulating-immune-response-after-histosonics-in-colorectal-cancer-echo-crc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365592/quimioterapia-neoadyuvante-anticuerpo-anti-pd-1-y-sitagliptina-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365592/neoadjuvant-chemotherapy-anti-pd-1-antibody-and-sitagliptin-for-locally-advanced-pmmr-crc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06698757/diferentes-ciclos-de-sintilimab-neoadyuvante-preoperatorio-en-cancer-colorrectal-localmente-avanzado-con-deficiencia-en-la-reparacion-de-errores-de-emparejamiento-alta-inestabilidad-de-microsatelites 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06698757/different-cycles-of-preoperative-neoadjuvant-sintilimab-in-mismatch-repair-deficient-microsatellite-instability-high-locally-advanced-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07363863/patron-de-tratamiento-y-resultados-en-el-carcinoma-rectal-localmente-avanzado 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07363863/pattern-of-treatment-and-outcomes-of-locally-advanced-rectal-carcinoma 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06312982/una-serie-de-casos-de-quimiorradioterapia-neoadyuvante-combinada-con-inmunoterapia-para-el-cancer-de-recto-localmente-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06312982/a-series-of-neoadjuvant-chemoradiotherapy-combined-with-immunotherapy-for-locally-advanced-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06210971/quimiorradiacion-neoadyuvante-con-nal-iri-y-capecitabina-guiada-por-el-estado-de-ugt1a1-en-pacientes-con-cancer-de-recto 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06210971/neoadjuvant-chemoradiation-with-nal-iri-and-capecitabine-guided-by-ugt1a1-status-in-patients-with-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07372300/electrohipertermia-modulada-en-combinacion-con-terapia-multimodal-para-el-cancer-de-recto-localmente-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07372300/modulated-electro-hyperthermia-in-combination-with-multimodal-therapy-for-locally-advanced-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07132008/quimioterapia-neoadyuvante-con-capox-mas-tislelizumab-frente-a-capox-en-cancer-colorrectal-localmente-avanzado-de-alto-riesgo-con-mss 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07132008/neoadjuvant-capox-plus-tislelizumab-vs-capox-in-mss-high-risk-locally-advanced-colon-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07183124/modelado-tridimensional-para-la-deteccion-del-cancer-colorrectal-localmente-avanzado-con-margenes-de-reseccion-circunferencial-positivos 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07183124/3d-modeling-for-detecting-locally-advanced-rectal-cancer-with-positive-circumferential-resection-margin 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT02572141/quimioterapia-perioperatoria-con-folfox-o-capox-frente-a-quimioterapia-postoperatoria-para-el-cancer-colorrectal-localmente-avanzado-optical 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT02572141/folfox-or-capox-perioperative-chemotherapy-versus-postoperative-chemotherapy-for-locally-advanced-colon-cancer-optical 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06244537/estudio-sobre-la-seguridad-y-la-eficacia-de-la-tecnica-mr-linac-en-pacientes-con-cancer-colorrectal-localmente-avanzado-irresecable 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06244537/study-on-the-safety-and-efficacy-of-mr-linac-technique-in-patients-with-unresectable-locally-advanced-colon-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06179602/estudio-de-cohorte-prospectivo-sobre-la-ablacion-termica-de-tumores-hepaticos-malignos 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06179602/prospective-cohort-study-on-thermal-ablation-of-malignant-liver-tumors 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06017583/quimioterapia-neoadyuvante-con-inhibidores-de-pd-1-combinada-con-sib-imrt-en-el-tratamiento-del-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06017583/neoadjuvant-chemotherapy-with-pd-1-inhibitors-combined-with-sib-imrt-in-the-treatment-of-locally-advanced-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05228431/regimen-terapeutico-sandwich-modificado-para-el-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05228431/modified-sandwich-therapeutic-regimen-for-locally-advanced-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04512937/cirugia-asistida-por-navegacion-computarizada-para-el-cancer-colorrectal-localmente-avanzado-y-recurrente 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04512937/computer-navigation-assisted-surgery-for-locally-advanced-and-recurrent-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06903858/toripalimab-mas-celecoxib-como-tratamiento-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-dmmr-msi-h 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06903858/toripalimab-plus-celecoxib-for-dmmr-msi-h-locally-advanced-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06287814/evaluacion-francesa-de-la-enfermedad-residual-minima-mediante-biopsias-liquidas-en-pacientes-con-cancer-colorrectal-en-estadio-iii-french-mrd-crc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06287814/french-assessment-of-mrd-by-liquid-biopsies-in-stage-iii-crc-patients-french-mrd-crc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06369259/estudio-de-fase-2-abierto-con-avutometinib-inhibidor-de-raf-mek-en-combinacion-con-defactinib-inhibidor-de-fak-y-cetuximab-en-pacientes-con-cancer-colorrectal-avanzado-irresecable-y-resistente-a-los 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06369259/open-label-phase-2-study-of-avutometinib-raf-mek-clamp-in-combination-with-defactinib-fak-inhibitor-and-cetuximab-in-patients-with-unresectable-anti-egfr-refractory-advanced-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07394192/radioterapia-de-corta-duracion-con-preservacion-de-los-ganglios-linfaticos-que-drenan-el-tumor-seguida-de-inhibidores-de-pd-1-en-el-cancer-de-recto-en-estadio-ii-iii-con-pmmr-mss 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07394192/short-course-radiotherapy-with-tumor-draining-lymph-node-preservation-followed-by-pd-1-inhibitors-in-pmmr-mss-stage-ii-iii-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06753136/electroquimioterapia-ect-en-pacientes-con-tumores-viscerales-primarios-y-o-localizaciones-viscerales-secundarias-de-cualquier-histotipo 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06753136/electrochemotherapy-ect-in-patients-with-primary-visceral-tumors-and-or-secondary-visceral-localizations-of-any-histotype 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06154538/inhibidores-de-los-puntos-de-control-inmunitario-quimioterapia-frente-a-quimioterapia-en-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06154538/immune-checkpoint-inhibitors-chemotherapy-versus-chemotherapy-in-the-neoadjuvant-treatment-of-locally-advanced-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03151564/evaluacion-de-la-deteccion-de-lesiones-en-el-higado-dosis-estandar-frente-a-dosis-baja-de-radiacion-utilizando-diversas-tecnicas-de-postprocesamiento 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03151564/lesion-detection-assessment-in-the-liver-standard-vs-low-radiation-dose-using-varied-post-processing-techniques 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06765616/inyeccion-de-adebrelimab-pd-l1-combinada-con-radioterapia-de-corta-duracion-y-quimioterapia-para-la-terapia-neoadyuvante-del-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06765616/adebrelimab-injection-pd-l1-combined-with-short-course-radiotherapy-and-chemotherapy-for-neoadjuvant-therapy-of-locally-advanced-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07393048/aplicacion-y-exploracion-de-la-tecnologia-de-deteccion-personalizada-de-ctdna-mrd-para-predecir-la-eficacia-de-la-terapia-neoadyuvante-en-el-cancer-de-recto 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07393048/application-and-exploration-of-personalized-ctdna-mrd-detection-technology-in-predicting-the-efficacy-of-neoadjuvant-therapy-for-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07580339/combinacion-de-dcsz11-con-radioterapia-y-quimioterapia-como-tratamiento-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-con-pmmr 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07580339/combining-dcsz11-with-radiation-and-chemotherapy-as-neoadjuvant-treatment-for-pmmr-locally-advanced-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06762405/prodige-90-ffcd-2204-dostarlimab-neoadyuvante-con-radioterapia-de-corta-duracion-en-una-estrategia-de-observacion-y-espera-para-pacientes-con-cancer-colorrectal-localmente-avanzado-inestable-en 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06762405/prodige-90-ffcd-2204-neoadjuvant-dostarlimab-with-short-course-radiotherapy-in-a-watch-and-wait-strategy-for-microsatellite-unstable-or-mismatch-repair-deficient-locally-advanced-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06940388/tratamiento-neoadyuvante-total-con-o-sin-tislelizumab-para-el-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06940388/total-neoadjuvant-treatment-with-or-without-tislelizumab-for-locally-advanced-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07403877/inmunoterapia-neoadyuvante-radioterapia-en-cancer-colorrectal-localmente-avanzado-msi-h-dmmr 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07403877/neoadjuvant-immunotherapy-radiotherapy-in-msi-h-dmmr-locally-advanced-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05731726/serplulimab-en-combinacion-con-capeox-y-celecoxib-como-tratamiento-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05731726/serplulimab-combined-with-capeox-celecoxib-as-neoadjuvant-treatment-for-locally-advanced-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05212012/d-l-metadona-y-mfolfox6-en-el-tratamiento-del-cancer-colorrectal-avanzado 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05212012/d-l-methadone-and-mfolfox6-in-treatment-of-advanced-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04223102/microbioma-y-cancer-de-recto 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04223102/microbiome-and-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03391843/quimioterapia-neoadyuvante-combinada-con-cetuximab-para-el-cancer-colorrectal-localmente-avanzado-con-egfr-de-tipo-salvaje 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03391843/neoadjuvant-chemotherapy-combined-with-cetuximab-for-egfr-wild-type-locally-advanced-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07409844/inmunoterapia-neoadyuvante-y-tratamiento-conservador-de-organos-en-pacientes-con-cancer-de-colon-en-estadio-i-iii-con-dmmr 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07409844/neoadjuvant-immunotherapy-and-organ-sparing-treatment-in-patients-with-stage-i-iii-dmmr-colon-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06855355/cbm588-reduce-la-recurrencia-de-polipos-colorrectales 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06855355/cbm588-reduces-colorectal-polyp-recurrence 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03525262/terapia-oncologica-para-el-cancer-de-prostata-que-garantiza-la-preservacion-de-los-nervios-y-los-vasos-sanguineos-poten-c 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03525262/prostate-oncologic-therapy-while-ensuring-neurovascular-conservation-poten-c 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07210502/efectos-secundarios-de-la-braquiterapia-de-baja-dosis-y-la-radioterapia-ultrafraccionada-en-el-cancer-de-prostata-de-riesgo-bajo-a-intermedio 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07210502/side-effects-of-low-dose-rate-brachytherapy-and-ultra-hypofractionated-radiotherapy-in-low-to-intermediate-risk-prostate-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05999812/ensayo-clinico-de-acido-al-trans-retinoico-bevacizumab-y-atezolizumab-en-cancer-colorrectal 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05999812/clinical-trial-of-all-trans-retinoic-acid-bevacizumab-and-atezolizumab-in-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07413146/quimioterapia-neoadyuvante-con-capeox-frente-a-cirugia-inicial-en-cancer-colorrectal-localmente-avanzado-con-niveles-elevados-de-cea-un-ensayo-clinico-aleatorizado-abierto-y-de-un-solo-centro 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07413146/neoadjuvant-capeox-versus-upfront-surgery-for-locally-advanced-colon-cancer-with-elevated-cea-a-single-center-open-label-randomized-controlled-trial 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06207981/estudio-de-fase-iii-que-evalua-la-quimioterapia-de-induccion-seguida-de-quimiorradioterapia-en-comparacion-con-la-quimiorradioterapia-estandar-para-el-carcinoma-de-celulas-escamosas-localmente 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06207981/phase-iii-study-evaluating-induction-chemotherapy-followed-by-chemoradiotherapy-compared-to-standard-chemoradiotherapy-for-locally-advanced-scca 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229041/tratamiento-neoadyuvante-total-inmunoterapia-para-cancer-colorrectal-localmente-avanzado-de-alto-riesgo-tnti 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06229041/total-neoadjuvant-treatment-immunotherapy-for-high-risk-locally-advanced-rectal-cancer-tnti 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06853769/terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06853769/neoadjuvant-therapy-for-locally-advanced-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT01696981/deteccion-del-cancer-colorrectal-en-pacientes-de-edad-avanzada-ensayo-de-deteccion-plco 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT01696981/screening-for-colorectal-cancer-in-older-patients-plco-screening-trial 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06035133/tratamiento-del-cancer-colorrectal-localmente-avanzado-con-radioterapia-eliminacion-de-la-terapia-tnt-y-terapia-neoadyuvante 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06035133/treatment-of-low-locally-advanced-rectal-cancer-with-radiotherapy-removal-tnt-plus-neoadjuvant-therapy 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03997435/folfoxiri-con-o-sin-intensificacion-para-el-cancer-de-recto 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03997435/folfoxiri-with-or-without-intensification-for-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07118800/estudio-que-evalua-dos-estrategias-de-tratamiento-para-el-cancer-de-recto-en-pacientes-75-anos 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07118800/study-evaluating-two-treatment-strategies-for-rectal-cancer-in-patients-75-years-old 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07407647/dhea-vaginal-para-mejorar-la-salud-vaginal-despues-de-la-radioterapia-en-mujeres-con-cancer-ginecologico-anal-o-de-recto 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07407647/vaginal-dhea-to-improve-vaginal-health-after-radiation-for-women-with-gynecologic-anal-or-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07405476/zanidatamab-antes-de-la-cirugia-para-el-tratamiento-del-cancer-colorrectal-her2-positivo-en-pacientes-candidatos-a-tratamiento-con-intencion-curativa 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07405476/zanidatamab-before-surgery-for-the-treatment-of-her2-positive-colon-and-rectal-cancer-in-patients-planned-for-curative-intent-treatment 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05054959/quimioterapia-de-consolidacion-frente-a-quimioterapia-de-induccion-en-la-terapia-neoadyuvante-total-del-cancer-de-recto-con-alto-riesgo-de-recurrencia 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05054959/consolidation-versus-induction-chemotherapy-in-total-neoadjuvant-therapy-of-rectal-cancer-with-high-risk-for-recurrence 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07425054/quimiocirradiacion-adaptada-a-la-respuesta-del-adn-tumoral-circulante-de-vph-tratamiento-con-retifanlimab-en-cancer-anal-en-estadio-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07425054/cthpvdna-response-adapted-chemoradiation-retifanlimab-treatment-in-locally-advanced-anal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05148767/terapia-con-irinotecan-basada-en-ugt1a1-para-el-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05148767/ugt1a1-based-irinotecan-therapy-for-locally-advanced-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05984485/la-eficacia-de-la-cirugia-primaria-de-reseccion-total-del-mesorrecto-tme-frente-a-la-quimioterapia-neoadyuvante-combinada-con-la-cirugia-tme-en-el-cancer-colorrectal-localmente-avanzado-de-bajo-riesgo 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05984485/the-efficacy-of-primary-total-mesorectal-excision-tme-surgery-versus-neoadjuvant-chemotherapy-combined-with-tme-surgery-in-low-risk-locally-advanced-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06998758/megestrol-acetato-para-mejorar-la-perdida-de-peso-relacionada-con-la-quimioterapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06998758/megestrol-acetate-in-improving-neoadjuvant-chemotherapy-related-weight-loss-in-locally-advanced-crc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03875781/estudio-de-no-inferioridad-de-la-quimioterapia-preoperatoria-sin-irradiacion-pelvica-para-el-cancer-de-recto 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03875781/non-inferiority-study-of-preoperative-chemotherapy-without-pelvic-irradiation-for-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06831981/hipertermia-con-quimiorradioterapia-en-el-cancer-de-recto 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06831981/hyperthermia-with-chemoradiotherapy-in-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277842/pd-1-folfoxiri-frente-a-capox-como-terapia-neoadyuvante-total-para-cancer-de-recto-pmmr 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07277842/pd-1-folfoxiri-vs-capox-as-total-neoadjuvant-therapy-for-pmmr-low-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06424522/un-programa-de-manejo-intestinal-enema-rectal-retrogrado-para-el-tratamiento-del-sindrome-de-reseccion-anterior-baja-en-pacientes-con-cancer-de-recto 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06424522/a-bowel-management-program-retrograde-rectal-enema-for-the-treatment-of-low-anterior-resection-syndrome-in-rectal-cancer-patients 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07192627/reseccion-endoscopica-con-dispositivo-de-corte-esd-en-el-cancer-colorrectal-localmente-avanzado-tras-quimiorradioterapia-qrt 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07192627/esd-in-locally-advanced-rectal-cancer-following-crt 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06812728/quimioterapia-neoadyuvante-con-folfirinox-y-quimiorradioterapia-preoperatoria-para-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06812728/neoadjuvant-folfirinox-and-preoperative-chemoradiotherapy-for-locally-advanced-rectal-cancer-patients 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05108298/mejora-de-los-datos-autoinformados-por-adolescentes-y-adultos-jovenes-en-los-ensayos-clinicos-de-ecog-acrin 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05108298/improving-adolescent-and-young-adult-self-reported-data-in-ecog-acrin-trials 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06596343/evaluacion-de-los-beneficios-de-la-medicina-tradicional-china-personalizada-en-el-tratamiento-postoperatorio-del-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06596343/evaluating-the-benefits-of-personalized-traditional-chinese-medicine-in-postoperative-treatment-for-locally-advanced-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07433283/nanoparticulas-de-carbono-cargadas-con-hierro-en-el-tratamiento-de-tumores-solidos-avanzados 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07433283/carbon-nanoparticle-loaded-iron-in-the-treatment-of-advanced-solid-tumor 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05673772/radioterapia-secuencial-preoperatoria-de-corta-duracion-y-folfox-para-el-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05673772/preoperative-sequential-short-course-radiation-therapy-and-folfox-for-locally-advanced-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05201430/quimioterapia-neoadyuvante-con-folfoxiri-frente-a-capeox-en-el-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05201430/neoadjuvant-folfoxiri-versus-capeox-chemotherapy-for-local-advanced-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06722534/celecoxib-para-la-prevencion-de-la-progresion-en-el-sindrome-de-peutz-jeghers 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06722534/celecoxib-for-prevention-of-progression-in-peutz-jeghers-syndrome 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05450029/quimiorradioterapia-neoadyuvante-mas-sintilimab-para-el-cancer-colorrectal-localmente-avanzado-de-riesgo-intermedio-alto-segun-el-indice-de-inmunidad 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05450029/neoadjuvant-chemoradiotherapy-plus-sintilimab-for-intermediate-high-immunoscore-locally-advanced-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05009069/un-estudio-de-atezolizumab-con-o-sin-tiragolumab-tras-la-quimiorradioterapia-neoadyuvante-en-participantes-con-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05009069/a-study-of-atezolizumab-with-or-without-tiragolumab-following-neoadjuvant-chemoradiotherapy-in-participants-with-locally-advanced-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06640049/un-estudio-de-dostarlimab-en-participantes-con-cancer-colorrectal-localmente-avanzado-no-tratado-en-china 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06640049/a-study-of-dostarlimab-in-participants-with-untreated-locally-advanced-rectal-cancer-in-china 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05355701/un-estudio-para-evaluar-el-medicamento-de-investigacion-pf-07799933-en-personas-con-tumores-solidos-avanzados-con-alteraciones-en-el-gen-braf 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05355701/a-study-to-learn-about-the-study-medicine-called-pf-07799933-in-people-with-advanced-solid-tumors-with-braf-alterations 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07134101/terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado-en-el-recto-inferior-smarti-rc01 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07134101/neoadjuvant-therapy-for-locally-advanced-low-rectal-cancer-smarti-rc01 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07433673/gemcitabina-cisplatino-nab-paclitaxel-gap-y-cemiplimab-para-el-cancer-de-las-vias-biliares-localmente-avanzado-btc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07433673/gemcitabine-cisplatin-nab-paclitaxel-gap-and-cemiplimab-for-locally-advanced-biliary-tract-cancer-btc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05563922/estrategia-de-preservacion-organica-mediante-quimiorradioterapia-neoadyuvante-total-para-el-carcinoma-rectal-bajo 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05563922/organ-preservation-strategy-of-total-neoadjuvant-chemoradiotherapy-for-low-rectal-carcinoma 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04230759/radioterapia-y-quimioterapia-con-o-sin-durvalumab-para-el-carcinoma-anal-localmente-avanzado-un-ensayo-multicentrico-aleatorizado-de-fase-ii-del-grupo-de-estudio-del-cancer-anal-aleman 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04230759/radiochemotherapy-durvalumab-for-locally-advanced-anal-carcinoma-a-multicenter-randomized-phase-ii-trial-of-the-german-anal-cancer-study-group 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05674422/estudio-gemcad-reveal-el-adn-tumoral-circulante-como-predictor-de-recurrencia-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05674422/gemcad-reveal-study-circulating-tumor-dna-as-a-predictor-of-relapse-in-patients-with-locally-advanced-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06718543/radioterapia-neoadyuvante-de-corta-duracion-con-o-sin-quimioterapia-y-ak112-en-el-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06718543/neoadjuvant-short-course-radiotherapy-with-or-without-chemotherapy-and-ak112-in-locally-advanced-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06948448/un-estudio-para-evaluar-la-seguridad-y-la-eficacia-de-dos-dosis-de-ono-4578-en-combinacion-con-opdivo-r-mas-mfolfox6-y-bevacizumab-en-comparacion-con-el-tratamiento-estandar-en-participantes-con 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06948448/a-study-to-evaluate-the-safety-and-efficacy-of-two-dose-levels-of-ono-4578-with-opdivo-r-in-combination-with-mfolfox6-and-bevacizumab-versus-standard-of-care-in-participants-with-non-msi-h-dmmr-pd-l1 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05794750/evaluar-la-eficacia-de-la-radioterapia-y-la-quimioterapia-secuencial-asi-como-de-ak104-antes-de-la-cirugia-de-reseccion-mesenterica-total-tme-en-el-cancer-colorrectal-local-ak104-iit-13 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05794750/assess-the-efficacy-of-radiotherapy-and-sequential-chemotherapy-and-ak104-before-tme-surgery-for-local-crc-ak104-iit-13 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07683949/ensayo-clinico-que-evalua-la-eficacia-de-capecitabina-mas-lenvatinib-en-pacientes-con-cancer-colorrectal-avanzado-refractario-a-irinotecan-oxaliplatino-y-fluoropirimidina 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07683949/clinical-trial-evaluating-the-efficacy-of-capecitabine-plus-lenvatinib-in-patients-with-advanced-colorectal-cancer-refractory-to-irinotecan-oxaliplatin-and-fluoropyrimidine 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05722288/alimentacion-con-horarios-restringidos-frente-a-asesoramiento-nutricional-para-la-reduccion-de-los-efectos-secundarios-del-tratamiento-con-radioterapia-o-quimiorradioterapia-en-pacientes-con-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05722288/time-restricted-eating-versus-nutritional-counseling-for-the-reduction-of-radiation-or-chemoradiation-tx-side-effects-in-patients-with-prostate-cervical-or-rectal-cancers 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04713618/cambios-en-la-salud-pelvica-la-funcion-sexual-y-la-calidad-de-vida-en-mujeres-con-cancer-pelvico-que-se-someten-a-radioterapia 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04713618/changes-in-pelvic-health-sexual-function-and-quality-of-life-in-women-with-pelvic-cancer-undergoing-radiation-therapy 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04920149/programa-de-prevencion-del-cancer-colorrectal-con-mesalamina-en-el-sindrome-de-lynch 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04920149/mesalamine-for-colorectal-cancer-prevention-program-in-lynch-syndrome 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07166263/seguridad-y-eficacia-de-nk510-en-el-tratamiento-del-cancer-gastrico-y-del-cancer-colorrectal 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07166263/safety-and-efficacy-of-nk510-to-treat-gastric-cancer-and-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06307249/terapia-de-precision-para-tumores-solidos-inhibicion-sinergica-de-cdk4-6-y-terapia-dirigida-anti-vegf-mediante-arn-no-codificante-largo-lncrna 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06307249/precision-therapy-for-solid-tumors-synergistic-cdk4-6-inhibition-and-anti-vegf-targeting-lncrna 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06550453/seguridad-y-eficacia-de-pembrolizumab-en-combinacion-con-bevacizumab-y-capecitabina-mas-oxaliplatino-en-el-tratamiento-neoadyuvante-del-cancer-colorrectal-localmente-avanzado-con-mutacion-en-ras-braf 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06550453/safety-and-efficacy-of-pembrolizumab-in-combination-with-bevacizumab-capeox-in-the-neoadjuvant-treatment-of-ras-mutated-braf-wild-type-microsatellite-stabilized-locally-advanced-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06307548/cirugia-guiada-por-imagen-de-fluorescencia-seguida-de-terapia-fotodinamica-intraoperatoria-para-mejorar-el-control-tumoral-local-en-pacientes-con-cancer-colorrectal-localmente-avanzado-o-recurrente 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06307548/fluorescence-image-guided-surgery-followed-by-intraoperative-photodynamic-therapy-for-improving-local-tumor-control-in-patients-with-locally-advanced-or-recurrent-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04677413/radioterapia-ultrafraccionada-para-el-cancer-de-recto 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04677413/ultra-fractionated-radiotherapy-for-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04215731/mfolfoxiri-neoadyuvante-mas-bevacizumab-en-pacientes-con-cancer-colorrectal-localmente-avanzado-de-alto-riesgo 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04215731/neoadjuvant-mfolfoxiri-plus-bevacizumab-in-patients-with-high-risk-locally-advanced-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04749108/estudio-que-evalua-el-tratamiento-personalizado-del-carcinoma-rectal-localmente-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04749108/study-evaluating-the-tailored-management-of-locally-advanced-rectal-carcinoma 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05780684/escalada-de-dosis-individualizada-de-5-fu-para-el-cancer-gastrointestinal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05780684/individualized-dose-escalation-of-5-fu-for-gastrointestinal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05794971/regorafenib-en-combinacion-con-irinotecan-administrado-mediante-microesferas-de-liberacion-de-farmacos-para-metastasis-hepaticas-del-cancer-colorrectal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05794971/regorafenib-combined-with-irinotecan-drug-eluting-beads-for-colorectal-cancer-liver-metastases 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04489238/recopilacion-de-informacion-para-comprender-mejor-el-cancer-colorrectal-de-inicio-temprano 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04489238/collection-of-information-to-better-understand-young-onset-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07176182/ensayo-clinico-de-mfolfox-neoadyuvante-mas-alvenor-en-pacientes-con-cancer-colorrectal-localmente-avanzado-larc-con-alta-expresion-de-ywhab 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07176182/clinical-trial-of-neoadjuvant-mfolfox-plus-alvenor-for-larc-patients-with-high-ywhab-expression 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06254521/los-efectos-del-tratamiento-neoadyuvante-con-tislelizumab-en-combinacion-con-quimioterapia-en-el-cancer-colorrectal-localmente-avanzado-mss 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06254521/the-effects-of-neoadjuvant-tislelizumab-combined-with-chemotherapy-in-locally-advanced-mss-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07696793/eficacia-y-tolerabilidad-de-una-solucion-evacuante-que-contiene-simeticona-para-la-colonoscopia-de-cribado-del-cancer-colorrectal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07696793/efficacy-and-tolerability-of-a-simethicone-containing-evacuating-solution-for-colorectal-cancer-screening-colonoscopy 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06402864/evaluacion-del-contacto-con-rayos-x-y-la-braquiterapia-para-la-preservacion-del-recto-en-el-adenocarcinoma-rectal-de-estadio-intermedio 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06402864/evaluation-contact-x-ray-brachytherapy-for-rectal-preservation-in-intermediate-substage-rectal-adenocarcinoma 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06890624/mfolfoxiri-mas-inhibidor-de-pd-1-frente-a-mfolfox6-como-terapia-neoadyuvante-para-el-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06890624/mfolfoxiri-plus-pd-1-inhibitor-vs-mfolfox6-as-neoadjuvant-therapy-for-locally-advanced-colon-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07596290/yang-et-al-inmunoterapia-dual-anti-pd-1-ctla-4-para-el-cancer-colorrectal-localmente-avanzado-larc 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07596290/yang-et-al-anti-pd-1-ctla-4-dual-immunotherapy-for-larc 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT02843191/quimioterapia-de-consolidacion-para-el-cancer-de-recto-localmente-avanzado-ya-sea-de-localizacion-media-o-baja-tras-la-quimiorradioterapia-neoadyuvante-concurrente 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT02843191/consolidation-chemotherapy-for-locally-advanced-mid-or-low-rectal-cancer-after-neoadjuvant-concurrent-chemoradiotherapy 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06832917/radioterapia-de-corta-duracion-scrt-seguida-de-6-ciclos-de-cadonilimab-mas-mfolfox6-como-terapia-neoadyuvante-para-pacientes-con-cancer-colorrectal-localmente-avanzado-larc-un-ensayo-multicentrico-de 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06832917/short-course-radiation-scrt-followed-by-6-cycles-of-cadonilimab-plus-mfolfox6-as-neoadjuvant-therapy-for-patients-with-locally-advanced-rectal-cancer-larc-a-multicenter-two-arm-parallel-open-label 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06783491/eficacia-del-uso-de-la-quimioterapia-neoadyuvante-con-o-sin-hipertermia-intraabdominal-en-el-tratamiento-del-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06783491/efficacy-of-the-use-of-neoadjuvant-with-without-hyperthermic-intraperitoneal-chemotherapy-in-the-treatment-of-locally-advanced-colon-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06620627/recopilacion-prospectiva-de-muestras-para-permitir-el-desarrollo-del-ensayo-de-deteccion-temprana-del-cancer-de-natera 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06620627/prospective-collection-of-samples-to-enable-the-development-of-natera-screening-assay-for-early-cancer-detection 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07600125/evaluacion-de-biomarcadores-fecales-multiobjetivo-en-el-cribado-de-canceres-del-tracto-digestivo 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07600125/evaluation-of-fecal-multi-target-biomarkers-in-the-screening-of-digestive-tract-cancers 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT01918527/quimioterapia-neoadyuvante-frente-al-tratamiento-estandar-en-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT01918527/neoadjuvant-chemotherapy-versus-standard-treatment-in-patients-with-locally-advanced-colon-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06616870/estudio-del-papel-predictivo-y-pronostico-de-las-variantes-farmacogeneticas-y-radiogenicas-en-la-respuesta-al-tratamiento-neoadyuvante-con-quimiorradiacion-en-pacientes-con-cancer-colorrectal 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06616870/study-of-the-predictive-and-prognostic-role-of-pharmacogenetic-and-radiogenic-variants-on-the-response-to-neoadjuvant-chemoradiation-therapy-in-patients-with-locally-advanced-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07472868/quimioterapia-neoadyuvante-con-folfoxiri-y-quimiorradioterapia-frente-a-quimioterapia-neoadyuvante-con-capox-folfox-y-quimiorradioterapia-seguida-de-cirugia-o-una-estrategia-de-observacion-activa-en 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07472868/neoadjuvant-folfoxiri-and-chemoradiotherapy-versus-neoadjuvant-capox-folfox-and-chemoradiotherapy-followed-by-surgery-or-a-watch-and-wait-approach-in-high-risk-locally-advanced-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03840239/tnt-para-aumentar-la-tasa-de-respuesta-completa-clinica-en-el-cancer-colorrectal-localizado-en-la-parte-distal 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03840239/tnt-to-increase-the-clinical-complete-response-rate-for-distal-larc 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06964438/estimulacion-electrica-muscular-postoperatoria-segunda-sesion 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06964438/postoperative-electrical-muscle-stimulation-two 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06014944/radioterapia-de-corta-duracion-combinada-con-furoquintinib-y-anticuerpo-monoclonal-anti-pd-1 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06014944/short-course-radiotherapy-combined-with-furoquintinib-and-pd-1-monoclonal-antibody 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04701476/tate-y-pembrolizumab-mk3475-en-el-tratamiento-del-mcrc-y-el-nsclc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04701476/tate-and-pembrolizumab-mk3475-in-mcrc-and-nsclc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06563388/radioterapia-ablativa-estereotactica-sabr-para-el-tratamiento-de-pacientes-con-cancer-metastasico-ensayo-id-comet 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06563388/stereotactic-ablative-radiotherapy-sabr-for-the-treatment-of-patients-with-metastatic-cancer-id-comet-trial 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224841/desarrollo-de-un-panel-de-biomarcadores-basado-en-la-metilacion-de-la-cfdna-5mc-5hmc-para-predecir-la-eficacia-de-las-terapias-dirigidas-en-el-mcrc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224841/development-of-a-cfdna-5mc-5hmc-based-biomarker-panel-to-predict-targeted-therapy-efficacy-in-mcrc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07720115/ensayo-de-fase-ii-de-s-531011-en-combinacion-con-radscopal-en-pacientes-con-cancer-colorrectal-metastasico-previamente-tratados 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07720115/phase-2-trial-of-s-531011-with-radscopal-in-previously-treated-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03828227/calidad-de-vida-en-pacientes-ancianos-con-cancer-colorrectal-metastasico-que-reciben-terapia-de-primera-linea-basada-en-parametros-geriatricos-simplificados 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03828227/qol-in-mcrc-elderly-patients-receiving-first-line-therapy-based-on-simplified-geriatric-parameters 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT02246634/deteccion-de-metastasis-sincronicas-en-el-cancer-colorrectal-mediante-resonancia-magnetica-con-difusion-serenade 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT02246634/screening-for-synchronous-metastases-in-colorectal-cancer-with-dw-mri-serenade 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05608044/un-estudio-de-botensilimab-y-balstilimab-para-el-tratamiento-del-cancer-colorrectal 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05608044/a-study-of-botensilimab-and-balstilimab-for-the-treatment-of-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07050394/un-ensayo-de-expansion-de-dosis-de-hnf4-srrna-intravenoso-para-el-cancer-colorrectal-irresecable-o-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07050394/a-dose-expansion-trial-of-intravenous-hnf4-srrna-for-unresectable-or-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05959356/cetuximab-y-envafolimab-mas-mfolfoxiri-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-irresecable-del-lado-izquierdo-con-ras-braf-de-tipo-salvaje-y-mss 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05959356/cetuximab-and-envafolimab-plus-mfolfoxiri-as-first-line-treatment-for-ras-braf-wild-type-mss-unresectable-left-side-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07724223/fruquintinib-mas-anticuerpo-anti-egfr-para-el-tratamiento-en-tercera-linea-del-mcrc-con-ras-tipo-salvaje 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07724223/fruquintinib-plus-anti-egfr-antibody-for-third-line-treatment-of-ras-wild-type-mcrc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06936527/xs-03-en-combinacion-con-folfox-o-folfiri-y-bevacizumab-para-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-en-el-gen-ras 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06936527/xs-03-in-combination-with-folfox-or-folfiri-and-bevacizumab-for-treatment-of-metastatic-colorectal-cancer-patients-with-ras-mutation 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06826092/metformina-para-el-tratamiento-de-pacientes-con-mcrc-que-reciben-folfiri-mas-terapia-dirigida 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06826092/metformin-for-the-treatment-of-mcrc-patients-undergoing-folfiri-plus-target-therapy 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06090994/prevencion-de-la-recurrencia-y-la-metastasis-del-cancer-colorrectal-mediante-la-comparacion-de-huaier-con-la-monoterapia-con-capecitabina 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06090994/prevention-of-recurrence-and-metastasis-of-colorectal-cancer-by-comparing-huaier-with-capecitabine-monotherapy 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07729605/folfiri-mas-bevacizumab-y-ql1706-como-tratamiento-de-segunda-linea-para-el-mcrc 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07729605/folfiri-plus-bevacizuamb-and-ql1706-in-second-line-treatment-for-mcrc 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06578559/estudio-de-fase-ii-de-encorafenib-mas-cetuximab-con-retratamiento-guiado-por-ctdna-en-pacientes-con-mcrc-con-mutacion-braf-v600e 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06578559/phase-ii-study-of-ctdna-guided-encorafenib-plus-cetuximab-retreatment-in-patients-braf-v600e-mutated-mcrc 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04991948/estudio-del-tratamiento-con-pembrolizumab-tras-la-administracion-de-cyad-101-con-acondicionamiento-previo-con-folfox-en-el-cancer-colorrectal-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04991948/study-of-pembrolizumab-treatment-after-cyad-101-with-folfox-preconditioning-in-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07030257/estudio-de-cp-383-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07030257/study-of-cp-383-in-patients-with-advanced-or-metastatic-solid-tumors 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07617610/resistencia-primaria-y-adquirida-al-tratamiento-dirigido-en-el-cancer-colorrectal-metastasico-con-mutacion-braf-v600e 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07617610/primary-and-acquired-resistance-to-targeted-treatment-in-braf-v600e-mutated-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT01762813/evaluacion-de-los-resultados-clinicamente-relevantes-y-analisis-de-biomarcadores-para-su-integracion-traslacional-en-el-cancer-colorrectal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT01762813/assessment-of-clinically-related-outcomes-and-biomarker-analysis-for-translational-integration-in-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07306390/distribucion-y-analisis-de-los-ganglios-linfaticos-metastasicos-en-pacientes-con-cancer-colorrectal-diamond 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07306390/distribution-and-analysis-of-metastatic-lymph-nodes-in-colorectal-cancer-patients-diamond 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07503756/js212-terapias-combinadas-en-el-cancer-colorrectal-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503756/js212-combination-therapies-in-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06959693/un-estudio-clinico-para-evaluar-la-eficacia-y-la-seguridad-de-envafolimab-en-combinacion-con-cetuximab-y-mfolfox6-en-pacientes-con-cancer-colorrectal-metastasico-mcrc-mss-y-ras-braf-de-tipo-salvaje 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06959693/a-clinical-study-to-evaluate-the-efficacy-and-safety-of-envafolimab-combined-with-cetuxima-and-mfolfox6-in-patients-with-mss-ras-braf-wild-type-metastatic-colorectal-cancer-mcrc 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04959604/mapeo-de-los-ganglios-linfaticos-mediante-un-tinte-fluorescente-en-el-cancer-de-colon 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04959604/lymph-node-mapping-via-flourescent-dye-in-colon-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04678583/reseccion-anatomica-de-metastasis-hepaticas-en-pacientes-con-cancer-colorrectal-con-mutaciones-en-los-genes-ras 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04678583/anatomical-resection-of-liver-metastases-in-patients-with-ras-mutated-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06258525/same-en-la-prevencion-de-la-lesion-hepatica-asociada-a-oxaliplatino 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06258525/same-in-prevention-of-oxaliplatin-associated-liver-injury 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06111105/guia-mrd-01-crc-validacion-clinica-y-evaluacion-comparativa-de-los-mejores-diagnosticos-de-ctadn-en-el-cancer-colorrectal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06111105/guide-mrd-01-crc-clinical-validation-and-benchmarking-of-top-performing-ctdna-diagnostics-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07743723/un-estudio-de-iov-5001-en-adultos-con-tumores-solidos-avanzados 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07743723/a-study-of-iov-5001-in-adults-with-advanced-solid-tumors 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05299840/impacto-del-uso-del-dispositivo-oncogramme-r-en-la-seleccion-del-tratamiento-de-primera-linea-para-pacientes-con-cancer-colorrectal-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05299840/impact-of-using-the-oncogramme-r-device-to-select-the-first-line-of-treatment-for-patients-with-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07031570/eficacia-y-seguridad-de-la-combinacion-de-deb-tace-con-haic-frente-a-haic-sola-en-pacientes-con-metastasis-hepaticas-irresecables-de-cancer-colorrectal-crlm 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07031570/efficacy-and-safety-of-deb-tace-combined-with-haic-versus-haic-alone-in-patients-with-unresectable-crlm 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07321106/un-estudio-para-investigar-la-seguridad-la-tolerabilidad-la-farmacocinetica-y-la-actividad-antitumoral-de-cbi-1214-un-activador-de-celulas-t-en-participantes-con-cancer-colorrectal-avanzado-o 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07321106/a-study-to-investigate-the-safety-tolerability-pharmacokinetics-and-anti-tumor-activity-of-cbi-1214-t-cell-engager-in-participants-with-advanced-or-metastatic-mss-msi-l-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04564898/trifluridina-tipiracil-en-combinacion-con-capecitabina-y-bevacizumab-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04564898/trifluridine-tipiracil-in-combination-with-capecitabine-and-bevacizumab-in-metastatic-colorectal-cancer-patients 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05854498/irinotecan-liposomal-en-combinacion-con-tas102-y-bevacizumab-para-pacientes-con-cancer-colorrectal-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05854498/liposomal-irinotecan-with-tas102-and-bevacizumab-for-patients-with-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07623174/un-estudio-de-fruquintinib-en-adultos-con-cancer-colorrectal-metastasico-en-polonia 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07623174/a-study-of-fruquintinib-in-adults-with-metastatic-colorectal-cancer-in-poland 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05185245/trasplante-hepatico-para-metastasis-hepaticas-de-cancer-colorrectal-no-susceptibles-de-reseccion 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05185245/liver-transplantation-for-non-resectable-colorectal-liver-metastasis 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06470178/un-estudio-en-el-mundo-real-sobre-la-terapia-neoadyuvante-de-conversion-para-el-cancer-colorrectal-con-quimioterapia-y-agentes-dirigidos-antiangiogenicos 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06470178/a-real-world-study-of-neoadjuvant-conversion-therapy-for-colorectal-cancer-with-chemotherapy-and-anti-angiogenic-targeted-agents 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07512674/radioterapia-de-curso-corto-modificada-combinada-con-inmunoterapia-quimioterapia-y-terapia-dirigida-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-mss 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07512674/modified-short-course-radiotherapy-combined-with-immunochemotherapy-and-targeted-therapy-as-first-line-treatment-for-mss-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07321847/inyeccion-de-ip-001-en-tumores-hepaticos-sometidos-a-ablacion-termica-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07321847/injection-of-ip-001-into-thermally-ablated-hepatic-tumors-in-patients-with-colorectal-liver-metastases 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07752875/un-estudio-de-lg00313112-en-participantes-con-tumores-solidos-avanzados-que-presentan-una-mutacion-y220c-en-el-gen-tp53 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07752875/a-study-of-lg00313112-in-participants-with-advanced-solid-malignancies-harboring-a-tp53-y220c-mutation 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05931445/estudio-de-resultados-informados-por-el-paciente-mediante-un-sistema-de-monitorizacion-electronica-para-cancer-solido-avanzado-o-metastasico 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05931445/patient-reported-outcomes-study-using-electronic-monitoring-system-for-advanced-or-metastatic-solid-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07257653/seguridad-y-eficacia-de-cetuximab-beta-mas-fruquintinib-con-o-sin-inhibidores-de-los-puntos-de-control-inmunitario-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-irresecable 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07257653/the-safety-and-efficacy-of-cetuximab-beta-plus-fruquintinib-with-or-without-immune-checkpoint-inhibitorrs-in-first-line-treatment-of-ras-braf-wild-type-unresectable-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06287723/estudio-frances-sobre-la-evaluacion-de-la-enfermedad-residual-minima-mediante-biopsias-liquidas-en-pacientes-con-cancer-colorrectal-y-metastasis-hepaticas-french-mrd-crlm 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06287723/french-assessment-of-mrd-by-liquid-biopsies-in-colorectal-with-liver-metastasis-patients-french-mrd-crlm 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06184698/irinotecan-liposomal-y-leucovorina-5-fluorouracilo-mas-bevacizumab-en-el-cancer-colorrectal-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06184698/liposomal-irinotecan-and-leucovorin-5-fluorouracil-plus-bevacizumab-in-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03494946/trasplante-hepatico-en-comparacion-con-quimioterapia-en-pacientes-con-cancer-colorrectal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03494946/liver-transplantation-compared-to-chemotherapy-in-patients-with-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06107413/estudio-para-evaluar-los-eventos-adversos-y-los-cambios-en-la-actividad-de-la-enfermedad-en-participantes-adultos-previamente-tratados-que-reciben-abbv-400-por-via-intravenosa-iv-en-combinacion-con 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06107413/study-to-assess-adverse-events-and-change-in-disease-activity-in-previously-treated-adult-participants-receiving-intravenous-iv-abbv-400-with-unresectable-metastatic-colorectal-cancer-in-combination 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07631884/estudio-exploratorio-sobre-la-eficacia-y-la-seguridad-del-trastuzumab-rezetecan-en-el-tratamiento-de-tumores-solidos-avanzados-con-expresion-de-her2 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07631884/exploratory-study-on-the-efficacy-and-safety-of-trastuzumab-rezetecan-in-the-treatment-of-her2-expressiong-advanced-solid-tumor 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06255379/estudio-de-fruquintinib-en-combinacion-con-tegafur-gimeracil-y-oteracil-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06255379/study-of-fruquintinib-combined-with-tegafur-gimeracil-oteracil-in-patients-with-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07520578/eficacia-de-la-informacion-temprana-y-el-apoyo-por-parte-del-medico-de-cabecera-para-aumentar-el-seguimiento-mediante-colonoscopia-y-reducir-los-retrasos-en-personas-con-un-resultado-positivo-en-la 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07520578/effectiveness-of-early-information-and-endorsment-by-gp-to-increase-colonoscopy-follow-up-and-reduce-delays-in-people-with-a-positive-colorectal-cancer-screening-test-suivicolo 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07333651/implante-de-semillas-de-125i-mas-terapia-sistemica-para-el-cancer-de-pulmon-de-celulas-no-pequenas-cpcnp-u-el-cancer-colorrectal-oligoprogresivo 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07333651/125i-seed-implantation-plus-systemic-therapy-for-oligoprogressive-nsclc-or-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT02012699/repositorio-integral-de-cancer-para-la-investigacion-oncologica 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT02012699/integrated-cancer-repository-for-cancer-research 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06887218/5-fluorouracilo-leucovorina-5fu-lv-en-combinacion-con-regorafenib-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06887218/5-fluorouracil-leucovorin-5fu-lv-in-combination-with-regorafenib-in-patients-with-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06614192/un-estudio-que-evalua-los-eventos-adversos-y-la-actividad-de-la-enfermedad-al-comparar-la-administracion-intravenosa-iv-de-abbv-400-con-los-comprimidos-orales-de-trifluridina-y-tipiracil-lonsurf-mas 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06614192/a-study-assessing-adverse-events-and-disease-activity-of-intravenously-iv-infused-telisotuzumab-adizutecan-in-adult-participants-with-c-met-protein-above-cutoff-level-above-refractory-metastatic 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04224779/biopsias-liquidas-e-imagenologia-para-mejorar-la-atencion-oncologica 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04224779/liquid-biopsies-and-imaging-for-improved-cancer-care 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06012734/lb-100-inhibidor-de-pp2a-y-atezolizumab-inhibidor-de-pd-l1-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06012734/lb-100-pp2a-inhibitor-and-atezolizumab-pd-l1-inhibitor-in-metastatic-colorectal-cancer-patients 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT02595931/m6620-e-hidrocloruro-de-irinotecan-en-el-tratamiento-de-pacientes-con-tumores-solidos-metastasicos-o-que-no-pueden-ser-extirpados-mediante-cirugia 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT02595931/m6620-and-irinotecan-hydrochloride-in-treating-patients-with-solid-tumors-that-are-metastatic-or-cannot-be-removed-by-surgery 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06728072/adicion-de-antibioticos-al-regimen-de-tratamiento-inicial-para-el-cancer-colorrectal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06728072/addition-of-antibiotics-to-upfront-treatment-regimen-for-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04222413/metarrestin-ml-246-en-pacientes-con-tumores-solidos-metastasicos 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04222413/metarrestin-ml-246-in-subjects-with-metastatic-solid-tumors 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05609370/un-estudio-que-investiga-la-eficacia-y-la-seguridad-de-lbl-007-mas-tislelizumab-en-combinacion-con-bevacizumab-mas-fluoropirimidina-en-comparacion-con-bevacizumab-mas-fluoropirimidina-en 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05609370/a-study-investigating-the-efficacy-and-safety-of-alcestobart-lbl-007-plus-tislelizumab-in-combination-with-bevacizumab-plus-fluoropyrimidine-versus-bevacizumab-plus-fluoropyrimidine-in-participants 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03426904/quimioterapia-neoadyuvante-con-folfox-para-pacientes-con-cancer-colorrectal-localmente-avanzado 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03426904/neoadjuvant-folfox-chemotherapy-for-patients-with-locally-advanced-colon-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07543471/un-estudio-de-fase-i-multicentrico-aleatorizado-doble-ciego-y-controlado-en-paralelo-que-compara-hlx05-n-con-erbitux-r-en-el-cancer-colorrectal-metastasico 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07543471/a-phase-i-multicentre-randomized-double-blind-parallel-controlled-study-of-hlx05-n-vs-erbitux-r-in-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05755672/biomarcadores-durante-el-tratamiento-en-el-cancer-colorrectal-metastasico-para-mejorar-la-calidad-de-vida 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05755672/on-treatment-biomarkers-in-metastatic-colorectal-cancer-for-life 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06974110/estudio-de-moma-341-administrado-por-via-oral-en-participantes-con-tumores-solidos-avanzados-o-metastasicos 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06974110/study-of-orally-administered-moma-341-in-participants-with-advanced-or-metastatic-solid-tumors 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06601075/el-papel-del-pet-tc-con-18f-fdg-y-68ga-fapi-en-el-diagnostico-y-la-evaluacion-de-la-eficacia-del-cancer-colorrectal-avanzado-metastasis-peritoneal-con-o-sin-otras-metastasis 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06601075/the-role-of-18f-fdg-and-68ga-fapi-pet-ct-in-the-diagnosis-and-the-efficacy-evaluation-of-advanced-colorectal-cancer-peritoneal-metastasis-with-without-other-metastases 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07004413/cetuximab-en-administracion-continua-o-intermitente-combinado-con-folfiri-como-tratamiento-de-primera-linea-en-pacientes-con-cancer-colorrectal-metastasico-mcrc-con-ras-braf-tipo-salvaje 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07004413/continuous-or-intermittent-cetuximab-plus-folfiri-as-first-line-treatment-in-ras-braf-wild-type-mcrc-patients 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06879886/vigilancia-guiada-por-la-enfermedad-residual-minima-en-el-cancer-colorrectal-metastasico-en-estadio-iv-susceptible-de-reseccion-surveillance-ii 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06879886/mrd-guided-surveillance-in-resectable-stage-iv-metastatic-colorectal-cancer-surveillance-ii 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06820463/un-estudio-para-evaluar-los-eventos-adversos-y-la-eficacia-de-la-administracion-intravenosa-iv-de-telisotuzumab-adizutecan-en-combinacion-con-oxaliplatino-iv-fluorouracilo-acido-folinico-leucovorina 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06820463/a-study-to-evaluate-the-adverse-events-and-efficacy-of-intravenous-iv-of-telisotuzumab-adizutecan-in-combination-with-iv-oxaliplatin-fluorouracil-folinic-acid-leucovorin-bevacizumab-panitumumab-in 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06841159/radioterapia-estereotactica-adaptativa-ultrafraccionada-y-personalizada-pulsar-combinada-con-terapia-anti-pd1-quimioterapia-y-terapia-dirigida-para-el-cancer-colorrectal-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06841159/personalized-ultrafractionated-stereotactic-adaptive-radiotherapy-pulsar-combined-with-anti-pd1-chemotherapy-and-target-therapy-for-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05629442/ctdna-y-preservacion-de-organos-respuesta-completa-patologica-en-el-cancer-de-recto 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05629442/ctdna-and-organ-preservation-pathologic-cr-in-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07543744/un-estudio-comparativo-de-la-farmacocinetica-la-seguridad-y-la-inmunogenicidad-de-rph-030-y-vectibix-r-en-pacientes-con-cancer-colorrectal-metastasico-con-ras-de-tipo-salvaje-como-terapia-de-primera 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07543744/a-comparative-study-of-pharmacokinetics-safety-and-immunogenicity-of-rph-030-and-vectibix-r-in-patients-with-metastatic-colorectal-cancer-with-wild-type-ras-as-first-line-therapy-in-combination-with 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06607458/evaluacion-de-la-seguridad-y-la-eficacia-del-tratamiento-con-melfalan-a-dosis-altas-administrado-directamente-en-el-higado-seguido-de-tratamiento-con-un-farmaco-oncologico-aprobado-o-con-el-farmaco 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06607458/evaluation-of-the-safety-and-efficacy-of-treatment-w-high-dose-melphalan-given-directly-into-the-liver-followed-by-treatment-w-approved-cancer-treatment-or-approved-cancer-treatment-alone-in-patients 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05747716/terapia-de-radiacion-estereotactica-sbrt-combinada-con-fruquintinib-mas-un-anticuerpo-anti-pd-1-ctla-4-como-tratamiento-de-tercera-linea-en-pacientes-con-mcrc 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05747716/sbrt-combined-with-fruquintinib-plus-pd-1-ctla-4-antibody-for-third-line-treatment-in-mcrc 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07355764/ma-crc-ii-016-shr-1811 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04940546/seguridad-del-tratamiento-neoadyuvante-con-sintilimab-xelox-bevacizumab-en-pacientes-con-metastasis-colorrectales-mcrlm-con-pmmr-mss 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04940546/neoadjuvant-safety-of-sintilimab-xelox-bevacizumab-in-pmmr-mss-crlm-patients 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05501353/exploracion-de-biomarcadores-asociados-con-el-pronostico-del-cancer-colorrectal-recurrente-y-metastasico-tras-la-cirugia-mediante-metodos-multiomicos 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05501353/explore-biomarkers-associated-with-prognosis-of-recurrent-and-metastatic-crc-after-surgery-by-multi-omics-methods 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06829355/estudio-de-inmunoterapia-con-timalfasina-y-regimen-triple-en-cancer-colorrectal-avanzado-mss-pmmr 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06829355/thymalfasin-immunotherapy-study-with-triple-regimen-in-advanced-mss-pmmr-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06505551/estudio-de-fase-i-ii-de-celulas-t-con-receptores-de-celulas-t-autologas-scg142-en-pacientes-con-carcinoma-positivo-para-hpv16-52 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06505551/phase-1-2-study-of-autologous-scg142-tcr-t-cells-in-patients-with-hpv16-52-positive-carcinoma 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07261709/trifluridina-tipiracil-mas-fruquintinib-frente-a-trifluridina-tipiracil-mas-bevacizumab-en-cancer-colorrectal-metastasico-refractario-un-ensayo-aleatorizado-controlado-de-etiqueta-abierta-de-no 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07261709/trifluridine-tipiracil-plus-fruquintinib-vs-trifluridine-tipiracil-plus-bevacizumab-in-refractory-metastatic-colorectal-cancer-a-randomized-controlled-open-label-non-inferiority-trial 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06922383/un-estudio-clinico-de-arfolitixorina-en-pacientes-con-mcrc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06922383/a-clinical-study-of-arfolitixorin-in-patients-with-mcrc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07012954/cetuximab-o-bevacizumab-guiados-por-ctdna-mas-trifluridina-tipiracil-en-pacientes-con-mcrc-con-ras-braf-de-tipo-salvaje 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07012954/ctdna-guided-cetuximab-or-bevacizumab-plus-trifluridine-tipiracil-in-ras-braf-wild-type-mcrc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07085169/trifluridina-tipiracil-a-dosis-bajas-con-bevacizumab-en-mcrc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07085169/low-dose-trifluridine-tipiracil-with-bevacizumab-in-mcrc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07364656/analisis-de-la-presencia-y-los-efectos-sobre-la-funcion-cardiaca-de-los-autoanticuerpos-anti-nav1-5-en-pacientes-con-tumores-metastasicos 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07364656/analysis-of-the-presence-and-cardiac-functional-effects-of-anti-nav1-5-autoantibodies-in-patients-with-metastatic-tumors 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07362836/fruquintinib-frente-a-bevacizumab-mas-quimioterapia-en-el-tratamiento-de-segunda-linea-del-cancer-colorrectal-metastasico-con-mutacion-en-los-genes-ras-fru-ras 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07362836/fruquintinib-versus-bevacizumab-plus-chemotherapy-in-second-line-ras-mutant-metastatic-colorectal-cancer-fru-ras 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06980454/comparacion-de-la-farmacocinetica-en-la-fase-i-de-hlx05-frente-a-erbitux-r-en-hombres-chinos-sanos-seguridad-inmunogenicidad-y-farmacocinetica 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06980454/phase-i-pk-comparison-of-hlx05-vs-erbitux-r-in-healthy-chinese-males-safety-immunogenicity-and-pharmacokinetics 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05688280/inyeccion-intratumoral-de-ip-001-tras-ablacion-termica-en-pacientes-con-crc-nsclc-y-sts 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05688280/intratumoral-injection-of-ip-001-following-thermal-ablation-in-patients-with-crc-nsclc-and-sts 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05985954/estudio-de-fase-1b-abierto-con-ulixertinib-y-cetuximab-o-ulixertinib-en-combinacion-con-cetuximab-y-encorafenib-en-pacientes-con-cancer-colorrectal-irresecable-o-metastasico-que-previamente-han 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05985954/open-label-phase-1b-study-of-ulixertinib-and-cetuximab-or-ulixertinib-in-combination-with-cetuximab-and-encorafenib-in-patients-with-unresectable-or-metastatic-colorectal-cancer-who-have-previously 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07044362/histotripsia-mas-quimioterapia-frente-a-quimioterapia-sola-en-metastasis-hepaticas-avanzadas-de-cancer-colorrectal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07044362/histotripsy-plus-chemotherapy-vs-chemotherapy-alone-for-advanced-colorectal-liver-metastasis 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07381764/romance-irinotecan-mas-cetuximab-en-un-nuevo-ciclo-de-tratamiento-versus-trifluridina-tipiracil-mas-bevacizumab-en-cancer-colorrectal-metastasico-molecularmente-seleccionado 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07381764/romance-irinotecan-plus-cetuximab-rechallenge-versus-trifluridine-tipiracil-plus-bevacizumab-in-molecularly-selected-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05991102/tratamiento-con-campos-electromagneticos-de-radiofrecuencia-de-modulacion-de-amplitud-combinado-con-tas-102-lonsurf-y-bevacizumab-en-el-cancer-colorrectal-metastasico-refractario 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05991102/amplitude-modulated-radiofrequency-electromagnetic-field-treatment-combined-with-tas-102-lonsurf-and-bevacizumab-in-refractory-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06321081/estudio-ice-combinacion-de-irinotecan-mas-cetuximab-y-envafolimab-como-regimen-de-retreatment-en-mcrc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06321081/ice-study-combination-of-irinotecan-plus-cetuximab-and-envafolimab-as-a-rechallenge-regimen-in-mcrc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07011576/un-estudio-de-fruquintinib-mas-folfiri-como-tratamiento-de-segunda-linea-para-participantes-con-cancer-colorrectal-metastasico-mcrc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07011576/a-study-of-fruquintinib-plus-folfiri-as-second-line-treatment-for-participants-with-metastatic-colorectal-cancer-fruitful 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03488953/trasplante-de-higado-con-donante-vivo-y-hepatectomia-en-dos-etapas-para-pacientes-con-metastasis-hepaticas-irresecables-aisladas-de-cancer-colorrectal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03488953/living-donor-liver-transplantation-with-two-stage-hepatectomy-for-patients-with-isolated-irresectable-colorectal-liver-metastases 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07167446/potencial-neuroprotector-del-cannabidiol-cbd-en-la-prevencion-de-la-neuropatia-inducida-por-oxaliplatino-ox 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07167446/neuroprotective-potential-of-cannabidiol-cbd-in-preventing-oxaliplatin-ox-induced-neuropathy 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06244771/un-estudio-que-evalua-el-farmaco-fmc-376-en-participantes-con-tumores-solidos-que-presentan-la-mutacion-kras-g12c 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06244771/a-study-evaluating-fmc-376-in-participants-with-kras-g12c-mutated-solid-tumors 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05700656/galunisertib-en-combinacion-con-capecitabina-en-el-tratamiento-del-cancer-colorrectal-avanzado-con-microsatelites-estables-mss 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05700656/galunisertib-combined-with-capecitabine-in-advanced-crc-with-pm 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT02671435/un-estudio-de-durvalumab-medi4736-y-monalizumab-en-tumores-solidos 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT02671435/a-study-of-durvalumab-medi4736-and-monalizumab-in-solid-tumors 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05962502/cetuximab-mas-irinotecan-en-pacientes-con-cancer-colorrectal-metastasico-con-tipo-salvaje-de-neoras-en-terapia-de-tercera-linea 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05962502/cetuximab-plus-irinotecan-in-patients-with-neoras-wild-type-metastatic-colorectal-cancer-in-third-line-therapy 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT02885753/oxaliplatino-sistemico-o-quimioterapia-intraarterial-combinada-con-lv5fu2-irinotecan-y-una-terapia-dirigida-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-restringido-al-higado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT02885753/systemic-oxaliplatin-or-intra-arterial-chemotherapy-combined-with-lv5fu2-irinotecan-and-an-target-therapy-in-first-line-treatment-of-metastatic-colorectal-cancer-restricted-to-the-liver 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07229846/un-estudio-clinico-de-fase-ii-de-un-solo-brazo-y-en-un-solo-centro-para-evaluar-aipalolitovorelizumab-ql1706-en-combinacion-con-bevacizumab-y-quimioterapia-estandar-como-tratamiento-de-primera-linea 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07229846/a-single-arm-single-center-phase-ii-clinical-study-of-aipalolitovorelizumab-ql1706-combined-with-bevacizumab-and-standard-chemotherapy-as-first-line-treatment-for-mss-pmmr-metastatic-colorectal 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06298916/64cu-lnth-1363s-en-pacientes-con-sarcoma-o-cancer-del-tracto-gastrointestinal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06298916/64cu-lnth-1363s-in-patients-with-sarcoma-or-gastrointestinal-tract-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05536089/aplicacion-de-la-metilacion-del-ctdna-en-la-evaluacion-de-la-recurrencia-postoperatoria-y-la-eficacia-de-la-quimioterapia-adyuvante 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05536089/ctdna-methylation-application-in-postoperative-relapse-and-adjuvant-chemotherapy-efficacy-evaluation 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07044921/estudio-clinico-de-un-tratamiento-combinado-basado-en-irinotecan-liposomal-ii-para-el-cancer-colorrectal-resistente-al-irinotecan 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07044921/clinical-study-of-irinotecan-liposome-ii-based-combination-treatment-for-irinotecan-resistant-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07079462/comparacion-de-la-radioterapia-abdominal-guiada-por-pet-con-68ga-fapi-combinada-con-la-terapia-estandar-de-segunda-linea-y-cadonilimab-frente-a-la-terapia-estandar-de-segunda-linea-en-el-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07079462/comparing-18f-fapi-pet-guided-abdominal-radiotherapy-combined-with-second-line-standard-therapy-and-cadonilimab-versus-second-line-standard-therapy-in-colorectal-cancer-with-peritoneal-metastasis 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06412198/un-estudio-multicentrico-de-fase-1b-2-con-adagrasib-cetuximab-y-cemiplimab-para-el-cancer-colorrectal-metastasico-que-presenta-mutaciones-kras-g12c 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06412198/a-multicenter-phase-1b-2-study-of-adagrasib-cetuximab-and-cemiplimab-for-metastatic-colorectal-cancer-harboring-kras-g12c-mutations 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07585279/un-estudio-clinico-de-irinotecan-liposomal-para-la-terapia-de-segunda-linea-en-el-cancer-colorrectal-metastasico 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07585279/a-clinical-study-of-liposomal-irinotecan-for-second-line-therapy-in-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04607421/un-estudio-de-encorafenib-mas-cetuximab-con-o-sin-quimioterapia-en-pacientes-con-cancer-colorrectal-metastasico-no-tratado-previamente 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04607421/a-study-of-encorafenib-plus-cetuximab-with-or-without-chemotherapy-in-people-with-previously-untreated-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03587480/reseccion-mesorrectal-total-rmt-con-diseccion-de-los-ganglios-linfaticos-laterales-frente-a-rmt-tras-quimiorradioterapia-neoadyuvante 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03587480/total-mesorectal-excision-tme-with-lateral-lymph-node-dissection-versus-tme-after-neoadjuvant-chemo-radiotherapy 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06130280/un-estudio-sobre-la-radioterapia-estereotactica-de-cuerpo-unico-sbrt-guiada-por-resonancia-magnetica-rm-en-pacientes-con-metastasis-hepaticas-procedentes-del-cancer-colorrectal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06130280/a-study-of-single-fraction-stereotactic-body-radiation-therapy-sbrt-guided-by-magnetic-resonance-imaging-mri-in-people-with-liver-metastasis-from-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03978078/una-base-de-datos-clinicobiologica-en-canceres-digestivos-metastasicos 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03978078/a-clinicobiological-database-in-metastatic-digestive-cancers 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07410676/ebnk-001-celulas-nk-alogenicas-con-dosis-bajas-de-il-15-pembrolizumab-en-tumores-solidos-avanzados 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07410676/ebnk-001-allogeneic-nk-cells-with-low-dose-il-15-pembrolizumab-in-advanced-solid-tumors 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT02917707/analisis-integrativo-de-la-metastasis-hepatica-del-ccrc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT02917707/integrative-analysis-of-crc-liver-metastasis 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07415031/un-estudio-de-tumores-solidos-para-el-tratamiento-a-largo-plazo-de-pacientes-con-cancer-que-participaron-en-estudios-con-adagrasib 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07415031/a-solid-tumor-study-for-long-term-treatment-of-cancer-patients-who-participated-in-adagrasib-studies 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05434026/base-de-datos-china-de-cancer-colorrectal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05434026/chinese-colorectal-cancer-database 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06118762/estudio-clinico-de-fruquintinib-en-combinacion-con-raltitrexed-para-el-tratamiento-del-cancer-colorrectal-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06118762/clinical-study-of-fruquintinib-combined-with-raltitrexed-in-the-treatment-of-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06407518/midazolam-oral-preoperatorio-para-el-alivio-del-dolor-postoperatorio-en-pacientes-con-cancer-colorrectal-que-presentan-trastornos-del-sueno-o-ansiedad 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06407518/preoperative-oral-midazolam-to-postoperative-pain-relief-in-sleep-disturbance-or-anxiety-patients-with-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT02521844/un-estudio-para-evaluar-la-seguridad-y-la-tolerabilidad-de-etc-1922159-como-agente-unico-y-en-combinacion-con-pembrolizumab-en-tumores-solidos-avanzados 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT02521844/a-study-to-evaluate-the-safety-and-tolerability-of-etc-1922159-as-a-single-agent-and-in-combination-with-pembrolizumab-in-advanced-solid-tumours 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06657222/primer-estudio-en-humanos-de-tub-030-en-pacientes-con-tumores-solidos-avanzados 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06657222/first-in-human-study-of-tub-030-in-patients-with-advanced-solid-tumors 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04585035/estudio-para-evaluar-d-1553-en-sujetos-con-tumores-solidos 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04585035/study-to-evaluate-d-1553-in-subjects-with-solid-tumors 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04670679/un-estudio-de-escalada-de-dosis-expansion-de-eras-601-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04670679/a-dose-escalation-expansion-study-of-eras-601-in-patients-with-advanced-or-metastatic-solid-tumors 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07198958/registro-de-eventos-adversos-inmunologicos-en-pacientes-onco-hematologicos-tratados-con-inmunoterapia 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07198958/immune-adverse-events-registry-in-onco-hematologic-patients-treated-with-immunotherapy 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05655780/el-papel-del-perfil-molecular-tumoral-cms-el-genotipo-ugt1a1-y-la-actividad-de-la-beta-glucuronidasa-de-la-microbiota-intestinal-en-la-eficacia-del-tratamiento-la-toxicidad-la-supervivencia-y-la 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05655780/the-role-of-the-tumor-molecular-profile-cms-ugt1a1-genotype-and-beta-glucuronidase-activity-of-the-intestinal-microbiota-for-treatment-efficiency-toxicity-survival-and-quality-of-life-in-patients 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06997458/biopsia-liquida-cancer-de-pulmon-y-cancer-de-colon-en-andalucia 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06997458/liquid-biopsy-lung-and-colon-cancer-in-andalucia 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06853496/estudio-de-un-inhibidor-de-la-tanquirasa-el-rk-582-en-pacientes-con-cancer-colorrectal-metastasico-irresecable 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06853496/study-of-a-tankyrase-inhibitor-rk-582-for-patients-with-unresectable-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT01531595/estudio-de-bevacizumab-en-combinacion-con-esquemas-alternos-de-xeliri-y-xelox-en-cancer-colorrectal-metastasico 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT01531595/study-of-bevacizumab-in-combination-with-alternating-xeliri-and-xelox-in-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06746545/un-estudio-clinico-prospectivo-de-etiqueta-abierta-de-un-solo-brazo-de-fase-ii-para-evaluar-la-combinacion-de-fruquintinib-con-s-1-en-el-tratamiento-del-cancer-colorrectal-metastasico 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06746545/a-prospective-open-label-single-arm-phase-ii-clinical-study-of-fruquintinib-combined-with-s-1-for-the-treatment-of-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05379595/un-estudio-de-amivantamab-en-monoterapia-y-en-combinacion-con-la-quimioterapia-estandar-en-participantes-con-cancer-colorrectal-avanzado-o-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05379595/a-study-of-amivantamab-monotherapy-and-in-addition-to-standard-of-care-chemotherapy-in-participants-with-advanced-or-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06374173/un-estudio-de-fase-i-para-evaluar-tgi-6-en-sujetos-con-tumores-solidos-localmente-avanzados-o-metastasicos 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06374173/a-phase-1-study-to-evaluate-tgi-6-in-subjects-with-locally-advanced-metastatic-solid-tumors 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06959589/eficacia-y-seguridad-de-ibi351-cetuximab-en-combinacion-con-folfiri-como-tratamiento-de-primera-linea-y-de-ibi351-cetuximab-como-tratamiento-de-segunda-linea-en-el-tratamiento-del-cancer-colorrectal 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06959589/the-efficacy-and-safety-of-ibi351-cetuximab-combined-with-folfiri-as-first-line-ibi351-cetuximab-as-second-line-in-the-treatment-of-kras-g12c-mutated-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07277270/un-estudio-de-gsk5764227-en-combinacion-con-el-tratamiento-estandar-soc-u-otros-agentes-en-participantes-con-tumores-solidos-avanzados 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07277270/a-study-of-gsk5764227-in-combination-with-standard-of-care-soc-or-other-agents-in-participants-with-advanced-solid-tumors 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06530303/terapia-con-linfocitos-infiltrantes-tumorales-mediante-inmunoterapia-para-el-cancer-de-colon-y-recto 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06530303/biological-tumor-infiltrating-lymphocytes-therapy-with-immunotherapy-for-colon-and-rectum-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06630624/determinacion-de-la-dosis-eficacia-y-respuesta-inmunologica-de-ip-001-tras-ablacion-por-microondas-mwa-o-ablacion-por-radiofrecuencia-irreversible-ire-en-pacientes-con-metastasis-hepaticas-de-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06630624/dose-finding-efficacy-and-immunological-response-of-ip-001-following-mwa-or-ire-for-crlm 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07272642/un-estudio-de-fase-i-multicentrico-y-basado-en-imagenes-de-lnth-2403-en-participantes-con-tumores-solidos-localmente-avanzados-o-metastasicos 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07272642/a-phase-1-multicenter-imaging-study-of-lnth-2403-in-participants-with-locally-advanced-or-metastatic-solid-tumors 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07067385/vacuna-de-arnm-personalizada-contra-el-cancer-para-el-tratamiento-de-tumores-solidos-gastrointestinales 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07067385/personalized-mrna-cancer-vaccine-for-gastrointestinal-solid-tumor-treatment 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03692429/alloshrink-regimen-estandar-de-quimioterapia-e-inmunoterapia-con-celulas-t-receptor-de-antigeno-quimerico-alogenicas-basadas-en-nkg2d-cyad-101 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03692429/alloshrink-standard-chemotherapy-regimen-and-immunotherapy-with-allogeneic-nkg2d-based-cyad-101-chimeric-antigen-receptor-t-cells 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07001592/inyeccion-intratumoral-it-de-vvdd-hil2-2-rg-1-para-tumores-metastasicos-gastrointestinales-y-peritoneales 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07001592/intra-tumoral-it-injection-of-vvdd-hil2-2-rg-1-for-metastatic-gastrointestinal-and-peritoneal-tumors 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07441369/abemaciclib-en-combinacion-con-los-regimenes-folfox-folfiri-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal-avanzado 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07441369/abemaciclib-combined-with-folfox-folfiri-regimen-in-patients-with-advanced-colorectal-liver-metastases-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05167071/estudio-de-hbm4003-en-combinacion-con-toripalimab-en-pacientes-con-tumores-neuroendocrinos-avanzados-y-otros-tumores-solidos 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05167071/hbm4003-combine-with-toripalimab-in-patients-with-advanced-nen-and-other-solid-tumors-study 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03965234/perfusion-pulmonar-para-el-control-de-la-enfermedad-residual-minima-en-pacientes-con-sarcoma-o-metastasis-de-cancer-colorrectal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03965234/pulmonary-suffusion-in-controlling-minimal-residual-disease-in-patients-with-sarcoma-or-colorectal-metastases 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04294264/tas-102-y-oxaliplatino-para-el-tratamiento-del-cancer-colorrectal-en-estadio-iv-refractario 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04294264/tas-102-and-oxaliplatin-for-the-treatment-of-refractory-stage-iv-colon-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06008119/eficacia-y-seguridad-de-tunlametinib-mas-vemurafenib-en-pacientes-con-cancer-colorrectal-metastasico-con-mutacion-braf-v600e 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008119/efficacy-and-safety-of-tunlametinib-plus-vemurafenib-in-patients-with-braf-v600e-mutant-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05954429/un-estudio-para-evaluar-el-tratamiento-de-tercera-linea-con-fruquintinib-en-combinacion-con-serplulimab-en-pacientes-con-cancer-colorrectal-metastasico-avanzado-no-limitado-al-higado-un-estudio-de 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05954429/a-study-to-explore-the-third-line-treatment-of-fruquintinib-combined-with-serplulimab-in-advanced-non-liver-limited-metastatic-colorectal-cancer-a-single-center-phase-2-study 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07677579/nimble-crc-neoinmunomodulacion-antes-de-la-cirugia-en-el-cancer-colorrectal 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07677579/nimble-crc-neoimmunomodulation-before-leveraging-excision-in-colorectal-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06783569/un-estudio-de-escalada-y-expansion-en-humanos-el-primero-de-su-tipo-en-pacientes-con-tumores-solidos-avanzados 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06783569/a-first-in-human-escalation-and-expansion-study-of-patients-with-advanced-solid-tumors 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07448662/estrategias-de-tratamiento-local-para-las-metastasis-cerebrales-del-cancer-colorrectal 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07448662/local-treatment-strategies-for-brain-metastases-of-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07447050/riluzol-para-prevenir-la-disfuncion-cognitiva-en-pacientes-con-cancer-que-reciben-quimioterapia-refocus-ensayo-piloto 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07447050/riluzole-for-preventing-cognitive-dysfunction-in-ca-pts-receiving-chemo-refocus-pilot-trial 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07202364/un-estudio-de-yl202-en-pacientes-con-tumores-solidos-avanzados 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07202364/a-study-of-yl202-in-patients-with-advanced-solid-tumors 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06763029/irinotecano-en-liposomas-combinado-con-cetuximab-y-vermofenib-en-pacientes-con-cancer-colorrectal-avanzado-que-han-fracasado-en-la-primera-linea-de-tratamiento 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06763029/irinotecan-liposomes-combined-with-cetuximab-vermofenib-in-first-line-failure-of-advanced-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04430725/ablacion-por-microondas-o-reseccion-en-cuna-para-el-tratamiento-de-lesiones-pulmonares-de-sarcoma-y-colorrectales-estudio-allume 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04430725/microwave-ablation-or-wedge-resection-for-the-treatment-of-lung-sarcoma-and-colorectal-lesions-allume-study 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06856837/ikf-aio-quintis-evaluacion-de-fruquintinib-en-combinacion-con-tislelizumab-en-cancer-colorrectal-metastasico-con-microsatelites-estables-reparacion-deficiente-de-errores-de-apareamiento-mss-pmmr-sin 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06856837/ikf-aio-quintis-evaluating-fruquintinib-in-combination-with-tislelizumab-in-microsatellite-stable-proficient-mismatch-repair-mss-pmmr-metastatic-colorectal-cancer-without-active-liver-metastases 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06462963/oligocare-twics-ensayos-dentro-de-cohortes-ensayo-comparativo-de-la-toxicidad-aguda-en-la-radioterapia-estereotactica-ablativa-sbrt-en-una-sola-fraccion-frente-a-multiples-fracciones-para-el 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06462963/oligocare-twics-trials-within-cohorts-trial-comparing-acute-toxicity-in-single-fraction-vs-multiple-fraction-sbrt-for-metastasis-directed-treatment-sprint 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07070713/eficacia-y-seguridad-de-folfox-cetuximab-frente-a-folfoxiri-bevacizumab-ambos-en-combinacion-con-ql1706-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-mcrc-localizado-en-el 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07070713/efficacy-and-safety-of-folfox-cetuximab-vs-folfoxiri-bevacizumab-both-with-ql1706-in-first-line-treatment-of-left-sided-mcrc 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07462143/un-ensayo-clinico-de-fase-ii-iii-con-rc148-mas-quimioterapia-como-terapia-de-primera-linea-para-el-cancer-colorrectal-irresecable-o-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07462143/a-phase-ii-iii-clinical-trial-of-rc148-plus-chemotherapy-as-1l-therapy-for-unresectable-or-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07595276/comparacion-de-la-eficacia-y-la-seguridad-de-enlituo-r-frente-a-erbitux-r-mas-folfox-en-el-cancer-colorrectal-localmente-avanzado-metastasico-con-estado-ras-braf-de-tipo-salvaje-y-mss-pmmr 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07595276/comparing-efficacy-and-safety-of-enlituo-r-versus-erbitux-r-plus-folfox-in-locally-advanced-metastatic-colorectal-cancer-with-ras-braf-wild-type-and-mss-pmmr-status 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06823323/estudio-sobre-la-eficacia-y-la-seguridad-de-lactobacillus-johnsonii-en-combinacion-con-capeox-y-pembrolizumab-para-el-tratamiento-del-cancer-colorrectal-metastasico-mss-pmmr 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06823323/the-study-on-the-efficacy-and-safety-of-lactobacillus-johnsonii-in-combination-with-capeox-and-pembrolizumab-for-the-treatment-of-mss-pmmr-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07085091/un-estudio-de-fase-i-en-humanos-con-alx2004-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos-seleccionados 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07085091/a-first-in-human-study-of-alx2004-with-advanced-or-metastatic-selected-solid-tumors 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03829462/evaluacion-de-la-combinacion-de-regorafenib-e-irinotecan-frente-a-regorafenib-en-monoterapia-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03829462/assessing-a-regorafenib-irinotecan-combination-versus-regorafenib-alone-in-metastatic-colorectal-cancer-patients 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06575127/folfoxiri-modificado-mas-terapia-dirigida-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-avanzado-un-estudio-prospectivo-de-fase-ii 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06575127/modified-folfoxiri-plus-target-therapy-as-a-first-line-treatment-for-advanced-colorectal-cancer-a-prospective-phase-two-study 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06896162/progreso-oncologia-de-precision-mediante-evaluaciones-genomicas-reflexivas-para-la-seleccion-de-estudios-y-la-supervivencia 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06896162/progress-precision-oncology-using-genomic-reflexive-evaluations-for-study-selection-and-survival 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07051785/fruquintinib-frente-a-bevacizumab-en-combinacion-con-irinotecan-liposomal-y-capecitabina-como-terapia-de-segunda-linea-para-el-cancer-colorrectal-metastasico-avanzado 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07051785/fruquintinib-vs-bevacizumab-combined-with-irinotecan-liposome-and-capecitabine-as-second-line-therapy-for-advanced-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06243393/sacituzumab-govitecan-en-el-cancer-colorrectal-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06243393/sacituzumab-govitecan-in-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06873763/nelmastobart-en-combinacion-con-trifluridina-tipiracil-y-bevacizumab-en-el-cancer-colorrectal-metastasico-recurrente 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06873763/nelmastobart-in-combination-with-trifluridine-tipiracil-and-bevacizumab-in-metastatic-recurrent-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03164486/primer-estudio-en-humanos-mediante-tomografia-por-emision-de-positrones-que-utiliza-el-peptido-18f-v6 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03164486/first-in-human-positron-emission-tomography-study-using-the-18f-v6-binding-peptide 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04868877/estudio-de-fase-i-ii-que-evalua-mcla-129-un-anticuerpo-humano-bispecifico-anti-egfr-y-anti-c-met-en-pacientes-con-cancer-de-pulmon-no-microcitico-cpnm-avanzado-y-otros-tumores-solidos-tanto-en 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04868877/phase-1-2-study-evaluating-mcla-129-a-human-anti-egfr-anti-c-met-bispecific-antibody-in-advanced-nsclc-and-other-solid-tumors-alone-and-in-combination 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04699188/estudio-de-jdq443-en-pacientes-con-tumores-solidos-avanzados-que-presentan-la-mutacion-kras-g12c 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04699188/study-of-jdq443-in-patients-with-advanced-solid-tumors-harboring-the-kras-g12c-mutation 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04847063/respuesta-individual-al-tratamiento-con-quimioterapia-hipertermica-intraperitoneal-hipec-de-la-carcinomatosis-peritoneal-procedente-de-mesotelioma-peritoneal-o-proliferacion-mesotelial-atipica-o-de 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04847063/individual-response-to-hyperthermic-intraperitoneal-chemotherapy-hipec-treatment-of-peritoneal-carcinomatosis-from-peritoneal-mesothelioma-or-atypical-mesothelial-proliferation-or-from-ovarian 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06682247/un-estudio-en-el-mundo-real-de-chidamide-en-combinacion-con-anticuerpos-anti-pd-1-pd-l1-y-agentes-antiangiogenicos-en-el-cancer-colorrectal-avanzado-mss 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06682247/a-real-world-study-of-chidamide-in-combination-with-pd-1-pd-l1-antibodies-and-anti-angiogenic-agents-in-advanced-mss-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05815082/quimioterapia-adyuvante-guiada-por-ctdna-en-metastasis-hepaticas-del-cancer-colorrectal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05815082/ctdna-guided-adjuvant-chemotherapy-in-liver-metastasis-of-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05933876/el-impacto-de-la-radioterapia-en-el-cancer-oligometastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05933876/the-impact-of-radiotherapy-on-oligometastatic-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07491159/fruquintinib-mas-un-inhibidor-de-puntos-de-control-en-combinacion-o-de-forma-secuencial-junto-con-tas-102-en-pacientes-con-cancer-colorrectal-que-han-progresado-tras-recibir-una-terapia-estandar-de 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07491159/fruquintinib-plus-checkpoint-inhibitor-combined-or-sequential-tas-102-in-colorectal-cancer-patients-who-progressed-on-second-line-standard-therapy-a-prospective-multi-cohort-single-centered-phase-ib 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05691491/evaluacion-de-la-combinacion-de-los-farmacos-antineoplasicos-temozolomida-y-m1774-para-determinar-su-seguridad-y-eficacia 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05691491/testing-the-combination-of-the-anti-cancer-drugs-temozolomide-and-m1774-to-evaluate-their-safety-and-effectiveness 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04329494/pipac-para-el-tratamiento-de-la-carcinomatosis-peritoneal-en-pacientes-con-cancer-de-ovario-utero-apendice-colon-o-estomago 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04329494/pipac-for-the-treatment-of-peritoneal-carcinomatosis-in-patients-with-ovarian-uterine-appendiceal-colorectal-or-gastric-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07612007/hrx215-un-farmaco-inhibidor-de-mkk4-de-primera-generacion-para-el-tratamiento-de-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal-despues-de-someterse-a-una-embolizacion-de-la-vena-porta 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07612007/hrx215-a-first-generation-mkk4-inhibitor-drug-for-the-treatment-of-patients-with-colorectal-liver-metastasis-after-undergoing-a-portal-vein-embolization 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06449989/comparacion-de-la-concordancia-molecular-genetica-del-tumor-primario-y-las-metastasis-cerebrales-del-cancer-colorrectal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06449989/comparison-of-molecular-genetic-concordance-of-the-primary-tumor-and-brain-metastases-of-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07224022/cemiplimab-en-combinacion-con-fianlimab-para-el-cancer-colorrectal-no-metastasico-que-puede-ser-extirpado-quirurgicamente 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07224022/cemiplimab-with-fianlimab-for-resectable-non-metastatic-colon-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05705492/olanzapina-para-el-manejo-de-la-perdida-de-apetito-asociada-al-cancer-en-pacientes-con-cancer-avanzado-de-esofago-estomago-higado-pancreas-vias-biliares-colon-recto-o-pulmon 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05705492/olanzapine-for-the-management-of-cancer-associated-appetite-loss-in-patients-with-advanced-esophagogastric-hepatopancreaticobiliary-colorectal-or-lung-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07007689/un-estudio-multi-omico-del-cancer-colorrectal-con-mutacion-braf-v600e 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07007689/a-multi-omics-study-of-braf-v600e-mutant-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07114601/un-estudio-de-ly4257496-en-participantes-con-cancer-omniray 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07114601/a-study-of-ly4257496-in-participants-with-cancer-omniray 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06681038/tratamiento-antitumoral-sistemico-con-o-sin-quimioterapia-en-aerosol-intraabdominal-a-presion-para-metastasis-peritoneales-de-cancer-de-colon-pipox02 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06681038/systemic-antitumor-treatment-with-or-without-pressurized-intraperitoneal-aerosol-chemotherapy-for-colon-peritoneal-metastases-pipox02 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06011772/terapia-antigeno-egf-cimavax-egf-en-combinacion-con-la-terapia-estandar-para-el-cancer-colorrectal-metastasico-con-mutaciones-ras-y-braf-no-detectables 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06011772/egf-depleting-therapy-cimavax-egf-in-combination-with-standard-therapy-for-ras-and-braf-wild-type-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06555003/quimioterapia-con-debiri-mas-otros-farmacos-frente-a-quimioterapia-sola-en-metastasis-hepaticas-del-cancer-colorrectal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06555003/debiri-plus-chemotherapy-vs-chemotherapy-alone-in-colorectal-cancer-liver-metastases 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503808/un-estudio-de-ide034-en-participantes-adultos-con-tumores-solidos-avanzados-localmente-o-metastasicos 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07503808/a-study-of-ide034-in-adult-participants-with-locally-advanced-metastatic-solid-tumors-types 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07621497/folfox8-frente-a-mfolfox6-con-bevacizumab-o-cetuximab-para-el-cancer-colorrectal-metastasico-irresecable-en-primera-linea-fase-ii 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07621497/folfox8-versus-mfolfox6-with-bevacizumab-or-cetuximab-for-first-line-unresectable-metastatic-colorectal-cancer-phase-ii 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03493048/cetuximab-mas-folfoxiri-frente-a-cetuximab-mas-folfox-en-el-tratamiento-del-cancer-colorrectal-metastasico-crclm 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03493048/cetuximab-plus-folfoxiri-vs-cetuximab-plus-folfox-for-crclm 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03947385/estudio-de-ide196-en-pacientes-con-tumores-solidos-que-presentan-mutaciones-en-gnaq-11-o-fusiones-en-prkc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03947385/study-of-ide196-in-patients-with-solid-tumors-harboring-gnaq-11-mutations-or-prkc-fusions 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07309289/nalirifox-mas-terapia-dirigida-frente-a-folfox-mas-terapia-dirigida-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07309289/nalirifox-plus-targeted-therapy-versus-folfox-plus-targeted-therapy-as-first-line-treatment-for-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06776757/sintilimab-en-combinacion-con-cetuximab-y-quimioterapia-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-avanzado-con-ras-braf-de-tipo-salvaje 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06776757/sintilimab-in-combination-with-cetuximab-and-chemotherapy-as-first-line-treatment-for-ras-braf-wild-type-advanced-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07621159/un-estudio-de-fase-ib-ii-de-hdm2017-en-combinacion-con-el-tratamiento-estandar-en-el-cancer-colorrectal-avanzado 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07621159/a-phase-ib-ii-study-of-hdm2017-in-combination-with-standard-of-care-in-advanced-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06440005/un-estudio-para-evaluar-la-seguridad-la-tolerabilidad-y-la-actividad-preliminar-de-agx101-en-participantes-con-tumores-solidos-avanzados 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06440005/a-study-to-evaluate-safety-tolerability-and-preliminary-activity-of-agx101-in-participants-with-advanced-solid-tumors 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07509398/fmt-en-combinacion-con-la-terapia-estandar-de-primera-linea-en-el-cancer-colorrectal-inicialmente-irresecable 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07509398/fmt-combined-with-standard-first-line-therapy-in-initially-unresectable-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06589440/estudio-de-fase-ii-de-sr-8541a-en-combinacion-con-botensilimab-y-balstilimab-en-sujetos-con-cancer-colorrectal-metastasico-resistente-al-tratamiento-y-con-estabilidad-de-microsatelites-mss-crc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06589440/phase-2-study-of-sr-8541a-in-combination-with-botensilimab-and-balstilimab-in-subjects-with-refractory-metastatic-microsatellite-stable-colorectal-cancer-mss-crc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06973343/sintilimab-mas-bevacizumab-y-quimioterapia-en-pacientes-con-cancer-colorrectal-mss-pmmr-sin-metastasis-hepaticas 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06973343/sintilimab-plus-bevacizumab-and-chemotherapy-in-mss-pmmr-colorectal-with-no-liver-metastasis 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04188145/un-estudio-aleatorizado-de-fase-iii-que-compara-el-tratamiento-de-mantenimiento-con-fluoropirimidina-bevacizumab-frente-a-fluoropirimidina-despues-de-la-quimioterapia-de-induccion-en-pacientes-con 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04188145/a-randomized-phase-iii-study-comparing-maintenance-treatment-with-fluoropyrimidine-bevacizumab-versus-fluoropyrimidine-after-induction-chemotherapy-for-a-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06882915/eficacia-y-seguridad-de-trifluridina-tipiracil-tas-102-en-combinacion-con-bevacizumab-y-putalimab-en-el-tratamiento-de-pacientes-con-cmmr-despues-de-una-cirugia-citoreductora-un-estudio-clinico-de-un 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06882915/efficacy-and-safety-of-trifluridine-tipiracil-tas-102-combined-with-bevacizumab-and-serplulimab-in-patients-with-metastatic-colorectal-cancer-undergoing-cytoreductive-surgery-a-single-arm-single 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07328087/colonyvaq-tm-una-vacuna-neoantigenica-personalizada-guiada-por-metodos-cuanticos-y-clasicos-para-el-cancer-colorrectal-en-estadio-iii-con-mss 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07328087/colonyvaq-tm-a-quantum-classical-guided-personalized-neoantigen-vaccine-for-mss-stage-iii-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06992258/un-ensayo-aleatorizado-de-fase-ii-que-compara-fruquintinib-y-tas-102-con-fruquintinib-en-pacientes-con-cancer-colorrectal-avanzado-metastasico-refractario 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06992258/a-randomized-phase-2-trial-of-fruquintinib-and-tas-102-as-compared-to-fruquintinib-in-patients-with-refractory-advanced-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06787105/fruquintinib-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06787105/fruquintinib-in-patients-with-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07754513/circulating-tumor-extracellular-vesicles-for-non-invasive-monitoring-of-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07042685/ensayo-clinico-de-una-terapia-basada-en-5-fluorouracilo-5-fu-en-combinacion-con-fruquintinib-en-pacientes-con-cancer-colorrectal-localmente-avanzado-irresecable-o-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07042685/trial-of-5-fluorouracil-5fu-based-therapy-in-combination-with-fruquintinib-in-patients-with-locally-advanced-unresectable-or-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06663319/un-estudio-de-jnj-89402638-para-cancer-colorrectal-y-gastrico-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06663319/a-study-of-jnj-89402638-for-metastatic-colorectal-and-gastric-cancers 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035886/un-estudio-para-monitorizar-el-tratamiento-con-fruzaqla-en-adultos-con-cancer-colorrectal-metastasico-mcrc-en-corea-del-sur 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07035886/a-study-to-monitor-the-fruzaqla-treatment-of-adults-with-metastatic-colorectal-cancer-mcrc-in-south-korea 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05427487/estudio-de-ivx037-administrado-intratumoralmente-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05427487/study-of-intratumoral-ivx037-in-patients-with-advanced-or-metastatic-solid-tumours 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05093907/un-estudio-para-evaluar-la-seguridad-y-la-eficacia-de-bey1107-en-combinacion-con-capecitabina-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05093907/a-study-to-evaluate-safety-and-efficacy-of-bey1107-in-combination-with-capecitabine-in-patients-with-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06176885/eficacia-y-seguridad-de-la-combinacion-con-inmunoterapia-tras-la-terapia-de-induccion-con-quimioterapia-y-terapia-dirigida-en-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06176885/efficacy-and-safety-of-combined-with-immunotherapy-after-induction-therapy-with-chemotherapy-and-targeted-therapy-in-the-first-line-treatment-of-microsatellite-stable-mss-initially-unresectable 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06678919/registro-agmt-de-cancer-colorrectal-metastasico-mcrc-en-tercera-linea-de-tratamiento-y-posteriores 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06678919/agmt-metastatic-colorectal-cancer-registry-mcrc-third-line-and-beyond 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06907342/evaluacion-de-un-enfoque-de-medicina-de-precision-funcional-para-seleccionar-la-quimioterapia-en-el-cancer-colorrectal-metastasico-cosense-1 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06907342/testing-a-functional-precision-medicine-approach-to-select-chemotherapy-for-metastatic-colorectal-cancer-cosense-1 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04854213/prelude-1-evaluacion-prospectiva-de-los-efectos-biologicos-inducidos-por-la-radioterapia-en-pacientes-con-enfermedad-oligo-metastasica-de-cancer-colorrectal-y-enfermedad-limitada-a-los-pulmones 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04854213/prelude-1-prospective-evaluation-of-radiotherapy-induced-biologic-effects-in-colorectal-cancer-oligometastatic-patients-with-lung-limited-disease-evolution-of-cancer-genetics-and-regulatory-immune 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04754672/entrenamiento-de-aptitud-aerobica-o-de-masa-muscular-para-mejorar-el-resultado-en-el-cancer-colorrectal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04754672/aerobic-fitness-or-muscle-mass-training-to-improve-colorectal-cancer-outcome 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05808790/metastasis-pulmonares-de-cancer-colorrectal-metastasis-pulmonar-versus-radioterapia-ablativa-estereotactica 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05808790/colorectal-pulmonary-metastases-pulmonary-metastasectomy-versus-stereotactic-ablative-radiotherapy 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05652894/un-estudio-de-hx008-en-comparacion-con-la-quimioterapia-en-el-tratamiento-de-primera-linea-de-pacientes-con-cancer-colorrectal-metastasico-msi-h-dmmr 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05652894/a-study-of-hx008-compared-to-chemotherapy-in-the-first-line-treatment-of-subjects-with-msi-h-dmmr-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06867822/ensayo-clinico-de-proagio-en-cancer-colorrectal-avanzado-o-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06867822/trial-of-proagio-in-advanced-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07349043/ensayo-clinico-prospectivo-de-seguridad-y-eficacia-sobre-la-terapia-con-aerosol-intraperitoneal-presurizado-para-la-metastasis-peritoneal-del-cancer-colorrectal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07349043/a-prospective-safety-and-efficacy-clinical-trial-of-pressurized-intraperitoneal-aerosol-therapy-for-peritoneal-metastasis-of-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06911970/impacto-del-ejercicio-aerobico-en-la-respuesta-inmune-antitumoral-en-pacientes-que-reciben-tratamiento-contra-el-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06911970/impact-of-aerobic-exercise-on-the-anticancer-immune-response-in-patients-receiving-cancer-treatment 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04894370/combinacion-de-spartalizumab-mdcf-y-radioterapia-en-pacientes-con-carcinoma-anal-de-celulas-escamosas-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04894370/combination-of-spartalizumab-mdcf-and-radiotherapy-in-patients-with-metastatic-squamous-cell-anal-carcinoma 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06838338/jab-21822-en-combinacion-con-quimioterapia-y-bevacizumab-en-el-tratamiento-de-segunda-linea-del-ccrc-con-mutacion-kras-g12c 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06838338/jab-21822-combined-with-chemotherapy-and-bevacizumab-in-second-line-kras-g12c-crc 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07194616/ensayo-clinico-sobre-celulas-tumorales-circulantes-en-cancer-de-recto 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07194616/rectal-cancer-ctc-trial 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07268677/un-estudio-clinico-de-un-solo-brazo-que-evalua-la-combinacion-de-pirfenidona-y-sintilimab-con-la-quimioterapia-neoadyuvante-estandar-en-pacientes-con-cancer-colorrectal-y-metastasis-peritoneal 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07268677/a-single-arm-clinical-study-evaluating-pirfenidone-and-sintilimab-in-combination-with-standard-neoadjuvant-chemotherapy-for-colorectal-cancer-patients-with-peritoneal-metastasis 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03526835/un-estudio-del-anticuerpo-bispecifico-mcla-158-en-pacientes-con-tumores-solidos-avanzados 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03526835/a-study-of-bispecific-antibody-mcla-158-in-patients-with-advanced-solid-tumors 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07128355/botensilimab-balstilimab-y-radioterapia-estereotactica-ablativa-sbrt-en-el-cancer-colorrectal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07128355/botensilimab-balstilimab-and-sbrt-in-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07271355/quimioterapia-intraabdominal-en-aerosol-a-presion-con-mitomicina-para-el-tratamiento-del-cancer-de-apendice-o-de-colon-recto-irresecable-con-metastasis-peritoneales-el-ensayo-impact 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07271355/pressurized-intraperitoneal-aerosolized-chemotherapy-with-mitomycin-for-the-treatment-of-unresectable-appendix-or-colorectal-cancer-with-peritoneal-metastases-the-impact-trial 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05775146/radioterapia-estereotactica-ablativa-sbrt-de-metastasis-tras-el-tratamiento-neoadyuvante-para-el-cancer-colorrectal-con-metastasis-hepaticas-sincronicas 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05775146/sbrt-of-metastases-following-neo-adjuvant-treatment-for-colorectal-cancer-with-synchronous-liver-metastases 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05870800/ensayo-de-fase-ii-abierto-y-no-aleatorizado-sobre-quimioinmunoterapia-neoadyuvante-para-el-cancer-colorrectal-no-metastasico-y-resecable-nicer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05870800/phase-ii-open-label-trial-of-neoadjuvant-immunochemotherapy-for-resectable-non-metastatic-colon-cancer-nicer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06227728/analisis-de-la-dinamica-de-pd-l1-tmb-msi-y-ctdna-para-predecir-y-monitorizar-la-respuesta-a-la-inmunoterapia-en-el-cancer-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06227728/analysis-of-pd-l1-tmb-msi-and-ctdna-dynamics-to-predict-and-monitor-response-to-immunotherapy-in-metastatic-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03449914/el-estudio-gold-g8-en-pacientes-de-edad-avanzada 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03449914/the-gold-study-g8-in-older-patients 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06555133/y-90-capecitabina-y-atezolizumab-para-el-cancer-colorrectal-oligo-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06555133/y-90-capecitabine-and-atezolizumab-for-oligometastatic-crc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07549412/un-estudio-de-precemtabart-tocentecan-con-o-sin-bevacizumab-en-comparacion-con-trifluridina-tipiracil-mas-bevacizumab-en-participantes-con-cancer-colorrectal-metastasico-previamente-tratado-proceade 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07549412/a-study-of-precemtabart-tocentecan-with-or-without-bevacizumab-compared-to-trifluridine-tipiracil-plus-bevacizumab-in-participants-with-previously-treated-metastatic-colorectal-cancer-proceade-crc-03 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07361003/un-estudio-de-fase-ib-iii-de-suvemcitug-mas-ftd-tpi-en-participantes-con-cancer-colorrectal-metastasico-refractario 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07361003/a-phase-ib-iii-study-of-suvemcitug-plus-ftd-tpi-in-participants-with-refractory-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06616259/tratamiento-de-primera-linea-con-mcapox-cetuximab-frente-a-mfolfox6-cetuximab-en-pacientes-con-cmmr-no-operable-del-lado-izquierdo-con-ras-braf-tipo-salvaje-y-mss-un-estudio-multicentrico 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06616259/first-line-treatment-of-mcapox-cetuximab-vs-mfolfox6-cetuximab-for-ras-braf-wild-type-mss-unresectable-left-sided-mcrc-a-multicenter-randomized-controlled-phase-iii-study 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06202001/irinotecan-tas-102-mas-bevacizumab-como-terapia-de-segunda-linea-en-pacientes-con-mcrc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06202001/irinotecan-tas-102-plus-bevacizumab-as-a-second-line-therapy-in-mcrc-patients 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06423937/fruquintinib-mas-camrelizumab-y-haic-en-el-tratamiento-del-cancer-colorrectal-avanzado-no-msi-h 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06423937/fruquintinib-plus-camrelizumab-and-haic-in-the-treatment-of-non-msi-h-advanced-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07365527/sonoporacion-y-respuesta-del-microambiente-tumoral-en-metastasis-hepaticas-de-cancer-colorrectal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07365527/sonoporation-and-tumor-microenvironment-response-in-colorectal-liver-metastases 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07061210/un-estudio-exploratorio-de-hrs-2189-en-combinacion-con-adebrelimab-y-bp102-para-el-cancer-colorrectal-metastasico 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07061210/an-explorative-study-of-hrs-2189-combined-with-adebrelimab-and-bp102-for-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06192680/irinotecano-liposomal-y-capecitabina-mas-bevacizumab-como-terapia-de-segunda-linea-en-el-cancer-colorrectal-metastasico 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06192680/liposomal-irinotecan-and-capecitabine-plus-bevacizumab-as-second-line-therapy-in-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06356584/fruquintinib-en-combinacion-con-sintilimab-radioterapia-para-el-tratamiento-en-tercera-linea-del-cancer-colorrectal-con-metastasis-hepaticas 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06356584/fruquintinib-combined-with-sintilimab-radiotherapy-for-third-line-treatment-of-colorectal-cancer-with-liver-metastases 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07565831/estudio-sobre-la-prediccion-de-metastasis-en-los-ganglios-linfaticos-regionales-en-el-cancer-colorrectal-mediante-tomografia-computarizada-espectral-combinada-con-msi 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07565831/study-on-the-prediction-of-regional-lymph-node-metastasis-in-colorectal-cancer-by-spectral-ct-combined-with-msi 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06268015/optimizacion-de-botensilimab-y-balstilimab-en-el-cancer-colorrectal 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06268015/botensilimab-and-balstilimab-optimization-in-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06808685/estudio-nacional-multicentrico-en-el-mundo-real-para-evaluar-la-eficacia-y-la-seguridad-del-bevacizumab-biosimilar-elovie 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06808685/real-world-multicenter-national-study-to-evaluate-the-effectiveness-and-safety-of-biosimilar-bevacizumab-elovie 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05360277/tratamiento-de-mantenimiento-con-tislelizumab-y-capecitabina-para-el-cancer-colorrectal-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05360277/maintenance-tislelizumab-capecitabine-to-treat-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06848465/terapia-de-radiacion-intrahepatica-guiada-por-imagenes-combinada-con-inmunoterapia-y-quimioterapia-para-el-cancer-colorrectal-con-metastasis-hepaticas 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06848465/ldrt-combined-with-immunochemotherapy-for-colorectal-cancer-with-liver-metastasis 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07262619/eik1005-002-un-estudio-de-investigacion-clinica-que-evalua-eik1005-un-inhibidor-de-la-helicasa-de-werner-como-monoterapia-y-en-combinacion-con-pembrolizumab-en-participantes-con-tumores-solidos 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07262619/eik1005-002-a-clinical-research-study-evaluating-eik1005-a-werner-helicase-inhibitor-as-monotherapy-and-in-combination-with-pembrolizumab-in-participants-with-advanced-solid-tumors-including 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07149623/distribucion-de-los-ganglios-linfaticos-metastasicos-en-el-mesenterio-ileal-en-el-cancer-de-ciego-y-del-colon-ascendente-proximal 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07149623/metastatic-lymph-node-distribution-in-the-ileum-mesentery-of-cecal-and-proximal-ascending-colon-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06425133/regorafenib-en-combinacion-con-quimioterapia-metronomica-multimodal-para-cancer-colorrectal-metastasico-resistente-a-la-quimioterapia 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06425133/regorafenib-in-combination-with-multimodal-metronomic-chemotherapy-for-chemo-resistant-metastatic-colorectal-cancers 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07389265/continuacion-del-tratamiento-con-cetuximab-tras-la-progresion-en-primera-linea-en-el-cancer-colorrectal-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07389265/continuation-of-cetuximab-beyond-first-line-progression-in-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06496919/investigacion-en-el-mundo-real-sobre-la-prevencion-y-el-tratamiento-de-la-metastasis-peritoneal-y-la-ascitis-maligna-mediante-la-infusion-intraperitoneal-de-rmhtnf-en-tumores-malignos-gastricos-y 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06496919/a-real-world-research-on-the-prevention-and-treatment-of-peritoneal-metastasis-and-malignant-ascites-by-intraperitoneal-infusion-of-rmhtnf-in-gastric-and-colorectal-malignant-tumors 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06008054/un-estudio-de-si-b003-bl-b01d1-si-b003-y-bl-b01d1-anticuerpo-monoclonal-anti-pd-1-en-pacientes-con-cancer-de-esofago-localmente-avanzado-o-metastasico-cancer-gastrico-cancer-colorrectal-y-otros 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06008054/a-study-of-si-b003-bl-b01d1-si-b003-and-bl-b01d1-pd-1-monoclonal-antibody-in-patients-with-locally-advanced-or-metastatic-esophageal-cancer-gastric-cancer-colorectal-cancer-and-other-gastrointestinal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT01763125/creacion-de-un-biobanco-de-tumores-a-partir-de-muestras-de-sangre 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT01763125/establishment-of-a-tumor-bank-for-blood-samples 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07398326/anlotinib-en-combinacion-con-sintilimab-como-tratamiento-de-primera-linea-para-el-cancer-colorrectal-metastasico-avanzado-excluyendo-las-metastasis-hepaticas 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07398326/anlotinib-combined-with-sintilimab-as-first-line-treatment-for-advanced-non-liver-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03364621/analisis-genomico-exhaustivo-de-pacientes-con-cancer-colorrectal-y-metastasis-hepaticas-aisladas-para-comprender-la-respuesta-y-la-resistencia-a-la-terapia-contra-el-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03364621/comprehensive-genomic-profiling-of-colorectal-cancer-patients-with-isolated-liver-metastases-to-understand-response-resistance-to-cancer-therapy 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05141721/un-estudio-de-una-vacuna-neoantigenica-especifica-para-el-paciente-en-combinacion-con-el-bloqueo-de-los-puntos-de-control-inmunitario-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05141721/a-study-of-a-patient-specific-neoantigen-vaccine-in-combination-with-immune-checkpoint-blockade-for-patients-with-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07177742/estudio-de-cohorte-prospectivo-sobre-la-relacion-entre-la-peroxiredoxina-1-exosomal-prdx1-y-la-metastasis-hepatica-postoperatoria 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07177742/prospective-cohort-study-on-the-relationship-between-exosomal-peroxiredoxin-1-prdx1-and-postoperative-liver-metastasis 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03350126/relevancia-de-la-evaluacion-irecist-para-la-tasa-de-respuesta-global-dcr-en-pacientes-con-cancer-colorrectal-metastasico-mmr-msi-tratados-con-nivolumab-e-ipilimumab 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03350126/irecist-evaluation-s-relevance-for-dcr-in-mmr-msi-metastatic-colorectal-cancer-patients-on-nivolumab-and-ipilimumab 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05354674/firma-de-aprendizaje-profundo-multimodal-para-la-evaluacion-de-la-respuesta-al-bevacizumab-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05354674/multimodal-deep-learning-signature-for-evaluation-of-response-to-bevacizumab-in-patient-with-colorectal-cancer-liver-metastasis 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06547203/cetuximab-irinotecan-y-toripalimab-en-un-estudio-de-cancer-colorrectal-derecho-ultra-seleccionado-con-mutaciones-ras-braf-de-tipo-salvaje 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06547203/cetuximab-irinotecan-toripalimab-in-ras-braf-wild-type-ultraselected-right-sided-colorectal-cancer-study 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04743102/biopsia-multipunto-y-de-espesor-total-en-el-diagnostico-de-respuesta-clinica-completa-ccr-tras-la-terapia-neoadyuvante-para-el-cancer-de-recto 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04743102/multi-points-and-full-thickness-biopsy-in-the-diagnosis-of-ccr-after-neoadjuvant-therapy-for-rectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06978400/un-estudio-de-dabrafenib-mas-cetuximab-panitumumab-con-folfox-en-la-primera-linea-de-tratamiento-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06978400/a-study-of-dabrafenib-plus-cetuximab-panitumumab-with-folfox-in-the-first-line-of-therapy-in-people-with-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06967155/un-estudio-de-irinotecan-con-dabrafenib-mas-trametinib-y-anti-egfr-en-la-segunda-linea-de-tratamiento-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06967155/a-study-of-irinotecan-with-dabrafenib-plus-trametinib-and-anti-egfr-in-the-second-line-of-therapy-in-people-with-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07076823/seguridad-y-eficacia-de-canagliflozina-en-pacientes-con-cancer-colorrectal-metastasico-con-alta-inestabilidad-de-microsatelites-msi-h 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07076823/safety-and-efficacy-of-canagliflozin-in-patients-with-metastatic-high-microsatellite-instability-msi-h-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07193862/estudio-piloto-de-un-microdispositivo-implantable-para-la-evaluacion-in-situ-de-la-respuesta-a-farmacos-en-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07193862/pilot-study-of-an-implantable-microdevice-for-in-situ-evaluation-of-drug-response-in-patients-with-colorectal-liver-metastasis 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06218810/cadonilimab-en-combinacion-con-bevacizumab-y-el-regimen-folfox-para-el-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-avanzado-irresecable-y-de-tipo-mss-con-mutacion-en-los-genes-ras 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06218810/cadonilimab-in-combination-with-bevacizumab-and-folfox-regimen-for-the-first-line-treatment-of-advanced-unresectable-mss-type-ras-mutated-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06889610/un-estudio-clinico-de-fase-ii-sobre-la-ablacion-multimodal-combinada-con-terapia-sistemica-en-tumores-solidos-avanzados 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06889610/a-phase-ii-clinical-study-of-multimodal-ablation-combined-with-systemic-drug-therapy-for-advanced-solid-tumors 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04516681/combinacion-de-acido-ascorbico-intravenoso-y-adebrelimab-en-cancer-colorrectal-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04516681/combination-of-iv-ascorbic-acid-and-adebrelimab-in-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT00569127/octreotido-acetato-e-interferon-alfa-2b-recombinante-o-bevacizumab-en-el-tratamiento-de-pacientes-con-tumor-neuroendocrino-metastasico-o-localmente-avanzado-de-alto-riesgo 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT00569127/octreotide-acetate-and-recombinant-interferon-alfa-2b-or-bevacizumab-in-treating-patients-with-metastatic-or-locally-advanced-high-risk-neuroendocrine-tumor 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06621173/un-ensayo-clinico-que-evalua-la-seguridad-y-la-eficacia-del-srrna-intravenoso-hnf4-en-el-tratamiento-de-pacientes-con-crc-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06621173/a-clinical-trial-evaluating-the-safety-and-efficacy-of-intravenous-hnf4-srrna-in-treating-metastatic-crc-patients 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07172282/infinitive-inmunoterapia-para-pacientes-con-metastasis-hepaticas-de-cancer-colorrectal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07172282/infinitive-immunotherapy-for-patients-with-colorectal-liver-metastases 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07430540/optimizando-los-itinerarios-asistenciales-para-pacientes-con-cancer-colorrectal 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07430540/optimising-colorectal-cancer-patient-pathways 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06959550/estudio-de-fase-ii-del-anticuerpo-biespecifico-anti-pd-1-vegf-ivonescimab-en-pacientes-con-cancer-colorrectal-metastasico-previamente-tratado 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06959550/phase-ii-study-of-anti-pd-1-vegf-bispecific-antibody-ivonescimab-in-patients-with-previously-treated-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04585750/evaluacion-de-pc14586-en-pacientes-con-tumores-solidos-avanzados-que-presentan-una-mutacion-y220c-en-el-gen-tp53-pynnacle 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04585750/the-evaluation-of-pc14586-in-patients-with-advanced-solid-tumors-harboring-a-tp53-y220c-mutation-pynnacle 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07066657/un-estudio-de-mrg007-arr-217-en-pacientes-con-tumores-solidos-avanzados 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07066657/a-study-of-mrg007-arr-217-in-patients-with-advanced-solid-tumors 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07662031/tovecimig-mas-folfiri-en-segunda-linea-para-el-cancer-colorrectal-metastasico 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07662031/tovecimig-plus-folfiri-in-second-line-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07009145/ql1706-mas-bevacizumab-para-el-cancer-colorrectal-irresecable-o-metastasico-msi-h-dmmr 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07009145/ql1706-plus-bevacizumab-for-unresectable-or-metastatic-msi-h-dmmr-crc 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05768503/comparacion-de-chidamide-sintilimab-bevacizumab-con-el-regimen-estandar-de-segunda-linea-folfiri-bevacizumab-en-pacientes-con-mcrc-avanzado-mss-pmmr 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05768503/comparing-chidamide-sintilimab-bev-with-standard-second-line-folfiri-bev-in-advanced-mss-pmmr-mcrc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07000305/un-estudio-de-cetuximab-combinado-con-envolimab-y-mfolfox6-en-sujetos-con-cancer-colorrectal-avanzado 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07000305/a-study-of-cetuximab-combined-with-envolimab-and-mfolfox6-in-subjects-with-advanced-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05322590/bxq-350-en-pacientes-con-carcinoma-colorrectal-metastasico-de-diagnostico-reciente 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05322590/bxq-350-in-newly-diagnosed-metastatic-colorectal-carcinoma 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06934538/ensayo-clinico-de-fase-i-de-stc-1010-una-inmunoterapia-en-pacientes-con-cancer-colorrectal-localmente-avanzado-o-metastasico-irresecable 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06934538/first-in-human-trial-of-stc-1010-an-immunotherapy-in-patients-with-unresectable-locally-advanced-or-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07435584/everolimus-en-cancer-colorrectal-metastasico-con-deficiencia-de-cdk12-ever-recode 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07435584/everolimus-in-cdk12-deficient-metastatic-colorectal-cancer-ever-recode 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05611034/perfusion-pulmonar-in-vivo-ivlp-para-el-cancer-colorrectal-metastasico-en-pulmon 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05611034/in-vivo-lung-perfusion-ivlp-for-colorectal-cancer-metastatic-to-lung 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05240950/celulas-car-t-anti-cea-para-el-tratamiento-de-metastasis-hepaticas-de-cancer-colorrectal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05240950/anti-cea-car-t-cells-to-treat-colorectal-liver-metastases 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07446465/quimioterapia-folfox-combinada-con-fruquintinib-y-serplulimab-como-terapia-de-conversion-de-primera-linea-para-cancer-colorrectal-pmmr-mss-inicialmente-irresecable 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07446465/folfox-chemotherapy-combined-with-fruquintinib-and-serplulimab-as-first-line-conversion-therapy-for-initially-unresectable-pmmr-mss-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07201194/acupuntura-holistica-para-pacientes-con-nauseas-inducidas-por-la-quimioterapia 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07201194/holistic-acupuncture-for-patients-with-chemotherapy-induced-nausea 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06979908/un-estudio-clinico-sobre-la-eficacia-y-la-seguridad-de-fruquintinib-en-combinacion-con-un-anticuerpo-monoclonal-anti-pd-1-y-chidamide-en-el-cancer-colorrectal-metastasico-refractario-mss 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06979908/a-clinical-study-on-the-efficacy-and-safety-of-fruquintinib-in-combination-with-pd-1-monoclonal-antibody-and-chidamide-in-refractory-mss-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07453875/ldrt-quimioterapia-inmunologica-secuencial-con-nips-para-metastasis-peritoneales-de-cancer-gastrico-y-colorrectal 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07453875/ldrt-sequential-nips-immunochemotherapy-for-peritoneal-metastasis-of-gastric-and-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06760819/un-estudio-para-obtener-mas-informacion-sobre-la-eficacia-y-la-seguridad-del-tratamiento-con-tabletas-de-sevabertinib-bay-2927088-en-participantes-que-tienen-un-tumor-solido-con-mutaciones-del 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06760819/a-study-to-learn-more-about-how-well-treatment-with-sevabertinib-bay-2927088-tablets-works-and-how-safe-it-is-in-participants-who-have-a-solid-tumor-with-mutations-of-the-human-epidermal-growth 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06563986/ftd-tpi-bevacizumab-y-radioembolizacion-con-microsferas-de-166ho-en-el-cancer-colorrectal-metastasico-refractario 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06563986/ftd-tpi-bevacizumab-and-radioembolization-with-166ho-microspheres-in-refractory-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03908788/deteccion-de-la-aparicion-de-mutaciones-en-el-gen-ras-homologo-del-oncogen-viral-del-sarcoma-de-rata-en-el-adn-circulante-acido-desoxirribonucleico-en-pacientes-con-ccrc-metastasico-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03908788/detection-of-the-emergence-of-ras-rat-sarcoma-viral-oncogene-homolog-mutations-in-circulating-dna-deoxyribonucleic-acid-in-patients-with-mcrc-metastatic-colorectal-cancer-during-treatment-with-anti 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07213570/stream-2-tratamiento-de-segunda-linea-con-regorafenib-en-cancer-colorrectal-avanzado-con-mutacion-en-ras 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07213570/stream-2-second-line-treatment-with-regorafenib-in-advanced-ras-mutant-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05068531/deteccion-temprana-del-fracaso-del-tratamiento-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05068531/early-detection-of-treatment-failure-in-metastatic-colorectal-cancer-patients 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04444921/ea2176-ensayo-clinico-de-fase-iii-con-carboplatino-y-paclitaxel-nivolumab-en-pacientes-con-cancer-anal-metastasico 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04444921/ea2176-phase-3-clinical-trial-of-carboplatin-and-paclitaxel-nivolumab-in-metastatic-anal-cancer-patients 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03654131/ablacion-por-microondas-frente-a-radioterapia-estereotactica-para-metastasis-hepaticas-de-cancer-colorrectal-en-enfermedad-oligometastasica-un-ensayo-prospectivo-aleatorizado-de-fase-ii 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03654131/microwave-ablation-versus-stereotactic-body-radiotherapy-for-colorectal-liver-metastases-in-oligometastatic-disease-a-prospective-randomised-phase-2-trial 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07283575/uso-de-la-metilacion-del-ctdna-para-monitorizar-el-tratamiento-del-cancer-colorrectal-metastasico-promet 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07283575/using-ctdna-methylation-to-monitor-metastatic-colorectal-cancer-treatment-promet 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07003022/ensayo-clinico-de-fase-ii-de-cadonilimab-en-combinacion-con-agentes-antiangiogenicos-en-el-cancer-colorrectal-metastasico-dmmr-msi-h 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07003022/phase-ii-clinical-trial-of-cadonilimab-combined-with-anti-angiogenic-agents-in-metastatic-dmmr-msi-h-crc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07094893/agentes-anti-egfr-en-pacientes-con-cancer-colorrectal-avanzado-del-lado-derecho-con-ras-de-tipo-salvaje-y-alto-nivel-de-expresion-de-areg-ereg 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07094893/anti-egfr-agents-in-patients-with-right-sided-advanced-colorectal-cancer-with-wild-type-ras-and-areg-ereg-high-status 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06269978/oxaliplatino-y-fluorouracilo-administrados-por-via-intraperitoneal-para-el-tratamiento-de-pacientes-con-metastasis-peritoneales-procedentes-de-cancer-colorrectal 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06269978/intraperitoneal-oxaliplatin-and-fluorouracil-for-the-treatment-of-patients-with-peritoneal-metastases-from-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07229872/un-estudio-clinico-de-fase-ii-de-aipalolitovorelizumab-ql1706-en-combinacion-con-fruquintinib-para-el-tratamiento-del-cancer-colorrectal-metastasico-pmmr-mss-inmunodominante-que-ha-mostrado-falta-de 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07229872/a-phase-ii-clinical-study-of-aipalolitovorelizumab-ql1706-combined-with-fruquintinib-in-the-treatment-of-immunodominant-pmmr-mss-metastatic-colorectal-cancer-that-has-failed-second-line-or-above 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05171660/combinacion-con-sintilimab-y-xelox-bevacizumab-como-terapia-de-primera-linea-en-el-cancer-colorrectal-metastasico-con-mutacion-en-los-genes-ras 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05171660/combination-with-sintilimab-and-xelox-bevacizumab-as-1st-line-therapy-in-ras-mutant-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT04680260/optimizacion-de-la-seleccion-del-tratamiento-y-el-seguimiento-en-el-cancer-colorrectal-oligo-metastasico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04680260/optimization-of-treatment-selection-and-follow-up-in-oligometastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07474025/integracion-de-los-patrones-de-crecimiento-histologico-peritoneal-en-la-toma-de-decisiones-preoperatorias-para-las-metastasis-peritoneales-del-cancer-colorrectal 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07474025/integrating-peritoneal-histological-growth-patterns-into-preoperative-decision-making-for-colorectal-peritoneal-metastses 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07059338/bloqueo-dual-de-egfr-her2-combinado-con-irinotecan-para-el-tratamiento-del-cancer-colorrectal-metastasico-her2-positivo 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07059338/dual-egfr-her2-blockade-combined-with-irinotecan-for-the-treatment-of-her2-positive-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05129774/quimiorradioterapia-seguida-de-cirugia-radical-en-pacientes-con-cancer-colorrectal-con-palnm 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05129774/chemoradiotherapy-sequenced-radical-surgery-for-colorectal-cancer-with-palnm 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03401294/conversion-de-cancer-colorrectal-metastasico-irresecable-a-resecable 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03401294/conversion-from-unresectable-to-resectable-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07211230/estudio-del-biobanco-de-colagenasa 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07211230/collagenase-biobank-study 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03349762/huaier-granules-para-la-prevencion-de-la-recurrencia-y-la-metastasis-en-pacientes-con-cancer-colorrectal-tras-la-cirugia-radical 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03349762/huaier-granules-for-prevention-of-recurrence-and-metastasis-of-colorectal-cancer-patients-following-radical-surgery 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07714447/eficacia-y-seguridad-de-la-terapia-combinada-con-tunlametinib-en-el-tratamiento-del-cancer-colorrectal-metastasico-en-segunda-linea-o-posterior 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07714447/efficacy-and-safety-of-tunlametinib-combination-therapy-in-the-treatment-of-second-line-and-above-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06558773/inhibidor-de-la-sintetasa-gsl-en-combinacion-con-un-inhibidor-del-punto-de-control-inmunitario-y-o-regorafenib-en-pacientes-con-cancer-colorrectal-pmmr-mss-previamente-tratados 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06558773/gsl-synthetase-inhibitor-plus-immune-checkpoint-inhibitor-and-or-regorafenib-in-previously-treated-pmmr-mss-crc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05806931/administracion-secuencial-de-tas-ox-en-combinacion-con-tas-iri-alternada-con-bevacizumab-para-el-tratamiento-de-pacientes-con-cancer-colorrectal-metastasico-en-lineas-de-tratamiento-avanzadas 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05806931/sequential-tas-ox-alternating-with-tas-iri-plus-bevacizumab-for-late-line-metastatic-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07722754/bevacizumab-sintilimab-cetuximab-e-irinotecan-en-el-cancer-colorrectal-metastasico-refractario-con-ras-de-tipo-salvaje-ensayo-bond-4 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07722754/bevacizumab-sintilimab-cetuximab-and-irinotecan-in-refractory-ras-wild-type-metastatic-colorectal-cancer-bond-4-trial 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05719558/un-estudio-de-asp1002-en-adultos-para-el-tratamiento-de-tumores-solidos 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05719558/a-study-of-asp1002-in-adults-for-treatment-of-solid-tumors 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07494578/estudio-observacional-sobre-la-combinacion-de-fluoropirimidina-y-bevacizumab-en-pacientes-con-mcrc 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07494578/observational-study-regarding-the-combination-of-fluoropyrimidine-and-bevacizumab-in-patients-with-mcrc 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03776591/colecolectomia-derecha-abierta-versus-colecolectomia-minimamente-invasiva-laparoscopica-para-el-cancer-de-colon-derecho 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03776591/open-d3-right-hemicolectomy-compared-to-laparoscopic-cme-for-right-sided-colon-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06513221/un-estudio-prospectivo-de-cancer-colorrectal-metastasico-de-tipo-mss-que-recibe-multiples-lineas-de-quimioterapia-estandar-bevacizumab-en-combinacion-con-adebrelimab 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06513221/a-prospective-study-of-mss-type-metastatic-colorectal-cancer-receiving-multiple-lines-of-standard-chemotherapy-bevacizumab-combined-with-adebrelimab 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05783622/estudio-de-janx008-en-pacientes-con-tumores-solidos-avanzados-o-metastasicos 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05783622/study-of-janx008-in-subjects-with-advanced-or-metastatic-solid-tumor-malignancies 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT05059444/oracle-observacion-de-enfermedad-residual-mediante-evaluacion-con-biopsia-liquida 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT05059444/oracle-observation-of-residual-cancer-with-liquid-biopsy-evaluation 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07623369/un-estudio-de-fase-i-en-humanos-con-hh160-en-pacientes-con-tumores-solidos-avanzados 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07623369/a-first-in-human-study-of-hh160-in-patients-with-advanced-solid-tumors 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07510932/fruquintinib-en-pacientes-con-cancer-colorrectal-metastasico-refractario-a-las-quimioterapias-estandar-en-corea-del-sur-first-k 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07510932/fruquintinib-in-patients-with-metastatic-colorectal-cancer-refractory-to-standard-chemotherapies-in-south-korea-patients-first-k 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622550/un-estudio-clinico-multicentrico-de-un-solo-brazo-que-evalua-la-combinacion-de-fruquintinib-con-serplulimab-y-quimioterapia-como-tratamiento-de-primera-linea-en-pacientes-con-cancer-colorrectal 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07622550/a-single-arm-multicenter-clinical-study-of-fruquintinib-combined-with-serplulimab-and-chemotherapy-as-first-line-treatment-for-patients-with-ras-braf-mutated-advanced-colorectal-cance 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07623642/un-estudio-de-fase-ii-de-gv20-0251-en-combinacion-con-anticuerpos-monoclonales-anti-pd-1-en-pacientes-con-tumores-solidos-irresecables-localmente-avanzados-o-metastasicos 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07623642/a-phase-ii-study-of-gv20-0251-in-combination-with-anti-pd-1-monoclonal-antibodies-in-patients-with-unresectable-locally-advanced-or-metastatic-solid-tumors 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07318805/un-estudio-para-evaluar-el-medicamento-pf-08032562-en-personas-con-tumores-solidos-avanzados-o-metastasicos 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07318805/a-study-to-learn-about-the-study-medicine-called-pf-08032562-in-people-with-advanced-or-metastatic-solid-tumors 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07318389/ascend-crc-perfilado-y-abordaje-de-la-resistencia-tumoral-dinamica-en-pacientes-con-cancer-colorrectal-metastasico 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07318389/ascend-crc-profiling-and-targeting-dynamic-tumor-resistance-in-patients-with-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03961776/monitorizacion-de-la-respuesta-al-tratamiento-mediante-la-tecnica-de-difusion-ponderada-en-imagen-dwi-durante-la-quimiorradiacion-neoadyuvante-para-el-cancer-de-recto-utilizando-sistemas-de 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03961776/monitoring-treatment-response-with-on-board-dwi-during-neo-adjuvant-chemo-radiation-for-rectal-cancer-using-magnetic-resonance-guided-radiotherapy-systems 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06995898/el-estudio-vanguard-evaluacion-de-una-nueva-forma-de-deteccion-del-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06995898/the-vanguard-study-testing-a-new-way-to-screen-for-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07525206/un-estudio-para-evaluar-el-uso-de-telisotuzumab-adizutecan-intravenoso-iv-en-combinacion-con-bevacizumab-iv-en-comparacion-con-el-tratamiento-estandar-con-bevacizumab-iv-en-combinacion-con 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT07525206/a-study-to-access-intravenous-iv-telisotuzumab-adizutecan-in-combination-with-iv-bevacizumab-compared-to-standard-of-care-iv-bevacizumabin-combination-with-oral-trifluridine-and-tipiracil-in-adult 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06342440/deteccion-temprana-de-adenomas-avanzados-y-cancer-colorrectal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06342440/early-detection-of-advanced-adenomas-and-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06395519/un-estudio-del-inhibidor-de-parg-etx-19477-en-pacientes-con-tumores-solidos-avanzados 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06395519/a-study-of-parg-inhibitor-etx-19477-in-patients-with-advanced-solid-malignancies 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06106308/estudio-de-onvansertib-en-combinacion-con-folfiri-y-bevacizumab-o-folfox-y-bevacizumab-en-comparacion-con-folfiri-y-bevacizumab-o-folfox-y-bevacizumab-para-el-tratamiento-de-primera-linea-del-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06106308/study-of-onvansertib-in-combination-with-folfiri-and-bevacizumab-or-folfox-and-bevacizumab-versus-folfiri-and-bevacizumab-or-folfox-and-bevacizumab-for-first-line-treatment-of-metastatic-colorectal 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06784947/ensayo-clinico-de-atezolizumab-bevacizumab-y-tiragolumab-en-pacientes-con-cancer-colorrectal-metastasico-con-estabilidad-microsatelital 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06784947/trial-of-atezolizumab-bevacizumab-and-tiragolumab-in-patients-with-microsatellite-stable-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT02568267/estudio-basket-de-entrectinib-rxdx-101-para-el-tratamiento-de-pacientes-con-tumores-solidos-que-presentan-reordenamientos-fusiones-en-los-genes-ntrk-1-2-3-trk-a-b-c-ros1-o-alk 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT02568267/basket-study-of-entrectinib-rxdx-101-for-the-treatment-of-patients-with-solid-tumors-harboring-ntrk-1-2-3-trk-a-b-c-ros1-or-alk-gene-rearrangements-fusions 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06646341/emvi-como-factor-determinante-de-la-metastasis-en-el-cancer-colorrectal 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06646341/emvi-as-a-determinant-of-metastasis-in-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06543836/tratamiento-guiado-por-ctdna-con-tki-mas-inhibidor-de-pd-1-en-el-cancer-colorrectal-avanzado-pmmr-mss 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06543836/ctdna-guided-treatment-of-tki-plus-pd-1-inhibitor-for-advanced-pmmr-mss-colorectal-cancer 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06449937/tratamiento-local-hepatico-para-metastasis-de-cancer-colorrectal-multiorganico 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06449937/local-liver-treatment-for-multi-organ-colorectal-cancer-metastases 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06593548/lvosidenib-ak112-en-combinacion-con-capeox-y-radioterapia-en-pacientes-con-cancer-colorrectal-metastasico-irresecable-de-tipo-mss 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06593548/lvosidenib-ak112-combined-with-capeox-and-radiotherapy-in-patients-with-unresectable-metastatic-mss-type-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06270017/evaluacion-de-la-enfermedad-metastasica-y-del-tratamiento-oncologico-en-pacientes-con-cancer-de-colon-mediante-el-uso-de-avatares-de-pez-cebra 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06270017/evaluation-of-metastatic-disease-and-oncological-treatment-in-patients-with-colon-cancer-using-zebra-fish-avatars 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06342401/deteccion-temprana-del-cancer-colorrectal-en-pacientes-jovenes 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06342401/early-onset-colorectal-cancer-detection 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06549907/un-estudio-exploratorio-de-biomarcadores-sobre-el-bloqueo-dual-de-pd1-pdl1-y-ctla4-y-la-terapia-antiangiogenica 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06549907/a-biomarker-exploratory-study-of-dual-blockade-of-pd1-pdl1-and-ctla4-and-anti-angiogenic-therapy 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04851119/tegavivint-para-el-tratamiento-de-tumores-solidos-recurrentes-o-refractarios-incluidos-los-linfomas-y-los-tumores-desmoides 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT04851119/tegavivint-for-the-treatment-of-recurrent-or-refractory-solid-tumors-including-lymphomas-and-desmoid-tumors 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT03657641/regorafenib-y-pembrolizumab-en-el-tratamiento-de-participantes-con-cancer-colorrectal-avanzado-o-metastasico 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT03657641/regorafenib-and-pembrolizumab-in-treating-participants-with-advanced-or-metastatic-colorectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07175636/ql1706-radioterapia-y-quimioterapia-a-corto-plazo-para-el-cancer-colorrectal-mss 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT07175636/ql1706-with-short-course-radiotherapy-and-chemotherapy-for-mss-rectal-cancer 2026-08-11 weekly 0.6 https://crcwarriors.org/ensayo/NCT06149481/estudio-de-fase-i-ii-del-regimen-de-inmunoterapia-combinada-sx-682-vacuna-triadeno-retifanlimab-y-agonista-de-il-15-n-803-star15-para-el-cancer-colorrectal-metastasico-mcrc 2026-08-11 weekly 0.7 https://crcwarriors.org/ensayo/NCT06149481/phase-i-ii-study-of-the-combination-immunotherapy-regimen-sx-682-triadeno-vaccine-retifanlimab-and-il-15-agonist-n-803-star15-for-metastatic-colorectal-cancer-mcrc 2026-08-11 weekly 0.7 https://crcwarriors.org/medicamento/oxaliplatin 2026-08-11 weekly 0.7 https://crcwarriors.org/medicamento/oxaliplatin/ensayos 2026-08-11 weekly 0.6 https://crcwarriors.org/medicamento/uracil 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/uracil/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/fluorouracil 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/fluorouracil/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/5-fluorouracil 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/5-fluorouracil/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/leucovorin 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/leucovorin/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/capecitabine 2026-08-11 weekly 0.7 https://crcwarriors.org/medicamento/capecitabine/ensayos 2026-08-11 weekly 0.6 https://crcwarriors.org/medicamento/irinotecan 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/irinotecan/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/cetuximab 2026-07-25 weekly 0.7 https://crcwarriors.org/medicamento/cetuximab/ensayos 2026-07-25 weekly 0.6 https://crcwarriors.org/medicamento/pembrolizumab 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/pembrolizumab/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/met 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/met/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/panitumumab 2026-06-23 weekly 0.7 https://crcwarriors.org/medicamento/panitumumab/ensayos 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/nivolumab 2026-07-16 weekly 0.7 https://crcwarriors.org/medicamento/nivolumab/ensayos 2026-07-16 weekly 0.6 https://crcwarriors.org/medicamento/regorafenib 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/regorafenib/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/rego 2026-08-07 weekly 0.7 https://crcwarriors.org/medicamento/rego/ensayos 2026-08-07 weekly 0.6 https://crcwarriors.org/medicamento/tislelizumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tislelizumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/fruquintinib 2026-07-30 weekly 0.7 https://crcwarriors.org/medicamento/fruquintinib/ensayos 2026-07-30 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/paclitaxel 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/paclitaxel/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine 2026-07-30 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine/ensayos 2026-07-30 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamid 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamid/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cyclophosphamide 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cyclophosphamide/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/atezolizumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/atezolizumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/carboplatin 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/carboplatin/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/cisplatin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cisplatin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sintilimab 2026-07-31 weekly 0.7 https://crcwarriors.org/medicamento/sintilimab/ensayos 2026-07-31 weekly 0.6 https://crcwarriors.org/medicamento/durvalumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/durvalumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ipilimumab 2026-07-16 weekly 0.7 https://crcwarriors.org/medicamento/ipilimumab/ensayos 2026-07-16 weekly 0.6 https://crcwarriors.org/medicamento/gemcitabine 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/gemcitabine/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/pemetrexed 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/pemetrexed/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/celecoxib 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/celecoxib/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/cele 2026-05-15 weekly 0.7 https://crcwarriors.org/medicamento/cele/ensayos 2026-05-15 weekly 0.6 https://crcwarriors.org/medicamento/s-1 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/s-1/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/aldesleukin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aldesleukin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fludarabine 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fludarabine/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/aspirin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aspirin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fulvestrant 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fulvestrant/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/encorafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/encorafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/docetaxel 2026-08-06 weekly 0.7 https://crcwarriors.org/medicamento/docetaxel/ensayos 2026-08-06 weekly 0.6 https://crcwarriors.org/medicamento/aflibercept 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/aflibercept/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/binimetinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/binimetinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trametinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trametinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tori 2026-06-26 weekly 0.7 https://crcwarriors.org/medicamento/tori/ensayos 2026-06-26 weekly 0.6 https://crcwarriors.org/medicamento/palbociclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/palbociclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/toripalimab 2026-06-26 weekly 0.7 https://crcwarriors.org/medicamento/toripalimab/ensayos 2026-06-26 weekly 0.6 https://crcwarriors.org/medicamento/erlotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/erlotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/everolimus 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/everolimus/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nab-paclitaxel 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/nab-paclitaxel/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/balstilimab 2026-07-31 weekly 0.7 https://crcwarriors.org/medicamento/balstilimab/ensayos 2026-07-31 weekly 0.6 https://crcwarriors.org/medicamento/botensilimab 2026-07-31 weekly 0.7 https://crcwarriors.org/medicamento/botensilimab/ensayos 2026-07-31 weekly 0.6 https://crcwarriors.org/medicamento/cadonilimab 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/cadonilimab/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/serplulimab 2026-07-10 weekly 0.7 https://crcwarriors.org/medicamento/serplulimab/ensayos 2026-07-10 weekly 0.6 https://crcwarriors.org/medicamento/vemurafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/vemurafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/avelumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avelumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cemiplimab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/cemiplimab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sargramostim 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sargramostim/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/metformin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/metformin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/olaparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/olaparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/temozolomide 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/temozolomide/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/dostarlimab 2026-08-04 weekly 0.7 https://crcwarriors.org/medicamento/dostarlimab/ensayos 2026-08-04 weekly 0.6 https://crcwarriors.org/medicamento/adebrelimab 2026-07-23 weekly 0.7 https://crcwarriors.org/medicamento/adebrelimab/ensayos 2026-07-23 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxteca 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxteca/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/trastuzumab+deruxtecan/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/adagrasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/adagrasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dexamethasone 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/dexamethasone/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/tremelimumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tremelimumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/apatinib 2026-07-09 weekly 0.7 https://crcwarriors.org/medicamento/apatinib/ensayos 2026-07-09 weekly 0.6 https://crcwarriors.org/medicamento/cabozantinib 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/cabozantinib/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/peg 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/peg/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mitomycin 2026-07-14 weekly 0.7 https://crcwarriors.org/medicamento/mitomycin/ensayos 2026-07-14 weekly 0.6 https://crcwarriors.org/medicamento/tucatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tucatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sorafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sorafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tipiracil 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/tipiracil/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/lidocaine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lidocaine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abemaciclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/abemaciclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/camrelizumab 2026-04-16 weekly 0.7 https://crcwarriors.org/medicamento/camrelizumab/ensayos 2026-04-16 weekly 0.6 https://crcwarriors.org/medicamento/ivonescimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ivonescimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/metronidazole 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/metronidazole/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/raltitrexed 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/raltitrexed/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pertuzumab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pertuzumab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ramucirumab 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/ramucirumab/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/ribociclib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ribociclib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amg 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/amg/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ql1706 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/ql1706/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/sirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/envafolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/envafolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sotorasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sotorasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/selumetinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selumetinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/letrozole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/letrozole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dabrafenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dabrafenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sunitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/sunitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tas 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tas/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ak112 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ak112/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/lenvatinib 2026-07-08 weekly 0.7 https://crcwarriors.org/medicamento/lenvatinib/ensayos 2026-07-08 weekly 0.6 https://crcwarriors.org/medicamento/hydroxychloroquine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hydroxychloroquine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/osimertinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/osimertinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/gefitinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gefitinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bortezomib 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/bortezomib/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/lapatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/lapatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/axitinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/axitinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/filgrastim 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/filgrastim/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/infliximab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/infliximab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/amivantamab 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/amivantamab/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/vandetanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vandetanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cediranib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cediranib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/chidamide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/chidamide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sulindac 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sulindac/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dasatinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dasatinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphala 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/melphala/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/retifanlimab 2026-07-02 weekly 0.7 https://crcwarriors.org/medicamento/retifanlimab/ensayos 2026-07-02 weekly 0.6 https://crcwarriors.org/medicamento/vorinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/vorinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vorinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vorinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/melphalan 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/melphalan/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/midazolam 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/midazolam/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/iparomlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/iparomlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/afatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/afatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tuvonralimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tuvonralimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cobimetinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/cobimetinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/doxorubicin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/doxorubicin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/indocyanine+green 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indocyanine+green/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tegafu 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tegafu/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sasanlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sasanlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/temsirolimus 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/temsirolimus/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zanidatamab 2026-06-09 weekly 0.7 https://crcwarriors.org/medicamento/zanidatamab/ensayos 2026-06-09 weekly 0.6 https://crcwarriors.org/medicamento/veliparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/veliparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/azacitidine 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/azacitidine/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/tegafur 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tegafur/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/enzalutamide 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/enzalutamide/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/pumitamig 2026-07-02 weekly 0.7 https://crcwarriors.org/medicamento/pumitamig/ensayos 2026-07-02 weekly 0.6 https://crcwarriors.org/medicamento/other 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/other/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/g17dt 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/g17dt/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eflornithine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eflornithine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/decitabine 2026-07-10 weekly 0.7 https://crcwarriors.org/medicamento/decitabine/ensayos 2026-07-10 weekly 0.6 https://crcwarriors.org/medicamento/bkm120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bkm120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/moviprep 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/moviprep/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/g17d 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g17d/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/jab-21822 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/jab-21822/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/propofol 2026-08-01 weekly 0.7 https://crcwarriors.org/medicamento/propofol/ensayos 2026-08-01 weekly 0.6 https://crcwarriors.org/medicamento/trifluridine-tipiracil 2026-07-24 weekly 0.7 https://crcwarriors.org/medicamento/trifluridine-tipiracil/ensayos 2026-07-24 weekly 0.6 https://crcwarriors.org/medicamento/sol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/entinostat 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/entinostat/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nw-301v 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/nw-301v/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/adc 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/adc/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pdr001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pdr001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tno155 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tno155/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hlx10 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hlx10/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pazopanib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pazopanib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/t3011 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/t3011/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/anlotinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/anlotinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/hrs-4642 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hrs-4642/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/nktr 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nktr/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/omeprazole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/omeprazole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rmc-6236 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-6236/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/crizotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/crizotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/dexmedetomidine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dexmedetomidine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tocilizumab 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/tocilizumab/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/fianlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/fianlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etrumadenant 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etrumadenant/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ropivacaine 2026-06-05 weekly 0.7 https://crcwarriors.org/medicamento/ropivacaine/ensayos 2026-06-05 weekly 0.6 https://crcwarriors.org/medicamento/ts-1 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ts-1/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/shr-8068 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-8068/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/nintedanib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nintedanib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/lenalidomide 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lenalidomide/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/methotrexate 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/methotrexate/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/prednisone 2026-08-06 weekly 0.7 https://crcwarriors.org/medicamento/prednisone/ensayos 2026-08-06 weekly 0.6 https://crcwarriors.org/medicamento/itraconazole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/itraconazole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/sym004 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym004/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/penpulimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/penpulimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ruxolitinib 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/ruxolitinib/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/lorigerlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/lorigerlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/spartalizumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/spartalizumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nw-301d 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/nw-301d/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/riluzole 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/riluzole/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tiragolumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tiragolumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pegfilgrastim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pegfilgrastim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zanzalintinib 2026-08-11 weekly 0.7 https://crcwarriors.org/medicamento/zanzalintinib/ensayos 2026-08-11 weekly 0.6 https://crcwarriors.org/medicamento/saline 2026-06-05 weekly 0.7 https://crcwarriors.org/medicamento/saline/ensayos 2026-06-05 weekly 0.6 https://crcwarriors.org/medicamento/nktr- 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/nktr-/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/sevoflurane 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sevoflurane/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/daraxonrasib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/daraxonrasib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/epacadostat 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/epacadostat/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/imatinib 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/imatinib/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/tivozanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tivozanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/shr-a1811 2026-07-01 weekly 0.7 https://crcwarriors.org/medicamento/shr-a1811/ensayos 2026-07-01 weekly 0.6 https://crcwarriors.org/medicamento/sgm-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgm-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bbi608 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bbi608/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bi-1701963 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/bi-1701963/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bp102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bp102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pf-07220060 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pf-07220060/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/imiquimod 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imiquimod/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/naliri 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/naliri/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/abbv-400 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/abbv-400/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hmn14 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hmn14/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/allostim 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/allostim/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/neratinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/neratinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bibf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/radiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/radiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/inavolisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inavolisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ganitumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ganitumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/e7386 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7386/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/semaxanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/semaxanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ibi363 2026-07-28 weekly 0.7 https://crcwarriors.org/medicamento/ibi363/ensayos 2026-07-28 weekly 0.6 https://crcwarriors.org/medicamento/osi-906 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/osi-906/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/rmc-9805 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-9805/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/etbx-011 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-011/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bupivacain 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bupivacain/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hdm201 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/hdm201/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hs-20093 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-20093/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/tucidinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tucidinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/indomethacin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/indomethacin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tucidinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tucidinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/doxycycline 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/doxycycline/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/enadenotucirev 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enadenotucirev/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/regn7075 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/regn7075/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/defactinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/defactinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/romidepsi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/romidepsi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/calderasib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/calderasib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amg-655 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-655/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mk-2206 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mk-2206/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eniluracil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eniluracil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vedolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vedolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/indomethaci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/indomethaci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/fleet 2026-07-11 weekly 0.7 https://crcwarriors.org/medicamento/fleet/ensayos 2026-07-11 weekly 0.6 https://crcwarriors.org/medicamento/nilotinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/nilotinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/plenvu 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plenvu/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pucotenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pucotenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastati 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastati/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/selpercatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/selpercatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/romidepsin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/romidepsin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gvax 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gvax/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/panobinosta 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/panobinosta/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipir 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipir/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/relatlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/relatlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/m9140 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/m9140/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/mcla-129 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/mcla-129/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/flucytosine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/flucytosine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/thymalfasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/thymalfasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/talazoparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/talazoparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/etrolizumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/etrolizumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nimotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nimotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cs-1008 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cs-1008/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dalotuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dalotuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selinexo 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexo/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ulixertinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ulixertinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/vismodegib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vismodegib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/zimberelimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/zimberelimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/egfr 2026-05-16 weekly 0.7 https://crcwarriors.org/medicamento/egfr/ensayos 2026-05-16 weekly 0.6 https://crcwarriors.org/medicamento/selinexor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/selinexor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/amg-479 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/amg-479/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/niraparib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/niraparib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/incb001158 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb001158/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gv20-0251 2026-06-04 weekly 0.7 https://crcwarriors.org/medicamento/gv20-0251/ensayos 2026-06-04 weekly 0.6 https://crcwarriors.org/medicamento/bibf-1120 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/bibf-1120/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/n-803 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/n-803/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/e7820 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7820/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abx-egf 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/abx-egf/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/onvansertib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/onvansertib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pd-0325901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pd-0325901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/chemoradiotherapy 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/chemoradiotherapy/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/brivanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/brivanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sg001 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sg001/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/cyclosporine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyclosporine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rosuvastatin 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rosuvastatin/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ner1006 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ner1006/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/alectinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/alectinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/panobinostat 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/panobinostat/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mangafodipi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mangafodipi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-10370 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-10370/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/mw4911 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/mw4911/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/neomyci 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomyci/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/maraviroc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/maraviroc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/eribulin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/eribulin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/magrolimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/magrolimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bbo-10203 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/bbo-10203/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/rnk08954 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/rnk08954/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/ci-1040 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ci-1040/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nis793 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/nis793/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cv301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cv301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ivosidenib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ivosidenib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/imc-a12 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/imc-a12/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tinzaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/napabucasi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/napabucasi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-10502 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-10502/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rimiducid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rimiducid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pralsetinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pralsetinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/calmangafodipir 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/calmangafodipir/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gdc-1971 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gdc-1971/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/reolysi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/st316 2026-07-30 weekly 0.7 https://crcwarriors.org/medicamento/st316/ensayos 2026-07-30 weekly 0.6 https://crcwarriors.org/medicamento/conatumumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/conatumumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/s-531011 2026-07-23 weekly 0.7 https://crcwarriors.org/medicamento/s-531011/ensayos 2026-07-23 weekly 0.6 https://crcwarriors.org/medicamento/ceralasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ceralasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/masitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/masitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/d-1553 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/d-1553/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rec-4881 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/rec-4881/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/budigalimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/budigalimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bms-986340 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986340/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inc280 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/inc280/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/kd018 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/kd018/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/arfolitixorin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/arfolitixorin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/sgn1 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/sgn1/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/ca102n 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ca102n/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/udenafil 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/udenafil/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/volrustomig 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/volrustomig/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/foxy-5 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/foxy-5/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cmab009 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cmab009/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/anastrozole 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/anastrozole/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/amt2003 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/amt2003/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/exemestane 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/exemestane/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/alt-803 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/alt-803/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/imlunestrant 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/imlunestrant/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/pro95780 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/pro95780/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/azd5305 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/azd5305/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ak119 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ak119/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/e7070 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/e7070/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/elimusertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/elimusertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bevacizumab-irdye800cw/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pirfenidone 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/pirfenidone/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enzastaurin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/enzastaurin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/nv1020 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nv1020/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/entrectinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/entrectinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bibw-2992 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bibw-2992/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/erdafitinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/erdafitinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ssgj-612 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/ssgj-612/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/dovitinib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/dovitinib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/enoxaparin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/enoxaparin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/denosumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/denosumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/vatalanib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/vatalanib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/fmt 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/fmt/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/floxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/floxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaba 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaba/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/xilonix 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/xilonix/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/artesunate 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/artesunate/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bms-986016 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bms-986016/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bli850 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bli850/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hs-20117 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hs-20117/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/hlx208 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hlx208/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nns309 2026-06-06 weekly 0.7 https://crcwarriors.org/medicamento/nns309/ensayos 2026-06-06 weekly 0.6 https://crcwarriors.org/medicamento/fluzoparib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/fluzoparib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/capivasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/capivasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/copanlisib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/copanlisib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rezatapop 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rezatapop/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/leflunomide 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/leflunomide/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ipatasertib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/ipatasertib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/camizestrant 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/camizestrant/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/larotrectinib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/larotrectinib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/dato-dxd 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/dato-dxd/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rmc-4630 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-4630/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/bi-765049 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bi-765049/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/dulanermin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dulanermin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cannabidiol 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cannabidiol/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ridaforolimus 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ridaforolimus/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ga-nns309 2026-06-06 weekly 0.7 https://crcwarriors.org/medicamento/ga-nns309/ensayos 2026-06-06 weekly 0.6 https://crcwarriors.org/medicamento/naproxen 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxen/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/lubiprostone 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/lubiprostone/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/neomycin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/neomycin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nalirifox 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/nalirifox/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/bupivacaine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bupivacaine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ufox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ufox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mrg007 2026-07-31 weekly 0.7 https://crcwarriors.org/medicamento/mrg007/ensayos 2026-07-31 weekly 0.6 https://crcwarriors.org/medicamento/dsp107 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/dsp107/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-4000 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-4000/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/oleclumab 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/oleclumab/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/trk-950 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/trk-950/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/hua33 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/hua33/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bisacodyl 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/bisacodyl/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hf50 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/hf50/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/jab-3312 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jab-3312/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bgb-43395 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/bgb-43395/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/cb-839 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cb-839/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/pm8002 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pm8002/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pemigatinib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pemigatinib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/gastrografin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gastrografin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/plerixafo 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/plerixafo/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sgi-110 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sgi-110/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/citrafleet 2026-07-11 weekly 0.7 https://crcwarriors.org/medicamento/citrafleet/ensayos 2026-07-11 weekly 0.6 https://crcwarriors.org/medicamento/mm-151 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-151/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/carmustine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/carmustine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/abiraterone 2026-06-03 weekly 0.7 https://crcwarriors.org/medicamento/abiraterone/ensayos 2026-06-03 weekly 0.6 https://crcwarriors.org/medicamento/ompenaclid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ompenaclid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-398 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-398/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/rivaroxaban 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rivaroxaban/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/js207 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/js207/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/thalidomide 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/thalidomide/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/il2 2026-05-06 weekly 0.7 https://crcwarriors.org/medicamento/il2/ensayos 2026-05-06 weekly 0.6 https://crcwarriors.org/medicamento/hsk42360 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/hsk42360/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/silymarin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/silymarin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/desflurane 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/desflurane/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamyci 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamyci/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/utidelone 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/utidelone/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/loperamide 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/loperamide/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gh21 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/gh21/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/si-b003 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/si-b003/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-051 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-051/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/can04 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/can04/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/etbx-061 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/etbx-061/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/gi-6301 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/gi-6301/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-c901 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-c901/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/grt-r902 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/grt-r902/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/nc410 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/nc410/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/a166 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/a166/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rifaximi 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/rifaximi/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3214996 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ly3214996/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/rapamycin 2026-05-10 weekly 0.7 https://crcwarriors.org/medicamento/rapamycin/ensayos 2026-05-10 weekly 0.6 https://crcwarriors.org/medicamento/avzo-021 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/avzo-021/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/famitinib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/famitinib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bmx-001 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bmx-001/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/shr-1701 2026-04-02 weekly 0.7 https://crcwarriors.org/medicamento/shr-1701/ensayos 2026-04-02 weekly 0.6 https://crcwarriors.org/medicamento/prexasertib 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/prexasertib/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tovorafenib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tovorafenib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/flox 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/flox/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sph5030 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/sph5030/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/plerixafor 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/plerixafor/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/simvastatin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/simvastatin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/resveratrol 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/resveratrol/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/cm-24 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cm-24/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cp-675 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/cp-675/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/g-csf 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/g-csf/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gemnabp 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/gemnabp/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rezatapopt 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rezatapopt/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ono-4578 2026-04-18 weekly 0.7 https://crcwarriors.org/medicamento/ono-4578/ensayos 2026-04-18 weekly 0.6 https://crcwarriors.org/medicamento/piritramid 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/piritramid/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/mm-121 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/mm-121/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/curcumin 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/curcumin/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/savolitinib 2026-07-07 weekly 0.7 https://crcwarriors.org/medicamento/savolitinib/ensayos 2026-07-07 weekly 0.6 https://crcwarriors.org/medicamento/bms-986504 2026-06-19 weekly 0.7 https://crcwarriors.org/medicamento/bms-986504/ensayos 2026-06-19 weekly 0.6 https://crcwarriors.org/medicamento/dtx 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/dtx/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/pds0101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds0101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/acetaminophen 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/acetaminophen/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/m7824 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/m7824/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/silymari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/silymari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/simvastati 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/simvastati/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/golytely 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/golytely/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/bl-b01d1 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/bl-b01d1/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/byl719 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/byl719/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/aipalolitovorelizumab 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/aipalolitovorelizumab/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mgd007 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/mgd007/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vactosertib 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/vactosertib/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/sym021 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/sym021/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/xl092 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/xl092/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/adalimumab 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/adalimumab/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/incb106385 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/incb106385/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/interferon 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/interferon/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/ly3023414 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/ly3023414/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tegavivint 2026-04-24 weekly 0.7 https://crcwarriors.org/medicamento/tegavivint/ensayos 2026-04-24 weekly 0.6 https://crcwarriors.org/medicamento/rp2 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/rp2/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovori 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovori/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/mesalamine 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/mesalamine/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/tg6002 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tg6002/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/jab-23e73 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/jab-23e73/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/yl-17231 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/yl-17231/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/alpelisib 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/alpelisib/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ropidoxuridine 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ropidoxuridine/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/citraflee 2026-07-11 weekly 0.7 https://crcwarriors.org/medicamento/citraflee/ensayos 2026-07-11 weekly 0.6 https://crcwarriors.org/medicamento/cyad-101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cyad-101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/glutamine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/glutamine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/kqb198 2026-05-27 weekly 0.7 https://crcwarriors.org/medicamento/kqb198/ensayos 2026-05-27 weekly 0.6 https://crcwarriors.org/medicamento/lazertinib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/lazertinib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/ezabenlimab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ezabenlimab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/ngm438 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ngm438/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/isis 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/isis/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/vs-7375 2026-06-23 weekly 0.7 https://crcwarriors.org/medicamento/vs-7375/ensayos 2026-06-23 weekly 0.6 https://crcwarriors.org/medicamento/epinephrine 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/epinephrine/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/propranolol 2026-05-01 weekly 0.7 https://crcwarriors.org/medicamento/propranolol/ensayos 2026-05-01 weekly 0.6 https://crcwarriors.org/medicamento/naproxe 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/naproxe/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/nsaid 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/nsaid/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/sc-201 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/sc-201/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/tegavivi 2026-03-29 weekly 0.7 https://crcwarriors.org/medicamento/tegavivi/ensayos 2026-03-29 weekly 0.6 https://crcwarriors.org/medicamento/ethynyluracil 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/ethynyluracil/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/gsk5764227 2026-08-04 weekly 0.7 https://crcwarriors.org/medicamento/gsk5764227/ensayos 2026-08-04 weekly 0.6 https://crcwarriors.org/medicamento/avx701 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/avx701/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tinzapari 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/tinzapari/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hmbd-001 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/hmbd-001/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/surufatinib 2026-05-19 weekly 0.7 https://crcwarriors.org/medicamento/surufatinib/ensayos 2026-05-19 weekly 0.6 https://crcwarriors.org/medicamento/ixabepilone 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ixabepilone/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/selenium 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/selenium/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/hlx07 2026-04-19 weekly 0.7 https://crcwarriors.org/medicamento/hlx07/ensayos 2026-04-19 weekly 0.6 https://crcwarriors.org/medicamento/jdq443 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jdq443/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tazemetostat 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/tazemetostat/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/pds01adc 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/pds01adc/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/krn330 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/krn330/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/inca33890 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/inca33890/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ensartinib 2026-06-18 weekly 0.7 https://crcwarriors.org/medicamento/ensartinib/ensayos 2026-06-18 weekly 0.6 https://crcwarriors.org/medicamento/rmc-6291 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/rmc-6291/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/levoleucovorin 2026-03-30 weekly 0.7 https://crcwarriors.org/medicamento/levoleucovorin/ensayos 2026-03-30 weekly 0.6 https://crcwarriors.org/medicamento/pf-07799933 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/pf-07799933/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/rifaximin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/rifaximin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jx-594 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jx-594/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/reolysin 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/reolysin/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/tas-102 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/tas-102/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/star0602 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/star0602/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/ferumoxytol 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/ferumoxytol/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/jmt101 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/jmt101/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/bl-m17d1 2026-06-17 weekly 0.7 https://crcwarriors.org/medicamento/bl-m17d1/ensayos 2026-06-17 weekly 0.6 https://crcwarriors.org/medicamento/b1962 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/b1962/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/cibisatamab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/cibisatamab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/elironrasib 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/elironrasib/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/medicamento/obinutuzumab 2026-03-31 weekly 0.7 https://crcwarriors.org/medicamento/obinutuzumab/ensayos 2026-03-31 weekly 0.6 https://crcwarriors.org/regimen/folfox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capox 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfox-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfiri-panitumumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/folfoxiri-bevacizumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/capecitabine-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/pembrolizumab-mono 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/encorafenib-cetuximab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trastuzumab-pertuzumab 2026-02-13 monthly 0.8 https://crcwarriors.org/regimen/trifluridine-tipiracil 2026-02-13 monthly 0.8 https://crcwarriors.org/articulo/2850/aspirina-para-la-prevencion-del-cancer-en-individuos-con-sindrome-de-lynch-primeros-resultados-del-ensayo-multicentrico-aleatorizado-doble-ciego-de-no-inferioridad-capp3 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2850/aspirin-for-cancer-prevention-in-individuals-with-lynch-syndrome-first-results-from-the-capp3-multicentre-randomised-double-blind-non-inferiority-trial 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2828/efectos-antitumorales-de-las-celulas-car-nk92mi-dirigidas-contra-cd133-en-el-cancer-colorrectal 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2828/anti-tumor-effects-of-cd133-targeted-car-nk92mi-cells-in-colorectal-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2826/estrategias-de-administracion-de-virus-oncoliticos-en-los-canceres-gastrointestinales-avances-mecanismos-y-traslacion-clinica 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2826/delivery-strategies-for-oncolytic-viruses-in-gastrointestinal-cancers-progress-mechanisms-and-clinical-translations 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2810/arid1a-regula-la-metastasis-del-cancer-colorrectal-a-traves-de-la-via-akt-mtor-p70s6k 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2810/arid1a-regulates-colorectal-cancer-metastasis-through-the-akt-mtor-p70s6k-pathway 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2802/factores-pronosticos-en-el-borde-de-invasion-y-en-el-area-peritumoral-del-cancer-colorrectal-perspectivas-actuales-y-consideraciones-futuras 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2802/invasive-front-and-peritumoral-prognostic-factors-in-colorectal-cancer-current-perspectives-and-future-considerations 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2783/dependencia-de-la-enzima-tipo-furina-en-el-cancer-colorrectal-con-mutacion-en-kras-como-diana-para-estrategias-de-tratamiento-personalizadas 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2783/furin-like-enzyme-dependency-in-kras-mutant-colorectal-cancer-as-a-target-for-personalized-treatment-strategies 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2687/dirigirse-a-lig1-para-superar-la-resistencia-al-oxaliplatino-mediante-la-induccion-de-la-panoptosis-en-el-cancer-colorrectal 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2687/targeting-lig1-to-overcome-oxaliplatin-resistance-by-inducing-panoptosis-in-colorectal-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2686/analisis-del-microambiente-inmunosupresor-en-el-cancer-colorrectal-resistente-a-la-quimioterapia-mediante-el-analisis-transcriptomico-de-celulas-individuales 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2686/dissecting-immunosuppressive-microenvironment-in-chemotherapy-resistant-colorectal-cancer-through-single-cell-transcriptomic-analysis 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2504/quien-rechaza-el-asesoramiento-genetico-evaluacion-del-rechazo-al-asesoramiento-genetico-entre-los-participantes-en-un-programa-de-cribado-genomico-a-nivel-poblacional 2026-08-03 monthly 0.5 https://crcwarriors.org/articulo/2504/who-declines-genetic-counseling-an-assessment-of-genetic-counseling-declination-among-individuals-participating-in-a-population-wide-genomic-screening-program 2026-08-03 monthly 0.5 https://crcwarriors.org/articulo/2483/identificacion-sistematica-de-biomarcadores-genomicos-de-falta-de-respuesta-a-los-tratamientos-contra-el-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2483/systematic-identification-of-genomic-nonresponse-biomarkers-to-cancer-therapies 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2479/mecanismos-y-avances-en-la-resistencia-a-los-farmacos-en-el-cancer-colorrectal-una-revision-sistematica-de-las-redes-reguladoras-multicapa 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2479/mechanisms-and-advances-of-drug-resistance-in-colorectal-cancer-a-systematic-overview-of-multi-layered-regulatory-networks 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2476/mecanismos-y-desafios-clinicos-de-la-remodelacion-del-microambiente-tumoral-mediada-por-la-inmunoterapia-con-inhibidores-de-puntos-de-control-en-el-carcinoma-nasofaringeo 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2476/mechanisms-and-clinical-challenges-of-icb-mediated-remodeling-of-the-tumor-microenvironment-in-nasopharyngeal-carcinoma 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2429/redes-regulatorias-multidimensionales-de-la-resistencia-a-los-farmacos-en-el-cancer-colorrectal-desde-los-mecanismos-moleculares-hasta-nuevas-estrategias-terapeuticas 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2429/multidimensional-regulatory-networks-of-drug-resistance-in-colorectal-cancer-from-molecular-mechanisms-to-novel-therapeutic-counterstrategies 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2415/adcs-para-el-carcinoma-colorrectal-analisis-de-la-evidencia-clinica-para-la-innovacion-en-el-diseno-molecular 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2415/adcs-for-colorectal-carcinoma-decoding-clinical-evidence-for-molecular-design-innovation 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2317/alteraciones-especificas-del-subtipo-en-el-transporte-de-cobre-asociadas-con-las-mutaciones-de-kras-en-lineas-celulares-isogenicas-de-cancer-colorrectal 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2317/subtype-specific-alterations-in-copper-trafficking-associated-with-kras-mutations-in-isogenic-colorectal-cancer-cell-lines 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2303/sintesis-y-evaluacion-preclinica-de-89-zr-dfo-atezolizumab-para-la-imagen-pet-inmunitaria-en-el-cancer-colorrectal 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2303/synthesis-and-preclinical-evaluation-of-89-zr-dfo-atezolizumab-for-immuno-pet-imaging-in-colorectal-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2237/la-arn-polimerasa-i-endotelial-que-esta-regulada-por-spen-es-un-objetivo-para-mejorar-la-inmunoterapia-anti-pd-1-en-el-tratamiento-del-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2237/endothelial-rna-polymerase-i-which-is-regulated-by-spen-is-a-target-for-improving-anti-pd-1-immunotherapy-of-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2130/evaluaciones-endoscopicas-y-radiologicas-de-la-inmunoterapia-neoadyuvante-en-pacientes-con-cancer-colorrectal-localmente-avanzado-con-dmmr-msi-h-o-mutacion-en-los-genes-pole-pold1 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2130/endoscopic-and-imaging-evaluations-of-neoadjuvant-immunotherapy-in-patients-with-locally-advanced-colorectal-cancer-with-dmmr-msi-h-or-pole-pold1-mutation 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/1783/virus-oncoliticos-recubiertos-basados-en-una-estrategia-de-doble-ataque-que-desencadena-la-terapia-car-t-dirigida-a-cd19-en-tumores-gastrointestinales 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/1783/coated-oncolytic-viruses-based-double-strike-strategy-triggering-cd19-car-t-therapy-in-gastrointestinal-tumors 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2873/proceso-de-radiomica-de-tc-coclinica-para-identificar-posibles-biomarcadores-de-imagen-para-el-cancer-colorrectal 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2873/co-clinical-ct-radiomics-pipeline-to-establish-candidate-imaging-biomarkers-for-colorectal-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2872/m-6-a-modified-lncrna-miat-promotes-anoikis-resistance-and-peritoneal-metastasis-of-colorectal-cancer-through-mir-181a-5p-mcl1-signaling-axis 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2871/cost-effectiveness-analysis-of-nivolumab-plus-ipilimumab-versus-nivolumab-monotherapy-in-previously-treated-metastatic-colorectal-cancer-patients-with-dna-mismatch-repair-deficient-microsatellite 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2870/from-kras-inhibition-to-tumor-adaptation-mechanistic-layers-of-resistance-and-therapeutic-strategies 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2867/radioterapia-de-corta-duracion-combinada-con-capeox-e-inhibidor-de-pd-1-tras-la-escision-local-en-el-cancer-colorrectal-temprano-de-alto-riesgo-protocolo-de-estudio-para-un-ensayo-prospectivo-de-fase 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2867/short-course-radiotherapy-combined-with-capeox-and-pd-1-inhibitor-following-local-excision-in-high-risk-early-rectal-cancer-study-protocol-for-a-prospective-phase-ii-trial-torch-le 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2866/trifluridina-tipiracil-con-o-sin-bevacizumab-en-el-cancer-colorrectal-metastasico-con-inestabilidad-de-microsatelites-alta-deficiencia-en-la-reparacion-de-errores-de-emparejamiento-un-estudio 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2866/trifluridine-tipiracil-with-or-without-bevacizumab-in-microsatellite-instability-high-mismatch-repair-deficient-metastatic-colorectal-cancer-a-retrospective-observational-study 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2863/panorama-de-los-ensayos-clinicos-y-perspectivas-traslacionales-de-la-inmunoterapia-basada-en-celulas-asesinas-naturales-un-analisis-basado-en-la-base-de-datos-informa 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2863/clinical-trial-landscape-and-translational-prospects-of-natural-killer-cell-based-immunotherapy-an-analysis-based-on-the-informa-database 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2862/informe-breve-beneficio-terapeutico-de-isa-2011b-en-el-cancer-colorrectal 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2862/brief-report-therapeutic-benefit-of-isa-2011b-in-colorectal-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2861/modulacion-de-la-microbiota-intestinal-en-los-canceres-gastrointestinales-desde-las-caracteristicas-de-la-disbiosis-hasta-las-intervenciones-terapeuticas 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2861/gut-microbiota-modulation-of-gastrointestinal-cancers-from-dysbiosis-signatures-to-therapeutic-interventions 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2859/relacion-entre-los-sitios-de-mutacion-del-gen-kras-y-las-caracteristicas-clinicas-en-el-cancer-colorrectal 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2859/relationship-between-kras-gene-mutation-sites-and-clinical-characteristics-in-colorectal-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2858/panorama-genomico-e-implicaciones-terapeuticas-del-cancer-colorrectal-con-fusion-de-alk 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2858/genomic-landscape-and-therapeutic-implications-of-alk-fusion-positive-colorectal-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2857/predictores-genomicos-transcriptomicos-y-moleculares-de-la-respuesta-a-la-terapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado-una-revision-narrativa 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2857/genomic-transcriptomic-and-molecular-predictors-of-response-to-neoadjuvant-therapy-in-locally-advanced-rectal-cancer-a-narrative-review 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2852/un-modelo-de-radiomica-predice-la-eficacia-de-un-inhibidor-de-cdk4-6-en-primera-linea-combinado-con-terapia-endocrina-en-el-cancer-de-mama-avanzado-hr-her2 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2852/radiomics-model-predicts-efficacy-of-first-line-cdk4-6-inhibitor-combined-with-endocrine-therapy-in-hr-her2-advanced-breast-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2851/un-ensayo-de-fase-ii-de-un-solo-brazo-para-evaluar-la-reintroduccion-de-irinotecan-a-dosis-altas-guiada-por-el-genotipo-ugt1a1-en-pacientes-con-cancer-colorrectal-metastasico-refractario 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2851/a-single-arm-phase-ii-trial-of-ugt1a1-genotype-guided-high-dose-irinotecan-rechallenge-in-refractory-metastatic-colorectal-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2849/dirigirse-a-la-enfermedad-residual-molecular-y-a-la-evasion-inmune-en-la-recurrencia-del-cancer-colorrectal-inmunoterapia-y-terapias-celulares-guiadas-por-biomarcadores 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2849/targeting-molecular-residual-disease-and-immune-escape-in-colorectal-cancer-recurrence-biomarker-guided-immunotherapy-and-cell-therapies 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2847/fototerapia-inmunoterapia-del-carcinoma-de-colon-mediante-un-complejo-de-nanoparticulas-de-carbono-y-fe-ii-con-un-inmunoadyuvante 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2847/photothermal-immunotherapy-of-colon-carcinoma-by-carbon-nanoparticle-fe-ii-complex-with-immunoadjuvant 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2846/prediccion-multimodelo-del-pronostico-especifico-por-estadio-del-cancer-colorrectal-mediante-el-aprendizaje-profundo-en-conjunto-basado-en-la-atencion-aplicado-a-datos-de-perfiles-genomicos 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2846/a-multi-model-prediction-of-a-stage-specific-prognosis-for-colorectal-cancer-using-attention-driven-deep-ensemble-learning-on-genomic-profiling-data 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2845/descubrimiento-de-derivados-de-hidrazona-como-nuevos-antagonistas-de-stat3-para-el-tratamiento-del-cancer-de-pancreas-y-de-colon 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2845/discovery-of-hydrazone-derivatives-as-novel-stat3-antagonists-against-pancreatic-and-colorectal-cancers 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2840/linfoma-de-hodgkin-clasico-una-revision 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2840/classic-hodgkin-lymphoma-a-review 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2839/adicion-de-altas-dosis-de-vitamina-d3-al-tratamiento-estandar-en-pacientes-con-cancer-colorrectal-metastasico-el-ensayo-clinico-aleatorizado-solaris-alliance-a021703 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2839/addition-of-high-dose-vitamin-d3-to-standard-treatment-in-patients-with-metastatic-colorectal-cancer-the-solaris-randomized-clinical-trial-alliance-a021703 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2838/el-analisis-especifico-de-variantes-del-fenomeno-de-exclusion-mutua-entre-los-oncogenes-braf-egfr-y-kras-revela-una-superposicion-con-pares-de-mutantes-funcionalmente-antagonicos 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2838/variant-specific-landscape-of-mutual-exclusivity-among-braf-egfr-and-kras-oncogenes-reveals-overlap-with-functionally-antagonistic-mutant-pairs 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2835/el-foretinib-induce-la-muerte-celular-inmunogenica-y-potencia-la-eficacia-de-la-inmunoterapia-anti-cd47-en-el-cancer-colorrectal 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2835/foretinib-triggers-immunogenic-cell-death-and-enhances-efficacy-of-anti-cd47-immunotherapy-in-colorectal-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2834/asociacion-de-los-macrofagos-intratumorales-cd68-cd163-de-tipo-m2-con-la-supervivencia-en-el-cancer-colorrectal-metastasico-tratado-con-quimioterapia-mas-bevacizumab 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2834/association-of-intratumoral-cd68-cd163-m2-like-macrophages-with-survival-in-metastatic-colorectal-cancer-treated-with-chemotherapy-plus-bevacizumab 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2829/la-optimizacion-del-proceso-de-fabricacion-y-de-la-superficie-electrostatica-de-las-celulas-car-t-mejora-la-eficacia-terapeutica-en-las-neoplasias-hepaticas 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2829/manufacturing-and-electrostatic-surface-optimization-of-car-t-cells-improve-therapeutic-efficacy-in-liver-malignancies 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2824/perfil-genomico-y-caracteristicas-clinicas-de-los-canceres-colorrectales-con-mutaciones-en-erbb2-her2 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2824/genomic-landscape-and-clinical-characteristics-of-erbb2-her2-mutated-colorectal-cancers 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2823/respuesta-prolongada-a-la-inhibicion-combinada-de-braf-y-mek-en-cancer-colorrectal-con-mutacion-braf-un-caso-clinico 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2823/prolonged-response-to-combined-braf-and-mek-inhibition-in-braf-mutant-colorectal-cancer-a-case-report 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2820/quimioterapia-neoadyuvante-y-bevacizumab-para-metastasis-peritoneales-de-cancer-colorrectal-resultados-clinicos-y-traslacionales-del-ensayo-de-fase-ii-bev-ip 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2820/neoadjuvant-chemotherapy-and-bevacizumab-for-colorectal-peritoneal-metastases-clinical-and-translational-outcomes-of-the-phase-ii-bev-ip-trial 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2819/administracion-de-sirna-mediante-coacervados-peptidicos-para-el-bloqueo-dual-de-pd-1-pd-l1-con-el-fin-de-mejorar-la-inmunoterapia-del-cancer-colorrectal 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2819/peptide-coacervate-mediated-sirna-delivery-for-dual-pd-1-pd-l1-blockade-to-enhance-colorectal-cancer-immunotherapy 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2818/evaluacion-del-rendimiento-de-un-ensayo-de-genotipado-de-regiones-criticas-basado-en-massarray-para-el-diagnostico-de-cancer-colorrectal-que-analiza-los-genes-kras-nras-braf-y-pik3ca-utilizando 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2818/performance-evaluation-of-a-colorectal-cancer-associated-massarray-based-hotspot-genotyping-assay-for-kras-nras-braf-and-pik3ca-using-solid-tumor-specimens 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2817/dependencias-distintas-de-erk-y-pi3k-median-una-respuesta-heterogenea-a-la-inhibicion-de-ras-on-en-el-cancer-colorrectal-con-mutacion-en-kras 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2817/distinct-erk-and-pi3k-dependencies-mediate-a-heterogeneous-response-to-ras-on-inhibition-in-kras-mutant-colorectal-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2808/el-papel-multifacetico-de-socs3-en-el-cancer-colorrectal-mecanismos-moleculares-e-implicaciones-clinicas 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2808/the-multifaceted-role-of-socs3-in-colorectal-cancer-molecular-mechanisms-and-clinical-implications 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2807/commit-estudio-aleatorizado-de-mfolfox6-bevacizumab-atezolizumab-frente-a-atezolizumab-en-monoterapia-como-tratamiento-de-primera-linea-del-cancer-colorrectal-metastasico-con-deficiencia-en-la 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2807/commit-a-randomized-study-of-mfolfox6-bevacizumab-atezolizumab-or-atezolizumab-alone-as-first-line-treatment-of-deficient-dna-mismatch-repair-metastatic-colorectal-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2806/las-mutaciones-del-gen-kras-reprograman-las-modificaciones-m6a-del-arn-para-impulsar-la-evasion-inmunitaria-dependiente-de-cd73-en-el-cancer-colorrectal 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2806/kras-mutations-reprogram-rna-m6a-modifications-to-drive-cd73-dependent-immune-evasion-in-colorectal-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2804/afinacion-y-caracterizacion-de-la-maduracion-del-nuevo-anticuerpo-monoclonal-mab-pb-223-dirigido-contra-los-o-glicanos-especificos-del-cancer-que-terminan-en-2-6-acidos-sialicos 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2804/affinity-maturation-and-characterization-of-the-novel-monoclonal-antibody-mab-pb-223-targeting-cancer-specific-o-glycans-terminating-with-2-6-sialic-acids 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2803/comparacion-de-la-eficacia-y-la-seguridad-de-las-diferentes-opciones-de-tratamiento-en-tercera-linea-para-pacientes-con-cancer-colorrectal-metastasico-una-revision-sistematica-y-un-metaanalisis-de 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2803/comparing-the-effectiveness-and-safety-of-different-third-line-management-options-for-patients-with-metastatic-colorectal-cancer-a-systematic-review-and-reconstructed-individual-patient-data-meta 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2798/superar-la-resistencia-a-los-tratamientos-anti-egfr-mecanismos-de-resistencia-al-cetuximab-y-al-panitumumab-y-nuevas-estrategias-de-combinacion 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2798/overcoming-resistance-to-anti-egfr-therapies-mechanisms-of-cetuximab-and-panitumumab-resistance-and-emerging-combination-strategies 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2797/la-actividad-citolitica-inmune-se-correlaciona-con-las-alteraciones-del-microambiente-tumoral-en-el-cancer-colorrectal 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2797/immune-cytolytic-activity-correlates-with-tumor-microenvironmental-aberrations-in-colorectal-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2796/oncofertilidad-femenina-en-el-cancer-colorrectal-incertidumbres-reproductivas-y-posibles-beneficios-de-la-inmunoterapia 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2796/female-oncofertility-in-colorectal-cancer-reproductive-uncertainties-and-potential-benefits-of-immunotherapy 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2792/analisis-de-la-incidencia-y-los-resultados-perioperatorios-de-las-reacciones-adversas-relacionadas-con-el-sistema-inmunitario-en-la-inmunoterapia-preoperatoria-para-el-cancer-colorrectal-basado-en 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2792/analysis-on-the-incidence-and-perioperative-outcomes-of-immune-related-adverse-events-in-preoperative-immunotherapy-for-colorectal-cancer-based-on-multicenter-real-world-data 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2791/informe-de-la-27-a-conferencia-anual-de-consenso-sobre-el-cancer-gastrointestinal-del-oeste-de-canada-dedicada-al-cancer-colorrectal-celebrada-en-calgary-alberta-los-dias-26-y-27-de-septiembre-de 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2791/report-from-the-27th-annual-western-canadian-gastrointestinal-cancer-consensus-conference-on-colorectal-cancer-calgary-alberta-26-27-september-2025-advances-in-colon-and-rectal-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2790/sobreexpresion-amplificacion-de-her2-en-el-cancer-colorrectal-la-heterogeneidad-espacial-intratumoral-como-factor-clave-de-la-discordancia-en-la-deteccion-y-la-respuesta-al-tratamiento 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2790/her2-overexpression-amplification-in-colorectal-cancer-spatial-intratumoral-heterogeneity-as-a-key-determinant-of-detection-discordance-and-therapy-response 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2789/avances-recientes-en-la-investigacion-clinica-y-de-biologia-molecular-sobre-las-lesiones-serriladas-rectales 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2789/recent-progress-in-clinical-and-molecular-biological-research-in-rectal-serrated-lesions 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2784/dirigirse-a-las-vias-moleculares-y-geneticas-que-impulsan-la-tumorigenesis-para-lograr-una-terapia-de-precision-en-el-cancer-colorrectal 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2784/targeting-molecular-and-genetic-pathways-driving-tumorigenesis-for-precision-therapy-in-colorectal-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2779/impacto-en-la-supervivencia-de-los-eventos-adversos-graves-relacionados-con-la-inmunoterapia-en-los-canceres-digestivos-con-deficiencia-en-la-reparacion-del-desajuste-y-alta-inestabilidad-de 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2779/impact-on-survival-of-severe-immuno-related-adverse-events-in-deficient-mismatch-repair-microsatellite-instable-high-digestive-cancers-treated-with-immunotherapy 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2774/las-celulas-t-derivadas-de-ipsc-alogenicas-demuestran-eficacia-antitumoral-frente-a-tejidos-derivados-de-pacientes 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2774/allogeneic-ipsc-derived-t-cells-demonstrate-antitumor-efficacy-against-patient-derived-tissues 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2773/un-nuevo-anticuerpo-monoclonal-anti-caderina-17-ca-17-mab-5-para-multiples-aplicaciones 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2773/a-novel-anti-cadherin-17-monoclonal-antibody-ca-17-mab-5-for-multiple-applications 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2771/inmunoterapia-en-el-cancer-colorrectal-asociado-a-la-deficiencia-constitucional-del-sistema-de-reparacion-de-errores-de-emparejamiento-cmmrd-en-pacientes-pediatricos-informe-de-un-caso-de-una 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2771/immunotherapy-in-pediatric-constitutional-mismatch-repair-deficiency-cmmrd-associated-colorectal-cancer-report-of-a-rare-variant-and-recommendations-for-screening 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2770/terapia-neoadyuvante-total-basada-en-radioterapia-de-corta-duracion-mas-tislelizumab-para-el-cancer-colorrectal-localmente-avanzado-neo-star-resultados-preliminares-de-un-ensayo-aleatorizado-de-fase 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2770/short-course-radiotherapy-based-total-neoadjuvant-therapy-plus-tislelizumab-for-locally-advanced-rectal-cancer-neo-star-early-outcomes-of-a-randomized-phase-ii-trial 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2768/copanlisib-en-combinacion-con-nivolumab-para-el-tratamiento-del-cancer-colorrectal-con-microsatelites-estables-un-ensayo-de-fase-1-2 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2768/copanlisib-in-combination-with-nivolumab-formicrosatellite-stable-colorectal-cancer-a-phase-1-2-trial 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2767/dhodh-es-un-objetivo-sintal-letal-en-el-cancer-colorrectal-con-mutacion-en-pik3ca 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2767/dhodh-is-a-synthetic-lethal-target-in-pik3ca-mutant-colorectal-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2766/panorama-genomico-y-molecular-del-cancer-colorrectal-de-inicio-temprano-nuevos-conocimientos-e-implicaciones-clinicas-una-revision-sistematica 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2766/genomic-and-molecular-landscape-of-early-onset-colorectal-cancer-emerging-insights-and-clinical-implications-a-systematic-review 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2765/remodelacion-inmune-sistemica-tras-la-reseccion-curativa-r0-de-metastasis-hepaticas-de-cancer-colorrectal 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2765/systemic-immune-remodeling-following-curative-r0-resection-of-colorectal-liver-metastases 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2762/sirexatamab-en-combinacion-con-bevacizumab-y-quimioterapia-como-terapia-de-segunda-linea-para-el-adenocarcinoma-colorrectal-avanzado-el-ensayo-de-fase-ii-defiance 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2762/sirexatamab-in-combination-with-bevacizumab-and-chemotherapy-as-second-line-therapy-for-advanced-colorectal-adenocarcinoma-the-phase-ii-defiance-trial 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2761/resultados-de-supervivencia-y-factores-pronosticos-en-pacientes-con-cancer-colorrectal-metastasico-tratados-en-primera-linea-con-mfolfoxiri-mas-bevacizumab-un-estudio-observacional-en-vietnam 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2761/survival-outcomes-and-prognostic-factors-in-patients-with-metastatic-colorectal-cancer-treated-first-line-mfolfoxiri-plus-bevacizumab-a-real-world-study-in-vietnam 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2759/nueva-estrategia-de-tratamiento-y-lineas-de-investigacion-futuras-para-el-cancer-con-mutacion-en-el-gen-braf 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2759/new-treatment-strategy-and-future-research-direction-for-braf-mutated-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2758/la-inhibicion-de-kras-g12d-reprograma-el-microambiente-inmunosupresor-inducido-por-el-tumor-y-potencia-la-inmunidad-antitumoral-mediada-por-las-celulas-nk 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2758/kras-g12d-inhibition-reprograms-the-tumor-induced-immunosuppressive-environment-and-enhances-nk-cell-mediated-antitumor-immunity 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2757/el-potencial-terapeutico-de-los-conjugados-anticuerpo-farmaco-en-el-cancer-colorrectal-avanzado-una-revision-sistematica-y-metaanalisis 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2757/the-therapeutic-potential-of-antibody-drug-conjugates-in-advanced-colorectal-cancer-a-systematic-review-and-meta-analysis 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2756/revision-sistematica-y-comparacion-indirecta-ajustada-de-los-inhibidores-de-los-puntos-de-control-inmunitario-en-primera-linea-para-el-cancer-colorrectal-metastasico 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2756/systematic-review-and-adjusted-indirect-comparison-of-first-line-immune-checkpoint-inhibitors-in-metastatic-colorectal-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2755/un-dihidrofenantreno-derivado-de-pholidota-chinensis-actua-como-un-componente-bioactivo-que-induce-la-ferroptosis-mediada-por-gpx4-en-el-cancer-colorrectal 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2755/a-pholidota-chinensis-derived-dihydrophenanthrene-acts-as-a-bioactive-constituent-to-trigger-gpx4-mediated-ferroptosis-in-colorectal-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2753/vactosertib-mas-pembrolizumab-en-pacientes-con-cancer-colorrectal-o-gastrico-metastasico-con-inestabilidad-microsatelital-no-alta-un-estudio-multicentrico-de-fase-ib-iia 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2753/vactosertib-plus-pembrolizumab-in-patients-with-non-microsatellite-instability-high-metastatic-colorectal-or-gastric-cancer-a-multicenter-phase-ib-iia-study 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2751/evaluacion-in-vitro-e-in-silico-del-potencial-antitumoral-del-extracto-etanolico-de-las-semillas-de-bryonia-laciniosa-contra-el-cancer-colorrectal-y-el-cancer-hepatocelular 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2751/in-vitro-and-in-silico-evaluation-of-the-anticancer-potential-of-ethanolic-seed-extract-of-bryonia-laciniosa-against-colorectal-and-hepatocellular-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2750/el-contexto-tisular-determina-diferentes-resultados-premalignos-en-un-modelo-transgenico-de-raton-pik3ca-mutante-hpv16-e6-e7 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2750/tissue-context-shapes-distinct-premalignant-outcomes-in-an-hpv16-e6-e7-mutant-pik3ca-transgenic-mouse-model 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2749/conjugados-anticuerpo-farmaco-en-el-cancer-colorrectal-avances-desafios-y-perspectivas 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2749/antibody-drug-conjugates-in-colorectal-cancer-advances-challenges-and-prospectives 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2745/aspirina-como-terapia-adyuvante-para-el-cancer-colorrectal-con-tumores-con-mutacion-en-pik3ca-y-sobreexpresion-de-cox-2-el-estudio-de-investigacion-traslacional-ascolt-y-metaanalisis 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2745/adjuvant-aspirin-for-colorectal-cancer-with-pik3ca-mutated-and-cox-2-overexpressed-tumours-the-ascolt-translational-research-study-and-meta-analysis 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2744/eficacia-y-seguridad-a-corto-plazo-de-la-inmunoterapia-neoadyuvante-en-el-cancer-colorrectal-localmente-avanzado-con-deficiencia-en-la-reparacion-del-desajuste 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2744/short-term-efficacy-and-safety-of-neoadjuvant-immunotherapy-for-locally-advanced-colon-cancer-with-deficient-mismatch-repair 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2743/cancer-colorrectal-metastasico-diagnosticado-antes-de-los-35-anos-un-subgrupo-distinto-de-enfermedad-de-inicio-temprano 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2743/metastatic-colorectal-cancer-diagnosed-before-age-35-a-distinct-subset-of-early-onset-disease 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2739/tratamiento-del-cancer-de-recto-localizado-en-los-paises-nordicos-comparacion-de-las-guias-nordicas-con-las-guias-holandesas-de-la-esmo-y-de-la-nccn 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2739/treatment-of-localized-rectal-cancer-in-the-nordic-countries-comparison-of-nordic-to-dutch-esmo-and-nccn-guidelines 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2737/primer-caso-descrito-de-mutaciones-duales-de-resistencia-kras-y96c-y96s-detectadas-mediante-biopsia-liquida-en-un-cancer-colorrectal-metastasico-con-mutacion-kras-g12c 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2737/first-report-of-dual-kras-y96c-y96s-resistance-mutations-detected-by-liquid-biopsy-in-kras-g12c-mutant-metastatic-colorectal-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2736/inmunoterapia-de-primera-linea-frente-a-quimioterapia-en-el-cancer-colorrectal-metastasico-con-msi-h-dmmr-una-revision-sistematica-y-un-metaanalisis-de-estudios-de-fase-iii 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2736/first-line-immunotherapy-versus-chemotherapy-in-msi-h-dmmr-metastatic-colorectal-cancer-a-systematic-review-and-meta-analysis-of-phase-iii-studies 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2723/evolucion-de-la-resistencia-a-la-inmunoterapia-mediada-por-macrofagos-de-la-cavidad-spp1-en-la-metastasis-peritoneal-del-cancer-colorrectal 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2723/evolution-of-spp1-cavity-macrophage-mediated-immunotherapy-resistance-in-peritoneal-metastasis-of-colorectal-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2722/estudio-de-fase-i-de-escalada-de-dosis-que-combina-la-quimioembolizacion-con-microesferas-de-irinotecan-y-la-radioembolizacion-con-microesferas-de-vidrio-de-itrio-90-en-metastasis-hepaticas-de-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2722/phase-i-dose-escalation-study-combining-irinotecan-loaded-drug-eluting-bead-chemoembolization-with-yttrium-90-glass-microspheres-radioembolization-in-colorectal-liver-metastases-debir-90-y 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2721/la-terapia-con-celulas-car-t-dirigidas-contra-gcc-no-protegidas-demuestra-una-eficacia-significativa-en-pacientes-con-cancer-colorrectal-avanzado 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2721/non-armored-gcc-targeting-car-t-cell-therapy-demonstrates-significant-efficacy-in-patients-with-advanced-colorectal-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2719/prediccion-temprana-de-la-enfermedad-residual-minima-en-el-cancer-colorrectal-mediante-el-analisis-del-estado-de-metilacion-de-septin9-en-el-adn-tumoral-circulante 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2719/early-prediction-of-minimal-residual-disease-in-colorectal-cancer-via-septin9-methylation-status-in-circulating-tumor-dna 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2718/desde-la-fermentacion-hasta-los-farmabioticos-ingenieria-de-lactobacillus-derivado-del-kefir-para-una-inmunoterapia-intratumoral-dirigida-en-el-cancer-colorrectal 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2718/from-fermentation-to-pharmabiotics-engineering-kefir-derived-lactobacillus-for-targeted-intratumoral-immunotherapy-in-colorectal-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2717/dirigirse-al-ecosistema-espacial-metabolico-inmune-en-las-metastasis-hepaticas-del-cancer-colorrectal-estrategias-farmacologicas-y-el-paradigma-de-interrumpir-normalizar-restablecer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2717/targeting-the-spatial-metabolic-immune-ecosystem-in-colorectal-cancer-liver-metastasis-pharmacological-strategies-and-the-break-normalize-reset-paradigm 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2714/el-adn-tumoral-circulante-para-predecir-el-riesgo-de-tromboembolia-venosa-en-el-cancer-de-recto-localmente-avanzado 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2714/circulating-tumor-dna-to-predict-the-risk-of-venous-thromboembolism-in-locally-advanced-rectal-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2710/quimiocirugia-neoadyuvante-con-dosis-escaladas-frente-a-la-quimiocirugia-neoadyuvante-estandar-para-el-cancer-colorrectal-localmente-avanzado-resultados-a-9-anos-de-un-ensayo-aleatorizado-de-fase-2 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2710/dose-escalated-versus-standard-neoadjuvant-chemoradiation-therapy-for-locally-advanced-rectal-cancer-nine-year-results-of-a-randomized-phase-2-trial 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2708/alteraciones-del-genoma-mitocondrial-en-el-cancer-desde-mutaciones-y-epigenetica-hasta-terapias-dirigidas 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2708/mitochondrial-genome-alterations-in-cancer-from-mutations-and-epigenetics-to-targeted-therapiesack 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2707/imagenes-multimodales-y-caracterizacion-tisular-mediante-ecografia-mejorada-con-inteligencia-artificial-para-predecir-la-eficacia-de-la-inmunoterapia-en-el-cancer-de-recto 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2707/artificial-intelligence-enhanced-ultrasound-multimodal-imaging-and-tissue-characterization-for-predicting-immunotherapy-efficacy-in-rectal-cancer 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2705/oncologia-de-precision-de-ultima-generacion-en-el-cancer-colorrectal-con-estabilidad-en-los-microsatelites-enfoque-integrado-que-va-mas-alla-de-ras-y-raf 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2705/next-generation-precision-oncology-in-microsatellite-stable-colorectal-cancer-integrated-targeting-beyond-ras-and-raf 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2703/impacto-pronostico-de-la-diseminacion-a-traves-de-los-espacios-aereos-y-su-asociacion-con-la-mutacion-kras-y-los-factores-histopatologicos-en-metastasis-pulmonares-de-cancer-colorrectal-resecadas 2026-08-11 monthly 0.5 https://crcwarriors.org/articulo/2703/prognostic-impact-of-spread-through-air-spaces-and-its-association-with-kras-mutation-and-histopathologic-factors-in-resected-colorectal-lung-metastases 2026-08-11 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nuevas-funcionalidades-en-el-buscador-de-ensayos-clinicos-mapa-interactivo-filtros-avanzados-y-mas 2026-08-09 monthly 0.5 https://crcwarriors.org/news-detail.php?id=nueva-experiencia-de-noticias-cientificas-ia-personalizada-traduccion-en-tiempo-real-y-mucho-mas 2026-08-07 monthly 0.5 https://crcwarriors.org/news-detail.php?id=lanzamos-la-beta-de-crc-warriors-buscamos-testers 2026-08-09 monthly 0.5 https://crcwarriors.org/news-detail.php?id=glosario-de-farmacos-2-0-mas-inteligente-mas-completo-mas-potente 2026-08-08 monthly 0.5 https://crcwarriors.org/combinaciones/63 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/62 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/33 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/34 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/36 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/52 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/11 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/45 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/42 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/1 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/12 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/48 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/13 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/30 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/53 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/3 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/5 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/50 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/15 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/39 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/59 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/2 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/49 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/56 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/64 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/38 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/4 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/16 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/19 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/54 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/51 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/40 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/55 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/18 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/61 2025-12-21 monthly 0.5 https://crcwarriors.org/combinaciones/41 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/20 2025-12-20 monthly 0.5 https://crcwarriors.org/combinaciones/21 2025-12-07 monthly 0.5 https://crcwarriors.org/combinaciones/22 2025-12-07 monthly 0.5 https://crcwarriors.org/help/getting-started.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/clinical-trials-guide.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/understanding-mutations.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/medication-database.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/privacy-security.php 2026-08-01 monthly 0.4 https://crcwarriors.org/help/faq.php 2026-08-01 monthly 0.4